{
  "7 Toxicological information": {
    "7.1 Toxicokinetics, metabolism and distribution": {
      "7.1.1 Basic toxicokinetics": {
        "001 | Supporting | Experimental study": {
          "document_id": "IUC5-18ec2860-0961-4901-a83e-03fee53396a9_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Basic toxicokinetics\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nbasic toxicokinetics in vivo\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nSignificant methodological deficiencies.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [3-Hydroxylation of salicylamide in mice](fed4477d-1742-3201-9643-61187a5839c0_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\nObjective of study\n\n* metabolism\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nThe concentrations of salicylamide and its metabolites in blood and urine were determined at various time points after intraperitoneal injection of salicyclamide into mice.\n\nGLP compliance\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](ddcbef69-fda3-3f17-9fd8-3dc15afb6567_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\nRadiolabelling\n\nno\n\n### Radiolabelled test material\n\n### Test animals\n\nSpecies\n\nmouse\n\nStrain\n\nCF-1\n\nDetails on species / strain selection\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\nintraperitoneal\n\nVehicle\n\nphysiological saline\n\nDetails on exposure\n\nTEST MATERIAL\n\n- concentration (if solution): 20 mL/kg bw\n\nDuration and frequency of treatment / exposure\n\nSingle exposure\n\n### Doses / concentrations\n\n### #1 - Doses / concentrations\n\nTreatment group\n\n[Empty]\n\nSex\n\nmale\n\nNo. of animals per sex per dose / concentration\n\n274.3 mg/kg bw: 4 mice\n548.5 mg/kg bw: 8 mice\n\nDuration and frequency of treatment / exposure\n\n[Empty]\n\nDose type\n\n[Empty]\n\nDose / conc.\n\n[Empty]\n\nRemarks\n\nDoses / Concentrations:\n274.3 mg/kg bw and 548.5 mg/kg bw (2 and 4 mmol/kg bw)\n\nControl animals\n\n* yes\n\nPositive control reference chemical\n\nno\n\nDetails on study design\n\n[Empty]\n\nDetails on dosing and sampling\n\nPHARMACOKINETIC STUDY\n\n- Tissues and body fluids sampled: urine, blood\n\nMETABOLITE CHARACTERISATION STUDIES\n\n- Tissues and body fluids sampled: urine\n\n- From how many animals: (samples pooled or not): 4-8, pooled samples\n\n- Method type(s) for identification: HPLC-UV (240 nm)\n\nTREATMENT FOR CLEAVAGE OF CONJUGATES (if applicable): beta-glucuronidase: sulfatase\n\nStatistics\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary studies\n\n[Empty]\n\n### Main ADME results\n\n### Toxicokinetic / pharmacokinetic studies\n\nDetails on absorption\n\n[Empty]\n\nDetails on distribution in tissues\n\n[Empty]\n\n### Transfer into organs\n\nDetails on excretion\n\n[Empty]\n\n### Toxicokinetic parameters\n\n### Metabolite characterisation studies\n\nMetabolites identified\n\nyes\n\nDetails on metabolites\n\nIDENTIFIED METABOLITES:\n\n2.3-dihydroxybenzamide (2,3-DBA), 2.5-dihydroxybenzamide (gentisamide), and their sulfates and glucuronides\n\nQUANTIFICATION IN BLOOD:\n\nAfter intraperitoneal administration of salicylamide, gentisamide glucuronide and salicylamide glucuronide were the major metabolites present in blood, followed by 2,3-DBA glucuronide and salicylamide sulfate. Gentisamide and its sulfate were detected in trace amounts only whereas neither 2.3-DBA nor its sulfate were detected.\n\nQUANTIFICATION IN URINE:\n\nThe relative amount of each metabolite in urine generally reflected its maximum concentration in blood. Gentisamide glucuronide was the most abundant metabolite, followed by 2,3-DBA glucuronide and salicylamide sulfate. Unconjugated gentisamide and 2,3-DBA only accounted for a minor proportion; salicylamide was not detected.\n\n### Distribution of metabolites in matrices\n\n### Appendix: Metabolites and their parents in treatment groups\n\n### Metabolites in treatment groups\n\n### Enzymatic activity\n\nEnzymatic activity measured\n\n[Empty]\n\n### Bioaccessibility (or Bioavailability)\n\nBioaccessibility (or Bioavailability) testing results\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nInterpretation of results (migrated information): no bioaccumulation potential based on study results\n\nAfter i.p. administration of salicylamide into mice, 2,3-dihydroxybenzamide, 2,5-dihydroxybenzamide (gentisamide), and its sulfates and glucuronides could be identified as metabolites of salicylamide in both blood and urine.\n\nExecutive summary\n\nMetabolism of salicylamide in mice was assessed after intraperitoneal administration of 274.3 and 548.5 mg/kg bw. The concentrations of salicylamide and its metabolites in blood and urine were determined at various time points using HPLC-UV. Glucuronides and sulfates were detected using glucuronidase/sulfatase treatment of samples before injection.\n\n2.3-Dihydroxybenzamide (2,3-DBA), 2.5-dihydroxybenzamide (gentisamide), and their sulfates and glucuronides were identified besides the sulfates and glucuronides of salicylamide as major metabolites of salicylamide in blood and urine.\n\nBack to top",
          "content_length": 6538,
          "status": "success"
        }
      },
      "7.1.2 Dermal absorption": {},
      "S-01 | Summary": {
        "document_id": "IUC5-44f24185-9773-4e93-b5b3-1ba64fcff318_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
        "markdown_content": "#### Toxicokinetics, metabolism and distribution\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Empty]\n\nJustification\n\n[Empty]\n\nUse restricted to selected regulatory programmes\n\n[Empty]\n\n### Link to relevant study record(s)\n\nLink to relevant study record(s)\n\n* [001 | Supporting | Experimental study](IUC5-18ec2860-0961-4901-a83e-03fee53396a9_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\n### Description of key information\n\n```\nShort description of key information on bioaccumulation potential result:   \nmetabolites identified, mice, i.p., Howell 1988  \nmetabolites/kinetics identified, humans, oral/rectal, de Boer 1983\n```\n\n### Key value for chemical safety assessment\n\nBioaccumulation potential\n\nno bioaccumulation potential\n\nAbsorption rate - oral (%)\n\n[Empty]\n\nAbsorption rate - dermal (%)\n\n[Empty]\n\nAbsorption rate - inhalation (%)\n\n[Empty]\n\n### Additional information\n\nA very large body of work exists in the literature (see literature search) addressing the pharmacokinetics and pharmacodynamics of salicylamide, both in vitro and in vivo (several species). Various aspects of ADME were addressed, but none according to guideline methods, and usually with non-standard methodology. For oral administration, almost complete metabolism was observed after absorption and first-pass through the liver. Two studies were selected which identified the main metabolites, as well as the absorption and elimination kinetics.\n\n \n\n**Basic toxicokinetics**\n\nHowell (1988) investigated the metabolism of salicylamide in mice after intraperitoneal administration of 274.3 and 548.5 mg/kg bw. The concentrations of salicylamide and its metabolites in blood and urine were determined at various time points using HPLC-UV. Glucuronides and sulfates were detected using glucuronidase/sulfatase treatment of samples before injection. 2,3-Dihydroxybenzamide (2,3-DBA), 2,5-dihydroxybenzamide (gentisamide), and their sulfates and glucuronides were identified besides the sulfates and glucuronides of salicylamide as major metabolites of salicylamide in blood and urine.\n\n \n\n**Direct observations: clinical cases - toxicokinetics**\n\nDe Boer et al. (1983) gave salicylamide to 6 human volunteers by oral or rectal administration at 500 or 1500 mg/person. Blood samples were obtained in regular intervals to quantify free salicylamide in plasma. Urinary samples were also collected and checked for salicylamide and its conjugates (sulfate and glucuronide). After oral administration, salicylamide was absorbed very quickly into the plasma with a mean peak time of 12Â±2.7 min. The peak concentration was then 30.9Â±9.2 g/mL (dose administered: 1500 mg). Elimination from plasma was also quite fast with half-lives of 12 and 31 min after administration of 500 and 1500 mg salicylamide, respectively. Excretion was performed mainly via urine after conjugation with sulfate or glucuronic acid. Urinary excretion half life was 63 min (dose: 1500 mg). After rectal administration plasma concentration of free salicylamide and urinary concentration of conjugates were significantly lower compared to oral administration.\n\nThe rapid metabolism and excretion indicate no potential for bioaccumulation.\n\n### Attached background material\n\nBack to top",
        "content_length": 3244,
        "status": "success"
      }
    },
    "7.2 Acute Toxicity": {
      "7.2.1 Acute toxicity: oral": {
        "001 | No specified study adequacy | Justification/conclusion (weight of evidence)": {
          "document_id": "6c68ca61-581b-469e-9a0e-deb5075e8ab8_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nweight of evidence justification/conclusion\n\nAdequacy of study\n\n[Empty]\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n[Empty]\n\nRationale for reliability incl. deficiencies\n\n[Empty]\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\nNone of the published articles on the acute oral toxicity fulfils the data and quality requirements of a study conducted in accordance with present OECD testing guidelines. Nevertheless, the agreement between the results is high, independent of possible differences in animal species and strains, vehicles, and other experimental parameters. The acute oral toxicity of salicylamide can be reliably characterised by applying the weight-of-evidence approach and selecting the most conservative LD50 value.\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nweight of evidence source\n\nRelated information\n\n[007 | Weight of evidence | Experimental study](IUC5-7a423ba6-d092-4862-8fe9-210fd3c25441_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nRemarks\n\n[Not publishable]\n\n### #2 - Cross-reference\n\nReason / purpose for cross-reference\n\nweight of evidence source\n\nRelated information\n\n[006 | Weight of evidence | Experimental study](IUC5-2896a651-6eb8-4200-8e15-857da862afd3_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nRemarks\n\n[Not publishable]\n\n### #3 - Cross-reference\n\nReason / purpose for cross-reference\n\nweight of evidence source\n\nRelated information\n\n[005 | Weight of evidence | Experimental study](IUC5-2ef24ed8-7473-49ec-a7a7-48627e40e82c_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nRemarks\n\n[Not publishable]\n\n### #4 - Cross-reference\n\nReason / purpose for cross-reference\n\nweight of evidence source\n\nRelated information\n\n[004 | Weight of evidence | Experimental study](IUC5-b5e15b41-92d9-45a8-bcd4-86a60976bb02_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nRemarks\n\n[Not publishable]\n\n### #5 - Cross-reference\n\nReason / purpose for cross-reference\n\nweight of evidence source\n\nRelated information\n\n[003 | Weight of evidence | Experimental study](IUC5-b3741dda-4555-4d14-af33-f59753beb87b_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nRemarks\n\n[Not publishable]\n\n### #6 - Cross-reference\n\nReason / purpose for cross-reference\n\nweight of evidence source\n\nRelated information\n\n[002 | Weight of evidence | Experimental study](IUC5-e9c0c6e2-5561-4c8d-ae22-97e834b56ee0_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n[Empty]\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\n[Empty]\n\nTest type\n\n[Empty]\n\nLimit test\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Empty]\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\n[Empty]\n\nStrain\n\n[Empty]\n\nSex\n\n[Empty]\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\n[Empty]\n\nVehicle\n\n[Empty]\n\nDetails on oral exposure\n\n[Empty]\n\nDoses\n\n[Empty]\n\nNo. of animals per sex per dose\n\n[Empty]\n\nControl animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nStatistics\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nnot specified\n\nDose descriptor\n\nLD50\n\nEffect level\n\n980 \n\n<\n2,000 \n\nmg/kg bw\n\nBased on\n\nnot specified\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\nMortality\n\n[Empty]\n\nClinical signs\n\n[Empty]\n\nBody weight\n\n[Empty]\n\nGross pathology\n\n[Empty]\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\n[Empty]\n\nConclusions\n\n[Empty]\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5306,
          "status": "success"
        },
        "002 | Weight of evidence | Experimental study": {
          "document_id": "IUC5-e9c0c6e2-5561-4c8d-ae22-97e834b56ee0_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nweight of evidence\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n1958 or before\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards. Experimental details well documented, but no data on acclimatization and housing. Results: LD50 after 1,2,4 and 7 days, incl. statistical evaluation. Performed 1958, before GLP and OECD guidelines were introduced. Sufficient numbers of animals investigated, but only one sex (males). No necropsy reported for any animals that died during the study or were sacrificed thereafter.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Comparative pharmacological and toxicological evaluation of N-acetyl-p-aminophenol, salicylamide, and acetylsalicylic acid](a6a6b553-d104-368a-9e6b-96bfda443208_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nOECD Guideline 401 (Acute Oral Toxicity)\n\nVersion / remarks\n\nPrinciples for LD50 derivation followed as described in guideline\n\nDeviations\n\nyes\n\nOne sex only, no necropsy, no body weight development, no data on acclimatization and housing\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nno\n\nGLP not available at study time\n\nTest type\n\nstandard acute method\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](834526d1-13b7-379d-910c-910361745517_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrat\n\nStrain\n\nother:\nH L A\n\nSex\n\nmale\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Weight at study initiation: 95-180 g\n\n- Fasting period before study: 15-17 hours\n\n- Housing: no data\n\n- Diet: ad libitum, except during 6-h observation period after application\n\n- Water: ad libitum, except during 6-h observation period after application\n\n- Acclimation period: no data\n\nENVIRONMENTAL CONDITIONS\n\n- Temperature (Â°C): 24.4 - 25.5\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nVehicle\n\nother:\n10% gum acacia suspension in water\n\nDetails on oral exposure\n\nVEHICLE\n\n- Concentration in vehicle: depending on dose (not stated)\n\n- Amount of vehicle (if gavage): 10 - 20 ml / kg\n\nMAXIMUM DOSE VOLUME APPLIED: 20 ml / kg\n\nDoses\n\n5 doses to calculate LD50, not individually stated\n\nNo. of animals per sex per dose\n\n10 males\n\nControl animals\n\nno\n\nDetails on study design\n\n- Duration of observation period following administration: 7 days (for LD50 calculation), 21 days for some recovery experiments\n\n- Frequency of observations: 6 d, 1, 2, 4, 7 d for LD50; no weighing\n\n- Necropsy of survivors performed: no\n\n- Other examinations performed: clinical signs, body weight,organ weights, histopathology, other:\n\nStatistics\n\nLitchfield JT & Wilcoxon F, J. Pharmacol. Exptl. Therap. 96:99 (1949)\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nmale\n\nDose descriptor\n\nLD50\n\nEffect level\n\n980 \n\n\n \n\nmg/kg bw\n\nBased on\n\nact. ingr.\n\n95% CL\n\n817 \n\n\n1,176\n\nRemarks on result\n\nother:\nfasted animals, observation of mortality at 7 days\n\n### #2 - Effect levels\n\nKey result\n\nSex\n\nmale\n\nDose descriptor\n\nLD50\n\nEffect level\n\n1,020 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n842 \n\n\n1,234\n\nRemarks on result\n\nother:\nfasted animals, observation of mortality at 4 days\n\n### #3 - Effect levels\n\nKey result\n\nSex\n\nmale\n\nDose descriptor\n\nLD50\n\nEffect level\n\n1,100 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n921 \n\n\n1,310\n\nRemarks on result\n\nother:\nfasted animals, observation of mortality at 1 and 2 days\n\n### #4 - Effect levels\n\nKey result\n\nSex\n\nmale\n\nDose descriptor\n\nother:\nTD50 minimal neurological deficit dose\n\nEffect level\n\n71 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n59 \n\n\n84.5\n\nRemarks on result\n\nother:\nfasted animals, mean body weight 139.8 g, 24 h observation\n\n### #5 - Effect levels\n\nKey result\n\nSex\n\nmale\n\nDose descriptor\n\nother:\nTD50 minimal neurological deficit dose\n\nEffect level\n\n82 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n61 \n\n\n110\n\nRemarks on result\n\nother:\nfasted animals, mean body weight 208.8 g, 24 h observation\n\nMortality\n\n[Empty]\n\nClinical signs\n\n* other:\n  Ataxia, depression (progressing to hypnosis at higher doses). Labored respiration and cyanosis prior to death (result of respiratory failure). Occasionally (in some animals) bizarre motions (rapid vertical or horizontal movements of the head, rapid circul\n\nBody weight\n\n[Empty]\n\nGross pathology\n\n[Empty]\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nToxicity Category IV\n\nMigrated information\n\nCriteria used for interpretation of results: EU\n\nConclusions\n\nStudy suitable for use as part of a weight-of-evidence assessment.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 6889,
          "status": "success"
        },
        "003 | Weight of evidence | Experimental study": {
          "document_id": "IUC5-b3741dda-4555-4d14-af33-f59753beb87b_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nweight of evidence\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n1946 or before\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards. Experimental details documented, but no data on acclimatization and housing. Results: Mortalities tabulated after 1 and 7 days, but no statistical determination of LD50. Performed 1946, before GLP and OECD guidelines were introduced. Sufficient numbers of animals investigated, but sex not stated.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Pharmacological and toxicological studies on salicylamide](2707fc48-a1fc-3b9a-ad9c-d13d06ae71dd_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nOECD Guideline 401 (Acute Oral Toxicity)\n\nVersion / remarks\n\nPrinciples for LD50 derivation followed as described in guideline\n\nDeviations\n\nyes\n\nSex not stated, only 7 days of observation, no data on acclimatization and housing, no body weight data\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nno\n\nGLP not available at study time\n\nTest type\n\nstandard acute method\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](290fcf86-bcd4-3427-8f38-4a4438c2e448_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrat\n\nStrain\n\nnot specified\n\nSex\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nVehicle\n\nother:\n0.5% gum tragacanth in water\n\nDetails on oral exposure\n\nVEHICLE\n\n- Concentration in vehicle: 20 % suspension\n\n- Amount of vehicle (if gavage): 2 - 10 g/kg body weight\n\n- Justification for choice of vehicle: stability of test substance, tolerability of vehicle (confounding effect of alcohols)\n\n- Lot/batch no. (if required): no data\n\n- Purity: no data\n\nMAXIMUM DOSE VOLUME APPLIED: approx. 10 ml/kg body weight\n\nDoses\n\nPreliminary experiment: 400, 600, 800, 1000, 1600, and 2000 mg/kg body weight\nMain experiment: 500, 1000, and 2000 mg/kg body weight\n\nNo. of animals per sex per dose\n\nPreliminary experiment: 5 (sex not specified)\nMain experiment: 15 (sex not specified)\n\nControl animals\n\nno\n\nDetails on study design\n\n- Duration of observation period following administration: 7 days\n\n- Frequency of observations: 15, 30, 60, 90 min, 2, 3, 5, 24 h, daily until day 7; no weighing reported\n\n- Necropsy of animals dying on test: yes\n\n- Necropsy of survivors: not reported\n\n- Other examinations performed: clinical signs\n\nStatistics\n\nNone\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nnot specified\n\nDose descriptor\n\nLD50\n\nEffect level\n\n>\n1,600 \n\n<=\n2,000 \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\nother:\nNo statistical evaluation; no mortalities at 1000 and 1600 mg/kg; at 2000 mg/kg mortality 1/5 in preliminary test, 9/15 in main test\n\nMortality\n\nNo mortalities up to 1000 and 1600 mg/kg\nAt 2000 mg/kg: mortality 1/5 in preliminary test, 9/15 in main test\nAll mortalities within 24 h after application (7/15 within 1 hour)\n\nClinical signs\n\n* other:\n  Depression (dose-dependent, no response to tail pinch), hind leg incoordination\n  Recovery of survivors within 24 hours\n\nBody weight\n\n[Empty]\n\nGross pathology\n\nCongestion and edema of the lungs\nSome cases of local hemorrhages and hyperemia of the liver\nAll other organs grossly normal\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nToxicity Category IV\n\nMigrated information\n\nCriteria used for interpretation of results: EU\n\nConclusions\n\nStudy suitable for use as part of a weight-of-evidence assessment.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5902,
          "status": "success"
        },
        "004 | Weight of evidence | Experimental study": {
          "document_id": "IUC5-b5e15b41-92d9-45a8-bcd4-86a60976bb02_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nweight of evidence\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n1946 or before\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards. Some experimental details documented, but no data on acclimatization and housing. Results: Mortalities up to 48 hours considered for graphical determination of LD50. Performed 1946, before GLP and OECD guidelines were introduced. Sufficient numbers of animals per group, but sex not stated.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [The toxicity and analgetic potency of salicylamide and certain of its derivatives as compared with established analgetic-antipyretic drugs](e8fe096b-45d4-3b83-a459-c0edc904d9a1_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nAcute oral LD50, with 15 or more animals per dose (sex not specified). No doses and mortalities per dose tabulated. Observation period only 48 hours; no necropsy reported. Main emphasis on analgesia test.\n\nGLP compliance\n\nno\n\nPerformed 1946, before GLP and OECD guidelines were introduced.\n\nTest type\n\nstandard acute method\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](6167d75d-1a51-33ac-a342-a73f9c861977_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrat\n\nStrain\n\nnot specified\n\nSex\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nVehicle\n\nother:\n1-1.5 % gum tragacanth in water\n\nDetails on oral exposure\n\nVEHICLE\n\n- Concentration in vehicle: 5 or 10 % suspension\n\n- Amount of vehicle (if gavage): no data\n\n- Justification for choice of vehicle: No appropriate solvents found to produce a true solution under physiological conditions. Suspensions satisfactorily stable.\n\nMAXIMUM DOSE VOLUME APPLIED: no data\n\nDoses\n\nNo data\n\nNo. of animals per sex per dose\n\n15 or more\n\nControl animals\n\nno\n\nDetails on study design\n\n- Duration of observation period following administration: 48 hours (occasional later deaths considered due to extraneous factors)\n\n- Frequency of observations and weighing: No data\n\n- Necropsy of survivors performed: no\n\n- Other examinations performed: clinical signs\n\nStatistics\n\nLD50 approximated graphically\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nnot specified\n\nDose descriptor\n\nLD50\n\nEffect level\n\n1,400 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\nMortality\n\nNot tabulated\n\nClinical signs\n\n* other:\n  Depressant (or possibly paralytic) action\n\nBody weight\n\n[Empty]\n\nGross pathology\n\nNo data\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nAD50 (amount required to produce significant analgesia in 50 % of the rats): 60 mg/kg\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nToxicity Category IV\n\nMigrated information\n\nCriteria used for interpretation of results: EU\n\nConclusions\n\nStudy suitable for use as part of a weight-of-evidence assessment.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5324,
          "status": "success"
        },
        "005 | Weight of evidence | Experimental study": {
          "document_id": "IUC5-2ef24ed8-7473-49ec-a7a7-48627e40e82c_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nweight of evidence\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\nbefore 1953\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards, years before OECD guidelines were developed. Main focus was laid on analgetic activity, approximate median lethal dose (LD50) was determined in parallel, in the same animals that were used for pain response. Observation time was only 48 hours. Only few experimental details and no individual result data are reported.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [The toxicity and analgetic activity of some congeners of salicylamide](4564e4dd-f18c-3436-896c-9ed400f6eb4d_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline available\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n6-10 male and female rats were treated with salicylamide by the oral route at several logarithmical-spaced dosage levels, and tested in a pressure analgesiometric method (on the tail) at several time points, to determine the threshold force that elicited a cry response. Mortality was recorded in the same treated animals during a 48-hour observation period, and used to calculate an approximate median lethal dose (LD50). No husbandry conditions and no symptoms, body weights, necropsy results etc. are recorded.\n\nGLP compliance\n\nno\n\nTest type\n\nother:\napproximate LD50 from 48-hour mortality in analgetic activity study\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](6167d75d-1a51-33ac-a342-a73f9c861977_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrat\n\nStrain\n\nWistar\n\nSex\n\nmale/female\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Weight at study initiation: 50-80g\n\n- Housing, diet, water, acclimation: no data\n\nENVIRONMENTAL CONDITIONS\n\n- no data\n\n### Administration / exposure\n\nRoute of administration\n\noral: unspecified\n\nVehicle\n\nother:\nprobably 0.25% tragacanth in water (which was used for i.p. injection)\n\nDetails on oral exposure\n\nno data\n\nDoses\n\nlogarithmically spaced, sufficient to calculate an LD50 with confidence limits, but not individually reported\n\nNo. of animals per sex per dose\n\n6-10 males and females, exact numbers per sex not specified\n\nControl animals\n\nno\n\nDetails on study design\n\n[Empty]\n\nStatistics\n\nLitchfield JT & Wilcoxon F, J. Pharmacol. Exp. Therapeutics (1949) 96: 99\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nmale/female\n\nDose descriptor\n\napproximate LD50\n\nEffect level\n\n1,200 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n960 \n\n\n1,500\n\nRemarks on result\n\n[Empty]\n\nMortality\n\n[Empty]\n\nClinical signs\n\n[Empty]\n\nBody weight\n\n[Empty]\n\nGross pathology\n\n[Empty]\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nMedian analgetic dose (AD50): 440 (373 - 520) mg/kg body weight\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nToxicity Category IV\n\nMigrated information\n\nCriteria used for interpretation of results: EU\n\nConclusions\n\nStudy suitable for use as part of a weight-of-evidence assessment.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5320,
          "status": "success"
        },
        "006 | Weight of evidence | Experimental study": {
          "document_id": "IUC5-2896a651-6eb8-4200-8e15-857da862afd3_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nweight of evidence\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards. Some experimental details documented, but emphasis on cat data, and on comparison with other literature. Observation period only 1 week. Performed 1955, before GLP and OECD guidelines were introduced.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Salicylamid- und Salicylsaeure-Vergiftung bei der Katze im Vergleich mit anderen Tieren](c7f01d06-acf4-3920-bc19-3f88e68262cf_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nLD50 determination (oral, gavage) in 6-7 groups of 5 animals each. Mortality count after 1 week.\n\nGLP compliance\n\nno\n\nTest type\n\nstandard acute method\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](6167d75d-1a51-33ac-a342-a73f9c861977_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrat\n\nStrain\n\nnot specified\n\nSex\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Source, age, weight: no data\n\n- Fasting period before study: yes (application in the morning after fasting)\n\n- Housing, diet, water, acclimation: no data\n\nENVIRONMENTAL CONDITIONS\n\n- no data\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nVehicle\n\nother:\n2% methyl cellulose (tylose), neutral or weakly alkaline\n\nDetails on oral exposure\n\nVEHICLE\n\n- Concentration in vehicle: 3%\n\n- Amount of vehicle (if gavage): dose dependent, no individual data\n\nDoses\n\n6-7 dose groups, individual doses not specified\n\nNo. of animals per sex per dose\n\n5 (sex not specified)\n\nControl animals\n\nno\n\nDetails on study design\n\n[Empty]\n\nStatistics\n\nLD50 calculation according to Behrens, in: Burn, Biolog. Auswertungsmeth., Springer 1937\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nnot specified\n\nDose descriptor\n\nLD50\n\nEffect level\n\n1,600 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\nMortality\n\n[Empty]\n\nClinical signs\n\n* other:\n  Paresis of hind limbs at 300 - 1000 mg/kg (transient: 30-90 min), narcosis at (sub-)lethal doses, respiratory paralysis as cause of death.\n  Rapid recovery of survivors, no delayed or persistent symptoms.\n\nBody weight\n\n[Empty]\n\nGross pathology\n\nHyperemia of liver and lungs, meninges, and gastro-intestinal tract; hemorrhages of lung alveoli and lung edema. Some rats showed a diffuse fatty degeneration of the liver and the convoluted tubuli of the kidney.\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nToxicity Category IV\n\nMigrated information\n\nCriteria used for interpretation of results: EU\n\nConclusions\n\nStudy suitable for use as part of a weight-of-evidence assessment.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5167,
          "status": "success"
        },
        "007 | Weight of evidence | Experimental study": {
          "document_id": "IUC5-7a423ba6-d092-4862-8fe9-210fd3c25441_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nweight of evidence\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n1952 or before\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nMostly a review article on various toxicological and pharmacological properties of salicylamide; however, author reports LD50 values found in own experiments. No experimental details, few informations on clinical symptoms. No guideline available.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Salicylamid](1a8724f0-b3c1-3a44-90c2-b7b0df88bcb2_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nDetermination of LD50, no details given\n\nGLP compliance\n\nno\n\nTest type\n\nother:\nAcute LD50, not further specified\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](d6fb1963-0956-368a-9554-ff9b7284f55a_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrat\n\nStrain\n\nnot specified\n\nSex\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nVehicle\n\nnot specified\n\nDetails on oral exposure\n\n[Empty]\n\nDoses\n\nno data\n\nNo. of animals per sex per dose\n\nno data\n\nControl animals\n\nnot specified\n\nDetails on study design\n\n[Empty]\n\nStatistics\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nnot specified\n\nDose descriptor\n\nLD50\n\nEffect level\n\n1,490 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\nMortality\n\n[Empty]\n\nClinical signs\n\n* other:\n  Sedation, ataxia, hind limb paresis; moribund animals: deep coma, respiratory paralysis.\n\nBody weight\n\n[Empty]\n\nGross pathology\n\n[Empty]\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nMore toxic by slow intravenous injection: 300 mg/kg body weight lethal.\n\nNo irritating effect on skin: 20% salicylamide ointment causes no skin erythema (no species stated).\n\nHuman data (self-test of the author): Daily administration of 3 - 6 g salicylamide for 8 days causes no proteinuria.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nToxicity Category IV\n\nMigrated information\n\nCriteria used for interpretation of results: EU\n\nConclusions\n\nStudy suitable for use as part of a weight-of-evidence assessment.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 4488,
          "status": "success"
        },
        "008 | Supporting | Experimental study": {
          "document_id": "IUC5-29077cf4-b06c-40c5-83f9-17bca8c4302d_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n1958 or before\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards. Experimental details well documented, but no data on acclimatization and housing. Results: LD50 after 1,2,4 and 7 days, incl. statistical evaluation. Performed 1958, before GLP and OECD guidelines were introduced. Sufficient numbers of animals investigated, but only one sex (males). No necropsy reported for any animals that died during the study or were sacrificed thereafter.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Comparative pharmacological and toxicological evaluation of N-acetyl-p-aminophenol, salicylamide, and acetylsalicylic acid](a6a6b553-d104-368a-9e6b-96bfda443208_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nOECD Guideline 401 (Acute Oral Toxicity)\n\nVersion / remarks\n\nPrinciples of LD50 determination followed as described in guideline\n\nDeviations\n\nyes\n\nOne sex only, no necropsy, no body weight development, no data on acclimatization and housing\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nno\n\nGLP not available at study time\n\nTest type\n\nstandard acute method\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](834526d1-13b7-379d-910c-910361745517_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nmouse\n\nStrain\n\nother:\nH L A\n\nSex\n\nmale\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Weight at study initiation: 17-30 g\n\n- Fasting period before study: 15-17 hours (study performed with and without fasting)\n\n- Housing: no data\n\n- Diet: ad libitum, except during 6-h observation period after application\n\n- Water: ad libitum, except during 6-h observation period after application\n\n- Acclimation period: no data\n\nENVIRONMENTAL CONDITIONS\n\n- Temperature (Â°C): 24.4 - 25.5\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nVehicle\n\nother:\n10% gum acacia suspension in water\n\nDetails on oral exposure\n\nVEHICLE\n\n- Concentration in vehicle: depending on dose (not stated)\n\n- Amount of vehicle (if gavage): 10 - 30 ml / kg\n\nMAXIMUM DOSE VOLUME APPLIED: 20 ml / kg\n\nDoses\n\n4 doses to fasted animals, to calculate LD50, not individually stated\n6 doses to non-fasted animals, to calculate LD50, not individually stated\n\nNo. of animals per sex per dose\n\n10 males\n\nControl animals\n\nno\n\nDetails on study design\n\n- Duration of observation period following administration: 7 days (for LD50 calculation), 21 days for some recovery experiments\n\n- Frequency of observations: 6 d, 1, 2, 4, 7 d for LD50; no weighing\n\n- Necropsy of survivors performed: no\n\n- Other examinations performed: clinical signs, body weight,organ weights, histopathology, other:\n\nStatistics\n\nLitchfield JT & Wilcoxon F, J. Pharmacol. Exptl. Therap. 96:99 (1949)\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nmale\n\nDose descriptor\n\nLD50\n\nEffect level\n\n1,200 \n\n\n \n\nmg/kg bw\n\nBased on\n\nact. ingr.\n\n95% CL\n\n1,090 \n\n\n1,321\n\nRemarks on result\n\nother:\nfasted animals, observation of mortality at 2, 4, and 7 days\n\n### #2 - Effect levels\n\nKey result\n\nSex\n\nmale\n\nDose descriptor\n\nLD50\n\nEffect level\n\n1,210 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n1,077 \n\n\n1,355\n\nRemarks on result\n\nother:\nfasted animals, observation of mortality at 1 day\n\n### #3 - Effect levels\n\nKey result\n\nSex\n\nmale\n\nDose descriptor\n\nLD50\n\nEffect level\n\n1,500 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n1,340 \n\n\n1,679\n\nRemarks on result\n\nother:\nnon-fasted animals, observation of mortality at 7 days\n\n### #4 - Effect levels\n\nKey result\n\nSex\n\nmale\n\nDose descriptor\n\nLD50\n\nEffect level\n\n1,590 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n1,355 \n\n\n1,867\n\nRemarks on result\n\nother:\nnon-fasted animals, observation of mortality at 1, 2, and 4 days\n\n### #5 - Effect levels\n\nKey result\n\nSex\n\nmale\n\nDose descriptor\n\nother:\nTD50 minimal neurological deficit dose\n\nEffect level\n\n87 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n59.6 \n\n\n126.7\n\nRemarks on result\n\nother:\nfasted animals, mean body weight 20.7 g, 24 h observation\n\n### #6 - Effect levels\n\nKey result\n\nSex\n\nmale\n\nDose descriptor\n\nother:\nTD50 minimal neurological deficit dose\n\nEffect level\n\n142 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n107.7 \n\n\n187\n\nRemarks on result\n\nother:\nnon-fasted animals, mean body weight 20.8 g, 24 h observation\n\nMortality\n\n[Empty]\n\nClinical signs\n\n* other:\n  Ataxia, depression (progressing to hypnosis at higher doses). Labored respiration and cyanosis prior to death (result of respiratory failure). Either prolonged period of depression, or intermittent episodes of hyperactivity, coarse tremors, and convulsion\n\nBody weight\n\n[Empty]\n\nGross pathology\n\n[Empty]\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\n[Empty]\n\nConclusions\n\nStudy conducted using non-preferred test species. Provided as supporting information.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 7228,
          "status": "success"
        },
        "009 | Supporting | Experimental study": {
          "document_id": "IUC5-626b5dcd-a7b4-48a3-854d-af3797071155_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n1946 or before\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards. Some experimental details documented, but no data on acclimatization and housing. Results: Mortalities up to 48 hours considered for graphical determination of LD50. Performed 1946, before GLP and OECD guidelines were introduced. Sufficient numbers of animals per group, but sex not stated.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [The toxicity and analgetic potency of salicylamide and certain of its derivatives as compared with established analgetic-antipyretic drugs](213959ac-c247-383e-83e6-7ac4750d9e1d_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline available\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nAcute oral LD50, with 15 or more animals per dose (sex not specified). No doses and mortalities per dose tabulated. Observation period only 48 hours; no necropsy reported.\n\nGLP compliance\n\nno\n\nPerformed 1946, before GLP and OECD guidelines were introduced.\n\nTest type\n\nstandard acute method\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](6167d75d-1a51-33ac-a342-a73f9c861977_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nmouse\n\nStrain\n\nnot specified\n\nSex\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nVehicle\n\nother:\n1-1.5 % gum tragacanth in water\n\nDetails on oral exposure\n\nVEHICLE\n\n- Concentration in vehicle: 5 or 10 % suspension\n\n- Amount of vehicle (if gavage): no data\n\n- Justification for choice of vehicle: No appropriate solvents found to produce a true solution under physiological conditions. Suspensions satisfactorily stable.\n\nMAXIMUM DOSE VOLUME APPLIED: no data\n\nDoses\n\nNo data\n\nNo. of animals per sex per dose\n\n15 or more\n\nControl animals\n\nno\n\nDetails on study design\n\n- Duration of observation period following administration: 48 hours (occasional later deaths considered due to extraneous factors)\n\n- Frequency of observations and weighing: No data\n\n- Necropsy of survivors performed: no\n\n- Other examinations performed: clinical signs\n\nStatistics\n\nLD50 approximated graphically\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nnot specified\n\nDose descriptor\n\nLD50\n\nEffect level\n\n1,400 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\nMortality\n\nNot tabulated\n\nClinical signs\n\n* other:\n  Depressant (or possibly paralytic) action\n\nBody weight\n\n[Empty]\n\nGross pathology\n\nNo data\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\n[Empty]\n\nConclusions\n\nStudy conducted using non-preferred test species. Provided as supporting information.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5149,
          "status": "success"
        },
        "010 | Supporting | Experimental study": {
          "document_id": "IUC5-a355dd4e-4518-4a3b-aaff-bd3461470425_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards. Some experimental details documented, but emphasis on cat data, and on comparison with other literature. Observation period only 1 week. Performed 1955, before GLP and OECD guidelines were introduced.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Salicylamid- und Salicylsaeure-Vergiftung bei der Katze im Vergleich mit anderen Tieren](c7f01d06-acf4-3920-bc19-3f88e68262cf_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline available\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nLD50 determination (oral, gavage) in 6-7 groups of 5 animals each. Mortality count after 1 week.\n\nGLP compliance\n\nno\n\nTest type\n\nstandard acute method\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](6167d75d-1a51-33ac-a342-a73f9c861977_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nmouse\n\nStrain\n\nnot specified\n\nSex\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Source, age, weight: no data\n\n- Fasting period before study: yes (application in the morning after fasting)\n\n- Housing, diet, water, acclimation: no data\n\nENVIRONMENTAL CONDITIONS\n\n- no data\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nVehicle\n\nother:\n2% methyl cellulose (tylose), neutral or weakly alkaline\n\nDetails on oral exposure\n\nVEHICLE\n\n- Concentration in vehicle: 3%\n\n- Amount of vehicle (if gavage): dose dependent, no individual data\n\nDoses\n\n6-7 dose groups, individual doses not specified\n\nNo. of animals per sex per dose\n\n5 (sex not specified)\n\nControl animals\n\nno\n\nDetails on study design\n\n[Empty]\n\nStatistics\n\nLD50 calculation according to Behrens, in: Burn, Biolog. Auswertungsmeth., Springer 1937\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nnot specified\n\nDose descriptor\n\nLD50\n\nEffect level\n\n1,100 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\nMortality\n\n[Empty]\n\nClinical signs\n\n* other:\n  Paresis of hind limbs at 300 - 1000 mg/kg (transient: 30-90 min), narcosis at (sub-)lethal doses, respiratory paralysis as cause of death.\n  Rapid recovery of survivors, no delayed or persistent symptoms.\n\nBody weight\n\n[Empty]\n\nGross pathology\n\nHyperemia of liver and lungs, meninges, and gastro-intestinal tract; hemorrhages of lung alveoli and lung edema.\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\n[Empty]\n\nConclusions\n\nStudy conducted using non-preferred test species. Provided as supporting information.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5003,
          "status": "success"
        },
        "011 | Supporting | Experimental study": {
          "document_id": "IUC5-e79bdd83-32e6-439e-bb49-c2bcbea76638_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n1952 or before\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nMostly a review article on various toxicological and pharmacological properties of salicylamide; however, author cites LD50 values found in own experiments. No experimental details, few informations on clinical symptoms. No guideline available.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Salicylamid](1a8724f0-b3c1-3a44-90c2-b7b0df88bcb2_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline available\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nDetermination of LD50, no details given\n\nGLP compliance\n\nno\n\nTest type\n\nother:\nAcute LD50, not further specified\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](d6fb1963-0956-368a-9554-ff9b7284f55a_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nmouse\n\nStrain\n\nnot specified\n\nSex\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nVehicle\n\nnot specified\n\nDetails on oral exposure\n\n[Empty]\n\nDoses\n\nno data\n\nNo. of animals per sex per dose\n\nno data\n\nControl animals\n\nnot specified\n\nDetails on study design\n\n[Empty]\n\nStatistics\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nnot specified\n\nDose descriptor\n\nLD50\n\nEffect level\n\n1,140 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\nMortality\n\n[Empty]\n\nClinical signs\n\n* other:\n  Sedation, ataxia, hind limb paresis; moribund animals: deep coma, respiratory paralysis.\n\nBody weight\n\n[Empty]\n\nGross pathology\n\n[Empty]\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\n[Empty]\n\nConclusions\n\nStudy conducted using non-preferred test species. Provided as supporting information.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 4138,
          "status": "success"
        },
        "012 | Supporting | Experimental study": {
          "document_id": "IUC5-f109b4a6-d896-4bf9-b361-5b7d86018eaa_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n1958 or before\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards. Experimental details well documented, but no data on acclimatization and housing. Results: LD50 after 1,2,4 and 7 days, incl. statistical evaluation. Performed 1958, before GLP and OECD guidelines were introduced. Sufficient numbers of animals investigated, but the sex was not specified. No necropsy reported for any animals that died during the study or were sacrificed thereafter.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Comparative pharmacological and toxicological evaluation of N-acetyl-p-aminophenol, salicylamide, and acetylsalicylic acid](a6a6b553-d104-368a-9e6b-96bfda443208_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nOECD Guideline 401 (Acute Oral Toxicity)\n\nVersion / remarks\n\nPrinciples of LD50 followed, as many years later described in guideline\n\nDeviations\n\nyes\n\nSex not specified, no necropsy, no body weight development, no data on acclimatization and housing\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nno\n\nGLP not available at study time\n\nTest type\n\nstandard acute method\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](834526d1-13b7-379d-910c-910361745517_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nguinea pig\n\nStrain\n\nnot specified\n\nSex\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Weight at study initiation: 180-310 g\n\n- Fasting period before study: 15-17 hours\n\n- Housing: no data\n\n- Diet: ad libitum, except during 6-h observation period after application\n\n- Water: ad libitum, except during 6-h observation period after application\n\n- Acclimation period: no data\n\nENVIRONMENTAL CONDITIONS\n\n- Temperature (Â°C): 24.4 - 25.5\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nVehicle\n\nother:\n10% gum acacia suspension in water\n\nDetails on oral exposure\n\nVEHICLE\n\n- Concentration in vehicle: depending on dose (not stated)\n\n- Amount of vehicle (if gavage): 10 ml / kg\n\nMAXIMUM DOSE VOLUME APPLIED: 20 ml / kg\n\nDoses\n\n10 doses to calculate LD50, not individually stated\n\nNo. of animals per sex per dose\n\n10 animals (sex not specified)\n\nControl animals\n\nno\n\nDetails on study design\n\n- Duration of observation period following administration: 7 days (for LD50 calculation), 21 days for some recovery experiments\n\n- Frequency of observations: 6 d, 1, 2, 4, 7 d for LD50; no weighing\n\n- Necropsy of survivors performed: no\n\n- Other examinations performed: clinical signs, body weight,organ weights, histopathology, other:\n\nStatistics\n\nLitchfield JT & Wilcoxon F, J. Pharmacol. Exptl. Therap. 96:99 (1949)\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nmale\n\nDose descriptor\n\nLD50\n\nEffect level\n\n1,730 \n\n\n \n\nmg/kg bw\n\nBased on\n\nact. ingr.\n\n95% CL\n\n1,516 \n\n\n1,974\n\nRemarks on result\n\nother:\nfasted animals, observation of mortality at 4 and 7 days\n\n### #2 - Effect levels\n\nKey result\n\nSex\n\nmale\n\nDose descriptor\n\nLD50\n\nEffect level\n\n1,750 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n1,511 \n\n\n2,025\n\nRemarks on result\n\nother:\nfasted animals, observation of mortality at 2 days\n\n### #3 - Effect levels\n\nKey result\n\nSex\n\nmale\n\nDose descriptor\n\nLD50\n\nEffect level\n\n1,800 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n1,556 \n\n\n2,082\n\nRemarks on result\n\nother:\nfasted animals, observation of mortality at 1 day\n\nMortality\n\n[Empty]\n\nClinical signs\n\n* other:\n  Ataxia, depression (progressing to hypnosis at higher doses). Labored respiration and cyanosis prior to death (result of respiratory failure). Occasionally (in some animals) bizarre motions (rapid vertical or horizontal movements of the head, rapid circul\n\nBody weight\n\n[Empty]\n\nGross pathology\n\n[Empty]\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\n[Empty]\n\nConclusions\n\nStudy conducted using non-preferred test species. Provided as supporting information.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 6340,
          "status": "success"
        },
        "013 | Supporting | Experimental study": {
          "document_id": "IUC5-6e11a92a-3b7f-4b42-ab18-55dc813f3ece_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards. Some experimental details documented, but emphasis on cat data, and on comparison with other literature. Observation period only 1 week. Performed 1955, before GLP and OECD guidelines were introduced.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Salicylamid- und Salicylsaeure-Vergiftung bei der Katze im Vergleich mit anderen Tieren](c7f01d06-acf4-3920-bc19-3f88e68262cf_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline available\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nLD50 determination (oral, gavage) in 6-7 groups of 5 animals each. Mortality count after 1 week.\n\nGLP compliance\n\nno\n\nTest type\n\nstandard acute method\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](6167d75d-1a51-33ac-a342-a73f9c861977_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nguinea pig\n\nStrain\n\nnot specified\n\nSex\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Source, age, weight: no data\n\n- Fasting period before study: yes (application in the morning after fasting)\n\n- Housing, diet, water, acclimation: no data\n\nENVIRONMENTAL CONDITIONS\n\n- no data\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nVehicle\n\nother:\n2% methyl cellulose (tylose), neutral or weakly alkaline\n\nDetails on oral exposure\n\nVEHICLE\n\n- Concentration in vehicle: 5%\n\n- Amount of vehicle (if gavage): dose dependent, no individual data\n\nDoses\n\n6-7 dose groups, individual doses not specified\n\nNo. of animals per sex per dose\n\n5 (sex not specified)\n\nControl animals\n\nno\n\nDetails on study design\n\n[Empty]\n\nStatistics\n\nLD50 calculation according to Behrens, in: Burn, Biolog. Auswertungsmeth., Springer 1937\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nnot specified\n\nDose descriptor\n\nLD50\n\nEffect level\n\n1,800 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\nMortality\n\n[Empty]\n\nClinical signs\n\n* other:\n  Similar to other species, not explicitly specified\n\nBody weight\n\n[Empty]\n\nGross pathology\n\nSimilar to other species, not explicitly specified. One guinea pig showed pronounced diffuse fatty degeneration of the liver after 10 hours in the narcotic state.\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\n[Empty]\n\nConclusions\n\nStudy conducted using non-preferred test species. Provided as supporting information.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 4904,
          "status": "success"
        },
        "014 | Supporting | Experimental study": {
          "document_id": "IUC5-5808aa27-9b07-4622-aac1-84b8c8e1953d_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n1946 or before\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards. Some experimental details documented, but no data on acclimatization and housing. Results: Mortalities up to 48 hours considered for graphical determination of LD50. Performed 1946, before GLP and OECD guidelines were introduced. Sufficient numbers of animals per group, but sex not stated.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [The toxicity and analgetic potency of salicylamide and certain of its derivatives as compared with established analgetic-antipyretic drugs](e8fe096b-45d4-3b83-a459-c0edc904d9a1_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline available\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nAcute oral LD50, with 6 animals per dose (sex not specified). No doses and mortalities per dose tabulated. Observation period only 48 hours; no necropsy reported.\n\nGLP compliance\n\nno\n\nPerformed 1946, before GLP and OECD guidelines were introduced.\n\nTest type\n\nstandard acute method\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](6167d75d-1a51-33ac-a342-a73f9c861977_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrabbit\n\nStrain\n\nnot specified\n\nSex\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nVehicle\n\nother:\n1-1.5 % gum tragacanth in water\n\nDetails on oral exposure\n\nVEHICLE\n\n- Concentration in vehicle: 5 or 10 % suspension\n\n- Amount of vehicle (if gavage): no data\n\n- Justification for choice of vehicle: No appropriate solvents found to produce a true solution under physiological conditions. Suspensions satisfactorily stable.\n\nMAXIMUM DOSE VOLUME APPLIED: no data\n\nDoses\n\nNo doses higher than 3000 mg/kg, since the bulk of the dose in usable suspension approached stomach capacity\n\nNo. of animals per sex per dose\n\n6\n\nControl animals\n\nno\n\nDetails on study design\n\n- Duration of observation period following administration: 48 hours (occasional later deaths considered due to extraneous factors)\n\n- Frequency of observations and weighing: No data\n\n- Necropsy of survivors performed: no\n\n- Other examinations performed: clinical signs\n\nStatistics\n\nNone (less than 50% mortality at highest dose)\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nnot specified\n\nDose descriptor\n\nLD50\n\nEffect level\n\n>=\n3,000 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\nMortality\n\nLess than 50% at highest dose\n\nClinical signs\n\n* other:\n  Depressant (or possibly paralytic) action\n\nBody weight\n\n[Empty]\n\nGross pathology\n\nNo data\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\n[Empty]\n\nConclusions\n\nStudy conducted using non-preferred test species. Provided as supporting information.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5269,
          "status": "success"
        },
        "015 | Supporting | Experimental study": {
          "document_id": "IUC5-6fe72621-01f3-4301-9ad9-c5be12114196_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards. Some experimental details documented, but emphasis on cat data, and on comparison with other literature. Observation period only 1 week. Performed 1955, before GLP and OECD guidelines were introduced.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Salicylamid- und Salicylsaeure-Vergiftung bei der Katze im Vergleich mit anderen Tieren](c7f01d06-acf4-3920-bc19-3f88e68262cf_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline available\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nLD50 determination (oral, gavage) in 6 groups of 5 animals each. Mortality count after 1 week.\n\nGLP compliance\n\nno\n\nTest type\n\nother:\napproximate LD50\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](6167d75d-1a51-33ac-a342-a73f9c861977_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrabbit\n\nStrain\n\nnot specified\n\nSex\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Source, age, weight: no data\n\n- Fasting period before study: yes (application in the morning after fasting)\n\n- Housing, diet, water, acclimation: no data\n\nENVIRONMENTAL CONDITIONS\n\n- no data\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nVehicle\n\nother:\n2% methyl cellulose (tylose), neutral or weakly alkaline\n\nDetails on oral exposure\n\nVEHICLE\n\n- Concentration in vehicle: 5%\n\n- Amount of vehicle (if gavage): dose dependent, no individual data\n\nDoses\n\n6 dose groups mentioned: 2000 mg/kg, 3000 mg/kg, 3250 mg/kg (2 groups), 3500 mg/kg, 4000 mg/kg\n\nNo. of animals per sex per dose\n\n5 (sex not specified)\n\nControl animals\n\nno\n\nDetails on study design\n\n[Empty]\n\nStatistics\n\nLD50 calculation according to Behrens, in: Burn, Biolog. Auswertungsmeth., Springer 1937\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nnot specified\n\nDose descriptor\n\napproximate LD50\n\nEffect level\n\nca.\n3,200 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\nMortality\n\n3000 mg/kg: 0/5\n3250 mg/kg: 4/5 (in two groups)\n3500 mg/kg: 4/5\n4000 mg/kg: 4/5\n\nClinical signs\n\n* other:\n  Paresis of hind limbs at 300 - 1000 mg/kg (transient: 30-90 min), narcosis at (sub-)lethal doses, respiratory paralysis as cause of death.\n  Rapid recovery of survivors, no delayed or persistent symptoms.\n\nBody weight\n\n[Empty]\n\nGross pathology\n\nHyperemia of liver and lungs, meninges, and gastro-intestinal tract; hemorrhages of lung alveoli and lung edema.\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\n[Empty]\n\nConclusions\n\nStudy conducted using non-preferred test species. Provided as supporting information.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5139,
          "status": "success"
        },
        "016 | Supporting | Experimental study": {
          "document_id": "IUC5-514b9172-d60d-454f-b6b6-936f948fbee3_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards. Some experimental details documented, emphasis on cat data, and reasons for higher toxicity in cats, compared with other species. Observation period only 1 week. Performed 1955, before GLP and OECD guidelines were introduced.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Salicylamid- und Salicylsaeure-Vergiftung bei der Katze im Vergleich mit anderen Tieren](c7f01d06-acf4-3920-bc19-3f88e68262cf_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline available\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nApproximate LD50 determination (oral, gavage), number of dose groups and animals not specified. Mortality count after 1 week.\n\nGLP compliance\n\nno\n\nTest type\n\nother:\nApproximate LD50\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](6167d75d-1a51-33ac-a342-a73f9c861977_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\ncat\n\nStrain\n\nnot specified\n\nSex\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Source, age, weight: no data\n\n- Fasting period before study: yes (application in the morning after fasting)\n\n- Housing, diet, water, acclimation: no data\n\nENVIRONMENTAL CONDITIONS\n\n- no data\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nVehicle\n\nother:\n2% methyl cellulose (tylose), neutral or weakly alkaline\n\nDetails on oral exposure\n\nVEHICLE\n\n- Concentration in vehicle: 5%\n\n- Amount of vehicle (if gavage): dose dependent, no individual data\n\nDoses\n\nIndividual doses mentioned: 50, 75, 100, and 150 mg/kg\n\nNo. of animals per sex per dose\n\nno data\n\nControl animals\n\nno\n\nDetails on study design\n\n[Empty]\n\nStatistics\n\nLD50 calculation according to Behrens, in: Burn, Biolog. Auswertungsmeth., Springer 1937\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nnot specified\n\nDose descriptor\n\napproximate LD50\n\nEffect level\n\n>\n100 \n\n<\n150 \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\nMortality\n\n50 and 75 mg/kg: 2 survivors (of 5?)\n100 mg/kg: 4 survivors (of 5?)\n150 mg/kg: 6 dead (100%)\nMortalities occurred 5-8 days after application\n\nClinical signs\n\n* other:\n  Vomiting shortly after application. Slight transient paresis of hind limbs at 100 mg/kg. Slight albuminuria (2-4 days). Moribund animals died after 5-8 days , with uremic symptoms incl. vomiting and coma. Uremia proven by non-protein nitrogen determinati\n\nBody weight\n\n[Empty]\n\nGross pathology\n\nSerous-catarrhal gastroenterocolitis. Cerebral edema. Hyperemia of the lungs, with emphysematic and atelectatic regions. Ascites and pleural effusion. Histology of the kidney: Glomerulo-tubulonephrosis.\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\n[Empty]\n\nConclusions\n\nStudy conducted using non-preferred test species. Provided as supporting information.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5339,
          "status": "success"
        },
        "017 | Supporting | Experimental study": {
          "document_id": "IUC5-e26ff5c3-f4a6-4094-8afb-29bcde889112_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Acute toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards. Some experimental details documented, but emphasis on cat data, and on comparison with other literature. Observation period only 1 week. Performed 1955, before GLP and OECD guidelines were introduced.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Salicylamid- und Salicylsaeure-Vergiftung bei der Katze im Vergleich mit anderen Tieren](cd5ba109-158d-3206-abc2-aa1f2fddaca6_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline available\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nApproximate LD50 determination (oral, gavage), number of dose groups and animals not specified. Mortality count after 1 week.\n\nGLP compliance\n\nno\n\nTest type\n\nother:\nApproximate LD50\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](6167d75d-1a51-33ac-a342-a73f9c861977_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\ndog\n\nStrain\n\nnot specified\n\nSex\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Source, age, weight: no data\n\n- Fasting period before study: yes (application in the morning after fasting)\n\n- Housing, diet, water, acclimation: no data\n\nENVIRONMENTAL CONDITIONS\n\n- no data\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nVehicle\n\nother:\n2% methyl cellulose (tylose), neutral or weakly alkaline\n\nDetails on oral exposure\n\nVEHICLE\n\n- Concentration in vehicle: 5%\n\n- Amount of vehicle (if gavage): dose dependent, no individual data\n\nDoses\n\nIndividual doses mentioned: 400 and 800 mg/kg\n\nNo. of animals per sex per dose\n\nno data\n\nControl animals\n\nno\n\nDetails on study design\n\n[Empty]\n\nStatistics\n\nLD50 calculation according to Behrens, in: Burn, Biolog. Auswertungsmeth., Springer 1937\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPreliminary study\n\n[Empty]\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nnot specified\n\nDose descriptor\n\napproximate LD50\n\nEffect level\n\n>\n800 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\nMortality\n\n[Empty]\n\nClinical signs\n\n* other:\n  Vomiting. Slight paresis of hind limbs, staggering gait. Rapid recovery (1-2 h). No albuminuria. No delayed or persistent symptoms (observation period 2 years).\n\nBody weight\n\n[Empty]\n\nGross pathology\n\nNo findings reported\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\n[Empty]\n\nConclusions\n\nStudy conducted using non-preferred test species. Provided as supporting information.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 4892,
          "status": "success"
        }
      },
      "7.2.2 Acute toxicity: inhalation": {},
      "7.2.3 Acute toxicity: dermal": {},
      "7.2.4 Acute toxicity: other routes": {
        "001 | Supporting | Experimental study": {
          "document_id": "IUC5-176fa69b-846c-41bd-aa76-c4dbef3af098_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Acute toxicity: other routes\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: other routes\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n1946 or before\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards. Experimental details documented, but no data on acclimatization and housing. Results: Mortalities tabulated after 1 and 7 days, but no statistical determination of LD50. Performed 1946, before GLP and OECD guidelines were introduced. Sufficient numbers of animals investigated, but sex not stated.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Pharmacological and toxicological studies on salicylamide](1730da1b-faf3-3ca2-977e-ee4b254b9769_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline available\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nAcute toxicity study with intraperitoneal application, otherwise similar to acute oral toxicity.\n\nGLP compliance\n\nno\n\nGLP not available at study time\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](d9154718-77e0-3cf0-8f8e-b6f81727a39e_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrat\n\nStrain\n\nnot specified\n\nSex\n\nmale/female\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\nintraperitoneal\n\nVehicle\n\nother:\n0.5% gum tragacanth in water\n\nDetails on exposure\n\n[Empty]\n\nDoses\n\n250, 500, 1000, and 1500 mg/kg body weight\n\nNo. of animals per sex per dose\n\n10 (sex not specified)\n\nControl animals\n\nno\n\nDetails on study design\n\n- Duration of observation period following administration: 7 days\n\n- Frequency of observations: 15, 30, 60, 90 min, 2, 3, 5, 24 h, daily until day 7; no weighing reported\n\n- Necropsy of animals dying on test: yes\n\n- Necropsy of survivors: not reported\n\n- Other examinations performed: clinical signs\n\nStatistics\n\nnone\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nnot specified\n\nDose descriptor\n\nLD50\n\nEffect level\n\n>\n500 \n\n<\n1,000 \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\nother:\nNo statistical evaluation; mortalities 2/10 at 500 mg/kg bw; 9/10 at 1000 mg/kg bw\n\nMortality\n\nMortalities 1/10 at 250 mg/kg bw; 2/10 at 500 mg/kg bw; 9/10 at 1000 mg/kg bw; 10/10 at 1500 mg/kg bw\nAll mortalities within 2 h after application, except for one animal in the lowest dose group, which was reported to be in good condition, and whose time and circumstances of death are not stated\n\nClinical signs\n\nHeavy depression (dose-dependent), hind leg paralysis\nRecovery of survivors within 24 hours\n\nBody weight\n\nno data\n\nGross pathology\n\nCongestion and hemorrhages of the lungs\nHyperemia of the meninges\nAll other organs grossly normal\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\n[Empty]\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5058,
          "status": "success"
        },
        "002 | Supporting | Experimental study": {
          "document_id": "IUC5-15425418-76f0-4d72-98b8-07a2b8cf78aa_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Acute toxicity: other routes\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nacute toxicity: other routes\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\nbefore 1953\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards, years before OECD guidelines were developed. Main focus was laid on analgetic activity, approximate median lethal dose (LD50) was determined in parallel, in the same animals that were used for pain response. Observation time was only 48 hours. Only few experimental details and no individual result data are reported.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [The toxicity and analgetic activity of some congeners of salicylamide](6fb8efdf-2a3d-390f-8151-3fc6ffb46834_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline available\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\n4 male and female rats were injected intraperitoneally with salicylamide at several dosage levels (spaced by factors of 2, starting at 2000 mg/kg body weight) and tested in a pressure analgesiometric method (on the tail) at several time points, to determine the threshold force that elicited a cry response. Mortality was recorded in the same treated animals during a 48-hour observation period, and used to calculate an approximate median lethal dose (LD50). No husbandry conditions and no symptoms, body weights, necropsy results etc. are recorded.\n\nGLP compliance\n\nno\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](d6fb1963-0956-368a-9554-ff9b7284f55a_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrat\n\nStrain\n\nWistar\n\nSex\n\nmale/female\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Weight at study initiation: 50-80g\n\n- Housing, diet, water, acclimation: no data\n\nENVIRONMENTAL CONDITIONS\n\n- no data\n\n### Administration / exposure\n\nRoute of administration\n\nintraperitoneal\n\nVehicle\n\nother:\n0.25% tragacanth in water\n\nDetails on exposure\n\n[Empty]\n\nDoses\n\nFirst and maximum dose: 2000 mg/kg body weight, lower doses spaced with a factor 2 (one half of previous dose), until a no-activity dose was established for pain response.\n\nNo. of animals per sex per dose\n\n4 males and females, exact numbers per sex not specified\n\nControl animals\n\nno\n\nDetails on study design\n\n[Empty]\n\nStatistics\n\nLitchfield JT & Wilcoxon F, J. Pharmacol. Exp. Therapeutics (1949) 96: 99\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Effect levels\n\n### #1 - Effect levels\n\nKey result\n\nSex\n\nmale/female\n\nDose descriptor\n\nother:\napproximate LD50\n\nEffect level\n\n600 \n\n\n \n\nmg/kg bw\n\nBased on\n\ntest mat.\n\n95% CL\n\n[Empty]\n\nRemarks on result\n\n[Empty]\n\nMortality\n\n[Empty]\n\nClinical signs\n\n[Empty]\n\nBody weight\n\n[Empty]\n\nGross pathology\n\n[Empty]\n\nOther findings\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nMedian analgetic dose (AD50):175 mg/kg body weight\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\n[Empty]\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5071,
          "status": "success"
        }
      },
      "S-01 | Summary": {
        "document_id": "IUC5-d17b9f83-bb13-4968-b0f5-23b28da04f18_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
        "markdown_content": "#### Acute Toxicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Empty]\n\nJustification\n\n[Empty]\n\nUse restricted to selected regulatory programmes\n\n[Empty]\n\n### Description of key information\n\n```\nOral: LD50= 980 mg/kg bw (C.I. 817-1176 mg/kg bw), male, rat, OECD 401, Boxill 1958  \nOral: LD50 >1600 <2000 mg/kg bw, rat, OECD 401, Ichniowski 1946  \nOral: LD50=1400 mg/kg bw, rat, no guideline, Hart 1947  \nOral: LD50=1200 (960-1500) mg/kg bw, male/female, rat, no guideline, Way 1953  \nOral: LD50=1600 mg/kg bw, rat, no guideline, Bekemeier 1955  \nOral: LD50=1490 mg/kg bw, rat, no guideline, Drebinger 1952\n```\n\n### Key value for chemical safety assessment\n\n### Acute toxicity: via oral route\n\nLink to relevant study record(s)\n\n* [002 | Weight of evidence | Experimental study](IUC5-e9c0c6e2-5561-4c8d-ae22-97e834b56ee0_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n* [003 | Weight of evidence | Experimental study](IUC5-b3741dda-4555-4d14-af33-f59753beb87b_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n* [004 | Weight of evidence | Experimental study](IUC5-b5e15b41-92d9-45a8-bcd4-86a60976bb02_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n* [005 | Weight of evidence | Experimental study](IUC5-2ef24ed8-7473-49ec-a7a7-48627e40e82c_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n* [006 | Weight of evidence | Experimental study](IUC5-2896a651-6eb8-4200-8e15-857da862afd3_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n* [007 | Weight of evidence | Experimental study](IUC5-7a423ba6-d092-4862-8fe9-210fd3c25441_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nEndpoint conclusion\n\nadverse effect observed\n\nDose descriptor\n\nLD50\n\nEffect level\n\n980 \n\n\n \n\nmg/kg bw\n\n### Acute toxicity: via dermal route\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\n### Acute toxicity: via inhalation route\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nPhysical form\n\n[Empty]\n\n### Acute toxicity: other routes\n\nLink to relevant study record(s)\n\n[Empty]\n\n### Justification for classification or non-classification\n\n**Acute Oral Toxicity**\n\nThe key value selected for the acute oral toxicity, LD50=980mg/kg bw leads to the classification of the substance as Category 4, H302, Harmful if swallowed, according to the criteria in Regulation (EC) No. 1272/2008, Annex I, Part 3, 3.1.2.\n\n**Acute Dermal and Inhalation Toxicity**\n\nNo experimental data are available which are suitable for the purposes of classification and labelling.\n\n### Additional information\n\n**Oral toxicity to rats**\n\nA large body of information on the acute toxicity of salicylamide is available from articles following scientific standards and published in peer-reviewed journals, but all studies were performed before the introduction of OECD testing guidelines and GLP. However, compared with present-day methods, much larger numbers of animals were tested, and the agreement between different authors is high, independent of possible differences in animal strains, vehicles, and other experimental parameters: For the oral LD50 in rats, values from 980 to 1600 mg/kg bw are reported.\n\nThe study by Boxill (1958) is considered to be the most conservative and reliable, based on the quantity of information (including statistical confidence limits) reported, although only males were tested, and the observation period was only 7 days. No sex-specific LD50 values are reported in any of the studies, therefore the more susceptible sex cannot be determined. However, the value for males given by Boxill, 980 mg/kg bw, is 20% less than the lowest value for both sexes, 1200 mg/kg bw (Way, 1953). Since all deaths reported in rats by any of the authors occurred hours or (at latest) a few days after application, it is also unlikely that the limited observation time compromised the result. The lowest LD50, for male rats at 980 mg/kg bw, is selected as the most conservative value and is carried forward for risk assessment and classification and labelling.\n\n**Oral toxicity to other species**\n\nA wide variety of species was tested and compared with rats. Mice (1100-1400 mg/kg bw) and guinea pigs (1730-1800 mg/kg bw) had LD50 values similar to those found in rats, whereas rabbits (>3000 mg/kg bw) were less responsive. The only reported value for dogs (>800 mg/kg bw, no mortality) does not indicate any particular susceptibility, since no higher doses were tested. In cats, on the other hand, an almost tenfold lower LD50 (<150 mg/kg) and a completely different mode of action was observed. Deaths were delayed by several days, and were caused by kidney failure (glomerulo-tubulonephrosis and uremia), whereas in all other species, respiratory paralysis was the cause of death. This is a well known species-specific effect (Bekemeier, H., Proceedings of the European Society of Toxicology, 1975, 16, 229 -232).\n\n**Other routes of application**\n\nNo experimental data were found on dermal and inhalation toxicity. However, two consistent values for the intraperitoneal LD50 exist: 500 -1000 mg/kg bw (Ichniowski 1946), and 600 mg/kg bw (Way 1953).\n\nThe available acute oral toxicity data is considered to be complete and adequate for risk assessment and classification and labelling, based on a weight-of-evidence approach, according to Regulation (EC) No. 1907/2006, Annex XI, section 1.2.\n\n**Justification for selection of acute toxicity â oral endpoint**   \nA large body of information on the acute toxicity of salicylamide is available from articles following scientific standards and published in peer-reviewed journals, but all studies were performed before the introduction of OECD testing guidelines and GLP. The study by Boxill (1958) is considered to be the most conservative and reliable, based on the quantity of information (including statistical confidence limits) reported, although only males were tested, and the observation period was only 7 days.\n\n### Attached background material\n\nBack to top",
        "content_length": 6026,
        "status": "success"
      }
    },
    "7.3 Irritation / corrosion": {
      "7.3.1 Skin irritation / corrosion": {
        "001 | Key | Experimental study": {
          "document_id": "IUC5-a747b47b-9da3-409f-b991-440938476443_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Skin irritation / corrosion\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nskin corrosion: in vitro / ex vivo\n\nin vitro\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nkey study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n26-Apr-2010\n\nEnd date\n\n30-Apr-2010\n\nRemark\n\n26 April 2010 - 30 April 2010\n\nReliability\n\n1 (reliable without restriction)\n\nRationale for reliability incl. deficiencies\n\nother:\nGLP compliant, guideline study, no restrictions, fully adequate for assessment\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Reference](68fc12cd-c4df-3056-bca1-438ee8da7c90_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\naccording to guideline\n\nGuideline\n\nother:\nOECD 431\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\nno\n\n### #2 - Test guideline\n\nQualifier\n\naccording to guideline\n\nGuideline\n\nEU Method B.40 (In Vitro Skin Corrosion: Transcutaneous Electrical Resistance Test (TER))\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\nno\n\nPrinciples of method if other than guideline\n\nNot applicable\n\nGLP compliance\n\nyes\n\n### Test material\n\nTest material information\n\n[Test material information](d5d2a503-0de7-3524-b498-f4c386c4db5c_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### In vitro test system\n\nTest system\n\n[Empty]\n\nSource species\n\n[Empty]\n\nCell type\n\n[Empty]\n\nCell source\n\n[Empty]\n\nSource strain\n\n[Empty]\n\nDetails on animal used as source of test system\n\n[Empty]\n\nJustification for test system used\n\n[Empty]\n\nVehicle\n\n[Empty]\n\nDetails on test system\n\n[Empty]\n\nControl samples\n\n[Empty]\n\nAmount/concentration applied\n\n[Empty]\n\nDuration of treatment / exposure\n\n[Empty]\n\nDuration of post-treatment incubation (if applicable)\n\n[Empty]\n\nNumber of replicates\n\n[Empty]\n\n### Test animals\n\nSpecies\n\nother:\nin vitro using EpiDerm inserts (3-dimensional human skin model, comprising a reconstructed epidermis with a functional stratum corneum, supplied by MatTek Corporation, Ashland, Massachusetts, USA)\n\nStrain\n\nother:\nnot applicable\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Test system\n\nType of coverage\n\nother:\nnot applicable\n\nPreparation of test site\n\nother:\nnot applicable\n\nVehicle\n\nunchanged (no vehicle)\n\nControls\n\n* other:\n  not applicable\n\nAmount / concentration applied\n\n25 mg\n\nDuration of treatment / exposure\n\n3 minutes and 1 hour\n\nObservation period\n\nnot applicable\n\nNumber of animals\n\nnot applicable\n\nDetails on study design\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### In vitro\n\n### Results\n\n### #1 - Results\n\nKey result\n\nIrritation / corrosion parameter\n\n% tissue viability\n\nRun / experiment\n\nexperiment 1\n\nValue\n\n96\n\nVehicle controls validity\n\n[Empty]\n\nNegative controls validity\n\n[Empty]\n\nPositive controls validity\n\n[Empty]\n\nRemarks on result\n\nother:\n3 minute treatment\n\n### #2 - Results\n\nKey result\n\nIrritation / corrosion parameter\n\n% tissue viability\n\nRun / experiment\n\nexperiment 2\n\nValue\n\n101\n\nVehicle controls validity\n\n[Empty]\n\nNegative controls validity\n\n[Empty]\n\nPositive controls validity\n\n[Empty]\n\nRemarks on result\n\nother:\n3 minute treatment\n\n### #3 - Results\n\nKey result\n\nIrritation / corrosion parameter\n\n% tissue viability\n\nRun / experiment\n\nexperiment 1\n\nValue\n\n94\n\nVehicle controls validity\n\n[Empty]\n\nNegative controls validity\n\n[Empty]\n\nPositive controls validity\n\n[Empty]\n\nRemarks on result\n\nother:\n1 hour treatment\n\n### #4 - Results\n\nKey result\n\nIrritation / corrosion parameter\n\n% tissue viability\n\nRun / experiment\n\nexperiment 2\n\nValue\n\n102\n\nVehicle controls validity\n\n[Empty]\n\nNegative controls validity\n\n[Empty]\n\nPositive controls validity\n\n[Empty]\n\nRemarks on result\n\nother:\n1 hour treatment\n\nOther effects / acceptance of results\n\n[Empty]\n\n### In vivo\n\n### Results\n\nIrritant / corrosive response data\n\n[Empty]\n\nOther effects\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n3 minute: The viability of the tissues was 96% and 101% in experiments 1 and 2, respectively. The viability of tissues treated with the positive control was 37% and 24% confirming appropriate performance of the assay.\n\n \n\n1 hour: The viability of the tissues was 94% and 101% in experiments 1 and 2, respectively. The viability of tissues treated with the positive control was 20% and 14% confirming appropriate performance of the assay.\n\n \n\nNo other test substance treatment related effects were observed.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nother:\nnon corrosive\n\nCriteria used for interpretation of results: EU\n\nConclusions\n\nThe substance was not corrosive to the in vitro skin model EpiDerm.\n\nExecutive summary\n\nIn order to assess the in vitro skin corrosivity potential of salicylamide, duplicate EpiDerm inserts were treated with the substance, distilled water (negative control) and 8N potassium hydroxide (positive control) for 3 minutes and 1 hour. At the end of the treatment period, the tissues were washed with phosphate buffered saline (PBS) and cell viability was assessed using the MTT (3-(4, 5-Dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide, also known as Thiazolyl blue) assay. The skin corrosivity potential was classified according to the remaining cell viability obtained after test material treatment with either of the two treatment times.\n\nThe viability of the tissues following a 3 minute treatment was 96% and 101% in experiments 1 and 2, respectively.\n\nThe viability of the tissues following a 1 hour treatment was 94% and 102% in experiments 1 and 2, respectively.\n\nThe positive control gave appropriate responses indicating the correct performance of the assay.\n\nSalicylamide was not corrosive to the in vitro skin model EpiDerm.\n\nBack to top",
          "content_length": 7382,
          "status": "success"
        },
        "002 | Key | Experimental study": {
          "document_id": "IUC5-2bf7f79f-74c9-457a-a3c5-87c50d6a489e_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Skin irritation / corrosion\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nskin irritation: in vitro / ex vivo\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nkey study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n04-May-2010\n\nEnd date\n\n10-May-2010\n\nRemark\n\n04 May 2010 - 10 May 2010\n\nReliability\n\n1 (reliable without restriction)\n\nRationale for reliability incl. deficiencies\n\nother:\nGLP compliant, guideline study, no restrictions, fully adequate for assessment\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Reference](3b58d651-2f11-3173-a074-40492c7f740e_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\naccording to guideline\n\nGuideline\n\nother:\nB46 of Council Regulation (EC) No 761/2009\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\nno\n\nPrinciples of method if other than guideline\n\nNot applicable\n\nGLP compliance\n\nyes\n\n### Test material\n\nTest material information\n\n[Test material information](d660d571-a511-372e-95bb-43db4c8c954d_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### In vitro test system\n\nTest system\n\n[Empty]\n\nSource species\n\n[Empty]\n\nCell type\n\n[Empty]\n\nCell source\n\n[Empty]\n\nSource strain\n\n[Empty]\n\nDetails on animal used as source of test system\n\n[Empty]\n\nJustification for test system used\n\n[Empty]\n\nVehicle\n\n[Empty]\n\nDetails on test system\n\n[Empty]\n\nControl samples\n\n[Empty]\n\nAmount/concentration applied\n\n[Empty]\n\nDuration of treatment / exposure\n\n[Empty]\n\nDuration of post-treatment incubation (if applicable)\n\n[Empty]\n\nNumber of replicates\n\n[Empty]\n\n### Test animals\n\nSpecies\n\nother:\nin vitro using EpiSkin inserts (3-dimensional human skin model, comprising a reconstructed epidermis with a functional stratum corneum, supplied by SkinEthic Laboratories, Nice, France)\n\nStrain\n\nother:\nnot applicable\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Test system\n\nType of coverage\n\nother:\nnot applicable\n\nPreparation of test site\n\nother:\nnot applicable\n\nVehicle\n\nunchanged (no vehicle)\n\nControls\n\n* other:\n  not applicable\n\nAmount / concentration applied\n\n25 mg\n\nDuration of treatment / exposure\n\n15 minutes\n\nObservation period\n\nnot applicable\n\nNumber of animals\n\nnot applicable\n\nDetails on study design\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### In vitro\n\n### Results\n\n### #1 - Results\n\nKey result\n\nIrritation / corrosion parameter\n\nother:\nother: viability of tissues\n\nRun / experiment\n\n[Empty]\n\nValue\n\n98.1\n\nVehicle controls validity\n\n[Empty]\n\nNegative controls validity\n\n[Empty]\n\nPositive controls validity\n\n[Empty]\n\nRemarks on result\n\nother:\n\nTime point: 15 min treatment. (migrated information)\n\nOther effects / acceptance of results\n\n[Empty]\n\n### In vivo\n\n### Results\n\nIrritant / corrosive response data\n\n[Empty]\n\nOther effects\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nBased on the cell viability measurements obtained, the following mean viability measurements for the test article, negative control and positive control were calculated to be: 98.1%, 100% and 7.9% respectively.\n\n \n\nThese results indicate the viability of the epidermal tissue was not reduced to below 50% of the negative control and therefore may be considered to be non-irritant. The positive control showed an appropriate response in the assay system.\n\n \n\nNo other test substance related effects were observed.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nnot irritating\n\nMigrated information\n\nCriteria used for interpretation of results: EU\n\nConclusions\n\nThe substance was not irritant to the in vitro skin model EpiSkin.\n\nExecutive summary\n\nIn order to assess the in vitro skin irritation potential of salicylamide, EpiSkin inserts were treated with the substance, negative control (phosphate buffered saline (PBS)) and positive control (5% v/v sodium dodecyl sulphate (SDS)) for 15 minutes. At the end of the treatment period, the tissues were washed with PBS and cell viability was assessed using the MTT (3-(4, 5-Dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide, also known as Thiazolyl blue) interacting substances assay. The skin irritation potential was classified according to the remaining cell viability obtained after test article treatment.  \n\nThe group mean viability for the test article was 98.1%, for the negative control was 100% and for the positive control was 7.9%.\n\nSalicylamide was not irritant to the in vitro skin model EpiSkin.\n\nBack to top",
          "content_length": 6165,
          "status": "success"
        },
        "003 | Supporting | Experimental study": {
          "document_id": "IUC5-ddc9b6d0-9518-4bf2-a36a-9ff0ea3f117e_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Skin irritation / corrosion\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nskin irritation / corrosion\n\nno data\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nother:\nSecondary data source with no details other than result.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Relationship of pKa and acute skin irritation in humans](3f0f0d0c-d3c0-3f1a-b39a-951c82ec9e97_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nNo data.\n\nGLP compliance\n\nnot specified\n\n### Test material\n\nTest material information\n\n[Test material information](e81d3f9f-b332-3d57-a8c6-12815bdcc29b_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### In vitro test system\n\nTest system\n\n[Empty]\n\nSource species\n\n[Empty]\n\nCell type\n\n[Empty]\n\nCell source\n\n[Empty]\n\nSource strain\n\n[Empty]\n\nDetails on animal used as source of test system\n\n[Empty]\n\nJustification for test system used\n\n[Empty]\n\nVehicle\n\n[Empty]\n\nDetails on test system\n\n[Empty]\n\nControl samples\n\n[Empty]\n\nAmount/concentration applied\n\n[Empty]\n\nDuration of treatment / exposure\n\n[Empty]\n\nDuration of post-treatment incubation (if applicable)\n\n[Empty]\n\nNumber of replicates\n\n[Empty]\n\n### Test animals\n\nSpecies\n\nrabbit\n\nStrain\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Test system\n\nType of coverage\n\nnot specified\n\nPreparation of test site\n\nnot specified\n\nVehicle\n\nnot specified\n\nControls\n\n* not specified\n\nAmount / concentration applied\n\n[Empty]\n\nDuration of treatment / exposure\n\n[Empty]\n\nObservation period\n\n[Empty]\n\nNumber of animals\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### In vitro\n\n### Results\n\nOther effects / acceptance of results\n\n[Empty]\n\n### In vivo\n\n### Results\n\n### #1 - Results\n\nKey result\n\nIrritation parameter\n\n[Empty]\n\nBasis\n\n[Empty]\n\nTime point\n\n[Empty]\n\nScore\n\n[Empty]\n\nMax. score\n\n[Empty]\n\nReversibility\n\n[Empty]\n\nRemarks on result\n\nother:\nnot irritating\n\nIrritant / corrosive response data\n\n[Empty]\n\nOther effects\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nnot irritating\n\nMigrated information\n\nCriteria used for interpretation of results: not specified\n\nConclusions\n\nSecondary data source with no details other than result, hence supporting information.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 4465,
          "status": "success"
        }
      },
      "7.3.2 Eye irritation": {
        "001 | Key | Experimental study": {
          "document_id": "IUC5-a13fa5c2-8592-42fe-8fd9-5a7d49e65c0a_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Eye irritation\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\neye irritation: in vitro / ex vivo\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nkey study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n16-Jun-2010\n\nEnd date\n\n17-Jun-2010\n\nRemark\n\n16 June 2010 - 17 June 2010\n\nReliability\n\n1 (reliable without restriction)\n\nRationale for reliability incl. deficiencies\n\nother:\nGLP compliant, guideline study, no restrictions, fully adequate for assessment\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Reference](cc3696fe-d444-3265-898a-90f6e4dbac78_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\naccording to guideline\n\nGuideline\n\nother:\nOECD 437 (adopted 7 September 2009)\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\nno\n\nPrinciples of method if other than guideline\n\nnot applicable\n\nGLP compliance\n\nyes\n\n### Test material\n\nTest material information\n\n[Test material information](b3f5d127-d53e-3f4c-988f-b84942f2c95b_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\nTest material physicochemical properties\n\n[Empty]\n\n### Test animals / tissue source\n\nSpecies\n\nother:\nin vitro study using excised bovine corneas\n\nStrain\n\nother:\nnot applicable\n\nDetails on test animals / tissues or test method\n\nnot applicable\n\n### Test system\n\nVehicle\n\nother:\n0.9% sodium chloride solution\n\nControls\n\n* other:\n  3 corneas used with negative control (0.9% sodium chloride solution) and 3 with a positive control (20% w/v imidazole).\n\nAmount / concentration applied\n\n750 ÂµL\n\nDuration of treatment / exposure\n\nAssessment of corrosivity/severe irritation: 4 hour incubation. Permeability endpoint additional incubation for 1.5 hours Â± 5 minutes\n\nObservation period (in vivo)\n\nnot applicable\n\nDuration of post- treatment incubation (in vitro)\n\n[Empty]\n\nNumber of animals or in vitro replicates\n\n3 corneas per treatment (test, positive and negative control)\n\nDetails on study design\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### In vitro / ex vivo / in chemico\n\n### Results\n\n### #1 - Results\n\nKey result\n\nIrritation parameter\n\nin vitro irritation score\n\nRun / experiment\n\n[Empty]\n\nValue\n\n24.69\n\nVehicle controls validity\n\nvalid\n\nNegative controls validity\n\nnot examined\n\nPositive controls validity\n\nvalid\n\nRemarks on result\n\nother:\ndid not cause corrosion or severe irritation\n\nOther effects / acceptance of results\n\n[Empty]\n\n### In vivo\n\n### Results\n\nIrritant / corrosive response data\n\n[Empty]\n\nOther effects\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nCorneal opacity, permeability and in vitro irritation scores\n\n|  |  |  |  |  |\n| --- | --- | --- | --- | --- |\n| Chemical | mean corneal opacity | Permeability | | IVS score |\n| mean negative control corrected optical density | average group corrected optical density |  |\n| test substance | -1.7 | n/a | 1.7593 | 24.69 |\n| negative control | 0.0 | 0.0240 | 0.0000 | 0.00 |\n| positive control | 72.7 | n/a | -0.0053 | 72.62 |\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nother:\ndoes not cause corrosion or severe irritation\n\nCriteria used for interpretation of results: other: OECD\n\nConclusions\n\nThe substance was considered not to cause corrosion or severe irritation to the eye under the conditions of the assay.\n\nExecutive summary\n\nA volume of 750 ÂµL of salicylamide formulation, negative control (0.9% sodium chloride solution) or positive control (20% w/v imidazole) was applied to each of three excised bovine corneas followed by a 4 hour incubation at 32Â°C. After this incubation, each cornea was washed with media containing phenol red followed by media without phenol red, the opacities measured and then the anterior chamber emptied. For the permeability endpoint, sodium fluorescein solution was added into the anterior chamber and the corneas were incubated in the vertical position for 1.5 hours Â± 5 minutes. Following this period, the media in the posterior chamber was removed and three 200 Î¼L aliquots of this media (per cornea) were analysed for optical density at 490 nanometers.\n\nThe salicylamide formulation produced an In Vitro Irritation Score of 24.69.\n\nThe positive control article produced an In Vitro Irritation Score of 72.62.\n\nSalicylamide was considered not to cause corrosion or severe irritation to the eye under the conditions of the assay.\n\nBack to top",
          "content_length": 6067,
          "status": "success"
        },
        "002 | Supporting | Experimental study": {
          "document_id": "IUC5-1846b3ec-531a-4150-befa-3f3fe0c9cc4a_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Eye irritation\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\neye irritation: in vitro / ex vivo\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nIn-vitro study using a non-validated method (EpiOcular).\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Evaluation of the EpiOcular Tissue Model as an alternative to the Draize eye irritation test](598cbdb6-cee1-3281-919d-97bea8e488ff_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline available\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nNormal, human-derived epidermal keratinocytes cultured to form a stratified squamous epithelium (EpiOcular) were exposed to the test substance, and cell viability was assessed by incubation with MTT (3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide).\n\nGLP compliance\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](a646a75b-3265-37e7-bf3b-17e7c56b822c_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\nTest material physicochemical properties\n\n[Empty]\n\n### Test animals / tissue source\n\nSpecies\n\nother:\nnormal, human-derived epidermal keratinocytes cultured to form a stratified squamous epithelium similar to human cornea (EpiOcular System)\n\nStrain\n\n[Empty]\n\nDetails on test animals / tissues or test method\n\n[Empty]\n\n### Test system\n\nVehicle\n\nwater\n\n5% dispersion\n\nControls\n\n* other:\n  In-vitro method, no animals. Negative control substance: ultra-pure water. Positive control substance: 0.3% Triton X-100\n\nAmount / concentration applied\n\n100 microliter of dispersion\n\nDuration of treatment / exposure\n\n60, 120, and 240 min in initial phase; 3, 30, and 60 min at later stage\nThe exposure was terminated by removal of the test substance by washing with Dulbecco's phosphate buffered saline (DPBS), followed by immediate determination of the cytotoxic effect.\n\nObservation period (in vivo)\n\nIncubation with MTT (3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide) medium: 3 hours at 37Â°C.\nIncubation of the the tissues with extractant medium: 2 hours at room temperature, with gentle rocking, sometimes after overnight storage at 4Â°C.\n\nDuration of post- treatment incubation (in vitro)\n\n[Empty]\n\nNumber of animals or in vitro replicates\n\nIn-vitro method, no animals.\n\nDetails on study design\n\nAfter incubation with the test chemical and washing with DPBS, the EpiOcular tissues were incubated with MTT (3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide) medium at 37Â°C and 5 % CO2. After incubation, tissues were rinsed with DPBS and transferred into assay medium (Dulbecco's modified Eagle's medium DMEM). For extraction, the tissues were incubated with extractant medium: 2 hours at room temperature, with gentle rocking, sometimes after overnight storage at 4Â°C.\n\nAfter the extraction period, 200 microliter aliquots of the samples were transferred into a 96-well flat bottom microtiter plate, and the optical density (OD) was measured in a microplate reader at 540 nm.\n\n% viability was calculated as 100 x [OD(sample) / OD(negative control)]\n\nEffective time of exposure to reduce tissue viability to 50% (ET50) was determined by linear interpolation.\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### In vitro / ex vivo / in chemico\n\n### Results\n\n### #1 - Results\n\nKey result\n\nIrritation parameter\n\nother:\nET50 (time for 50% viability)\n\nRun / experiment\n\n[Empty]\n\nValue\n\n[Empty]\n\nVehicle controls validity\n\n[Empty]\n\nNegative controls validity\n\n[Empty]\n\nPositive controls validity\n\n[Empty]\n\nRemarks on result\n\nno indication of irritation\n\nOther effects / acceptance of results\n\n[Empty]\n\n### In vivo\n\n### Results\n\nIrritant / corrosive response data\n\n[Empty]\n\nOther effects\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n**Assay acceptance criteria, validity of the test:**\n\nHistorically (1996):\n\n-         negative control (ultra-pure water) averaged 1.274 +/- 0.138 OD\n\n-         positive control (0.3% Triton X-100): ET50 averaged 24.9 +/- 6.3 min.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nnot irritating\n\nMigrated information Criteria used for interpretation of results: not specified\n\nConclusions\n\nIn-vitro study using a non-validated method, hence to be used as supporting information. Not-irritating to the eyes according to the criteria of the test.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 6234,
          "status": "success"
        },
        "003 | Supporting | Experimental study": {
          "document_id": "IUC5-212fcb0b-06ec-4d73-8a47-5bcb56ecf8ca_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Eye irritation\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\neye irritation: in vivo\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n4 (not assignable)\n\nRationale for reliability incl. deficiencies\n\nother:\nIn-vivo results quoted from in-house database, quality cannot be assessed.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Evaluation of the EpiOcular Tissue Model as an alternative to the Draize Eye Irritation Test](eb194dc8-8228-3696-9a7c-8a1db046cd21_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline available\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nDraize test conducted prior to 1989. No guideline explicitely mentioned.\n\nGLP compliance\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](6167d75d-1a51-33ac-a342-a73f9c861977_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\nTest material physicochemical properties\n\n[Empty]\n\n### Test animals / tissue source\n\nSpecies\n\nrabbit\n\nStrain\n\nnot specified\n\nDetails on test animals / tissues or test method\n\n[Empty]\n\n### Test system\n\nVehicle\n\nnot specified\n\nControls\n\n* not specified\n\nAmount / concentration applied\n\n[Empty]\n\nDuration of treatment / exposure\n\n[Empty]\n\nObservation period (in vivo)\n\n[Empty]\n\nDuration of post- treatment incubation (in vitro)\n\n[Empty]\n\nNumber of animals or in vitro replicates\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### In vitro / ex vivo / in chemico\n\n### Results\n\nOther effects / acceptance of results\n\n[Empty]\n\n### In vivo\n\n### Results\n\n### #1 - Results\n\nKey result\n\nIrritation parameter\n\noverall irritation score\n\nMaximum average score\n\nBasis\n\nmean\n\nTime point\n\nother:\n24\n\nScore\n\n0\n\nMax. score\n\n[Empty]\n\nReversibility\n\nnot specified\n\nRemarks on result\n\n[Empty]\n\nIrritant / corrosive response data\n\n[Empty]\n\nOther effects\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nResults stored in historical data bank.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nnot irritating\n\nMigrated information\n\nCriteria used for interpretation of results: not specified\n\nConclusions\n\nOriginal data source not available, hence supporting information only.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 4036,
          "status": "success"
        }
      },
      "S-01 | Summary": {
        "document_id": "IUC5-898a47ff-def8-4ae2-a2db-1451f09a698a_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
        "markdown_content": "#### Irritation / corrosion\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Empty]\n\nJustification\n\n[Empty]\n\nUse restricted to selected regulatory programmes\n\n[Empty]\n\n### Description of key information\n\nSkin: Not corrosive, EpiDerm, EU method B40, Dreher 2010  \nSkin: Not irritant, EpiSkin, EU method B46, Dreher 2010  \nSkin: Not irritant, rabbit, Berner 1989  \nEye: Not severe irritant, OECD 437, Dreher 2010  \nEye: Non-irritating, EpiOcular, Stern 1998  \nEye: Non-irritating, draize, 24h maximum average score, Stern 1998\n\n### Key value for chemical safety assessment\n\n### Skin irritation / corrosion\n\nLink to relevant study record(s)\n\n* [002 | Key | Experimental study](IUC5-2bf7f79f-74c9-457a-a3c5-87c50d6a489e_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n* [001 | Key | Experimental study](IUC5-a747b47b-9da3-409f-b991-440938476443_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nEndpoint conclusion\n\nno adverse effect observed (not irritating)\n\n### Eye irritation\n\nLink to relevant study record(s)\n\n* [001 | Key | Experimental study](IUC5-a13fa5c2-8592-42fe-8fd9-5a7d49e65c0a_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nEndpoint conclusion\n\nno adverse effect observed (not irritating)\n\n### Respiratory irritation\n\nEndpoint conclusion\n\nno information available\n\n### Justification for classification or non-classification\n\n**Skin Irritation/Corrosion**\n\nResults from validated in vitro studies for skin corrosion and irritation, conducted according to Regulation (EC) No. 440/2008 and 761/2009, demonstrated the substance to be non-corrosive and non-irritating to skin. The EpiSkin, B46 test method states that it was prevalidated, optimised, and validated against irritant data based around the EU classification R38. Studies in human volunteers, and a unverifiable result in rabbits, also indicated no irritating effects. As a result, the substance is not considered to be classified under Directive 2001/59/EEC, and the result is conclusive.\n\nResults from validated in vitro studies for skin corrosion and irritation, conducted according to Regulation (EC) No. 440/2008 and 761/2009, demonstrated the substance to be non-corrosive and non-irritating to skin. The EpiSkin, B46 method has been demonstrated to be valid for discriminating between EU GHS Category 2 (H315) and non-irritants, but not between UN GHS Category 3 and non-irritants (comment by ECVAM). Studies in human volunteers, and a unverifiable result in rabbits, also indicated no irritating effects. As a result, the data are considered conclusive and the substance is not classified for skin irritation, according to Regulation (EC) No. 1272/2008.\n\n**Eye Irritation**\n\nTwo in vitro tests for eye irritation are available, one validated (OECD 437) and one currently unvalidated (EpiOcular). Both results were negative. ECVAM have commented that OECD 437 should only be used to identify corrosive or severe irritants. One negative, but unverifiable in vivo result from a Draize test was also available. Based on the available information the substance is considered to be not classified for R41, Risk of serious damage to eyes, and inconclusive as not classified as R36, Irritating to eyes.\n\nTwo in vitro tests for eye irritation are available, one validated (OECD 437) and one currently unvalidated (EpiOcular). Both results were negative. ECVAM have commented that OECD 437 should only be used to identify corrosive or severe irritants. One negative, but unverifiable in vivo result from a Draize test was also available. Based on the available information the substance is considered to be not classified for Serious eye damage, Category 1 (H318), and inconclusive as not classified as Irritating to eyes, Category 2 (H319), according to Regulation (EC) No. 1272/2008.\n\n### Additional information\n\n**Skin Irritation/Corrosion**\n\n**In Vitro Data**\n\nTwo in vitro studies are available, both done according to GLP, using guideline methods which are validated for regulatory use according to ECVAM.\n\n \n\nIn order to assess the in vitro skin corrosivity potential of salicylamide, duplicate EpiDerm inserts were treated with the substance, distilled water (negative control) and 8N potassium hydroxide (positive control) for 3 minutes and 1 hour. The skin corrosivity potential was classified according to the remaining cell viability obtained after test material treatment with either of the two treatment times. The viability of the tissues following a 3 minute treatment was 96% and 101% in experiments 1 and 2, respectively. The viability of the tissues following a 1 hour treatment was 94% and 102% in experiments 1 and 2, respectively. The positive control gave appropriate responses indicating the correct performance of the assay. Salicylamide was not corrosive to the in vitro skin model EpiDerm.\n\nIn order to assess the in vitro skin irritation potential of salicylamide, EpiSkin inserts were treated with the substance, negative control (phosphate buffered saline (PBS)) and positive control (5% v/v sodium dodecyl sulphate (SDS)) for 15 minutes. The skin irritation potential was classified according to the remaining cell viability obtained after test article treatment. The group mean viability for the test article was 98.1%, for the negative control was 100% and for the positive control was 7.9%. Salicylamide was not irritant to the in vitro skin model EpiSkin.\n\n**In Vivo Data**\n\nNo data with an identifiable/validated source were identified. Berner (1989) makes reference to salicylamide being non-irritant in studies with rabbits. No details were given.\n\n**Human Data**\n\nSkin irritation in human female volunteers was assessed before and after 1-day exposure to test substance-loaded hydrogel discs, and again 24 hours later, by assessment of erythema, edema, blood flow (by laser Doppler velocimetry), color, and primary irritation index (Berner 1990).\n\nHydroxyethyl methacrylate (HEMA) hydrogel films were prepared by polymerization from HEMA, carefully extracted to remove free monomer, and cut into 1 cm2 discs, which were loaded with the test substance by soaking in a saturated solution in ethanol/water (7:3) and dried. Immediately before application, discs were soaked in a saturated aqueous solution of the test material, and applied to the scapular region of the test subjects. The loaded test discs were occluded with an ethylene vinyl acetate membrane and secured with tape. The loading of the discs was determined by the weight difference of the disc before and after. The concentration was checked by extraction into a known volume of ethanol/water and analysis. Percent uptake per dry weight: 36.6 +- 5.9.\n\nUnder the conditions of the study, human volunteers treated with salicylamide were not significantly different from a water control in any of the observed variables.\n\n**Eye Irritation**\n\n**In Vitro Data**\n\nAn in-vitro study was reported using the non-validated EpiOcular method (Stern 1998). Normal human-derived epidermal keratinocytes cultured to form a stratified squamous epithelium (EpiOcular) were exposed to the test substance, and cell viability was assessed by incubation with MTT (3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide). Under the EpiOcular criteria, the substance tested non-irritating to the eyes.\n\nA validated in vitro method, conducted according to GLP and OECD 437 guidelines, was conducted (Dreher 2010). A volume of salicylamide formulation, negative control (0.9% sodium chloride solution) or positive control (20% w/v imidazole) was applied to each of three excised bovine corneas followed by a 4-hour incubation at 32Â°C. After this incubation, each cornea was washed with media containing phenol red followed by media without phenol red, the opacities measured and then the anterior chamber emptied. For the permeability endpoint, sodium fluorescein solution was added into the anterior chamber and the corneas were incubated in the vertical position for 1.5 hours Â± 5 minutes. Following this period, the media in the posterior chamber was removed and three 200 Î¼L aliquots per cornea were analysed for optical density. The salicylamide formulation produced an in vitro Irritation Score of 24.69. The positive control article produced an In Vitro Irritation Score of 72.62. Salicylamide was considered not to cause corrosion or severe irritation to the eye under the conditions of the assay.\n\n \n\n**In Vivo Data**\n\nStern (1998) reported the result that salicylamide as being non-irritating to the eye (based on 24-hour maximum average score MAS) in a Draize test conducted prior to 1989. The original data were not published.\n\n**Justification for selection of skin irritation / corrosion endpoint:**   \nGLP compliant, guideline study, no restrictions, fully adequate for assessment   \n   \n**Justification for selection of eye irritation endpoint:**   \nGLP compliant, guideline study, no restrictions, fully adequate for assessment\n\n### Attached background material\n\nBack to top",
        "content_length": 8942,
        "status": "success"
      }
    },
    "7.4 Sensitisation": {
      "7.4.1 Skin sensitisation": {
        "001 | Key | Experimental study": {
          "document_id": "IUC5-c7472cd6-8ff6-4f7d-b9b0-86b1eed500ae_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Skin sensitisation\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nskin sensitisation: in vivo (LLNA)\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nkey study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n1 (reliable without restriction)\n\nRationale for reliability incl. deficiencies\n\nother:\nGLP compliant, guideline study, no restrictions, fully adequate for assessment.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Reference](57d68292-6d00-3dc9-b55a-3fc873c56151_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\naccording to guideline\n\nGuideline\n\nOECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\nno\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nyes (incl. QA statement)\n\nType of study\n\nmouse local lymph node assay (LLNA)\n\nJustification for non-LLNA method\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](961bdf5c-8e3a-3076-9dcc-82c0f11b4ec1_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### In vitro test system\n\nDetails of test system\n\n[Empty]\n\nDetails on the study design\n\n[Empty]\n\nVehicle / solvent control\n\n[Empty]\n\nNegative control\n\n[Empty]\n\nPositive control\n\n[Empty]\n\n### In chemico test system\n\nDetails of test system\n\n[Empty]\n\nDetails on the study design\n\n[Empty]\n\nVehicle / solvent\n\n[Empty]\n\nPositive control\n\n[Empty]\n\n### In silico test system\n\nDetails of test system\n\n[Empty]\n\nDetails on the study design\n\n[Empty]\n\n### In vivo test system\n\n### Test animals\n\nSpecies\n\nmouse\n\nStrain\n\nCBA\n\nSex\n\nfemale\n\nDetails on test animals and environmental conditions\n\nTEST ANIMALS\n\n- Age at study initiation: 8 - 12 weeks\n\n- Weight at study initiation: 15 - 25 g\n\n- Housing:single caging\n\n- Diet (e.g. ad libitum): pelleted standard diet (Harlan Laboratories GmbH, 33178 Borchen), ad libidum\n\n- Water (e.g. ad libitum): tap water, (Gemeindewerke, 64380 Rossdorf), ad libitum\n\n- Acclimation period: At least 5 days prior to the start of dosing under test conditions after health examination. Only animals without any visible signs of illness will be used for the study\n\nENVIRONMENTAL CONDITIONS\n\n- Temperature (Â°C): 22 + 2Â°C\n\n- Humidity (%): 45-65%\n\n- Photoperiod (hrs dark / hrs light): artificial light 6:00 a.m. - 6:00 p.m.\n\n### Study design: in vivo (non-LLNA)\n\n### Induction\n\n### Challenge\n\nNo. of animals per dose\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nChallenge controls\n\n[Empty]\n\nPositive control substance(s)\n\n[Empty]\n\n### Study design: in vivo (LLNA)\n\nVehicle\n\ndimethylformamide\n\nConcentration\n\n10, 25, and 50% (w/v)\n\nNo. of animals per dose\n\n4\n\nDetails on study design\n\nVEHICLE AND DOSE SELECTION\n\nA solubility experiment was performed according to the recommendations given by OECD 429.Â The highest test item concentration, which could be technically used was a 50% (w/v) solution in dimethylformamide (DMF) after vortexing and warming to 37Â°C.Â The vehicle was chosen due to its solubilisation properties.\n\nTo determine the highest non-irritant test concentration that did at the same time not induce signs of systemic toxicity,a pre-test was performed in two animals.Â Two mice were treated by (epidermal) topical application to the dorsal surface of each ear with test item concentrations of 25 and 50% once daily each on three consecutive days.Â Furthermore, prior to the first application of the test item and before sacrifice the body weight was determined. Both animals gained weight during the course of the pre-test.\n\nIn the pre-test clinical signs were recorded within 1 hour and 24Â±4 hours after each application as well as on day 7.Â At the tested concentrations the animals did not show any signs of local irritation or systemic toxicity.\n\nThus the test item in the main study was assayed at 10, 25, and 50% (w/v).Â The top dose is the highest technically achievable concentration whilst avoiding systemic toxicity and excessive local irritation.\n\nMAIN TEST\n\nTOPICAL APPLICATION\n\nEach test group of mice was treated by topical (epidermal) application to the dorsal surface of each ear (left and right) with different test item concentrations of 10, 25, and 50% (w/v) in dimethylformamide.Â The application volume, 25Â Âµl, was spread over the entire dorsal surface (Ã~8 mm) of each ear once daily for 3 consecutive days.Â A further group of mice was treated with an equivalent volume of the vehicle alone (control animals).\n\nADMINISTRATION AND DETERMINATION OF INCORPORATED 3H-METHYL THYMIDINE\n\nFive days after the first topical application, all mice were administered with 250Â Âµl of 81.7Â ÂµCi/mL3HTdR (corresponds to 20.4 ÂµCi3HTdR per mouse) by intravenous injection via a tail vein. Approximately five hours after injection, the mice were sacrificed and the draining of auricular lymph nodes were excised and pooled per group. Single cell suspensions of lympg node cells were prepared from pooled lymph nodes, which were subsequently washed and incubated with trichloroacetic acid overnight. The proliferative capacity of pooled lymph node cells was determined by the incorporation of 3HTdR measured in a beta-scintilation counter.\n\nINTERPRETATION OF RAW DATA\n\nThe proliferative response of lymph node cells is expressed as the number of radioactive disintegrations per minute per lymph node (DPM/node) and as the ratio of 3HTdR incorporated into lymph node cells of test lymph nodes relative to that recorded for control lymph nodes (Stimulation Index; S.I.). Before DPM/node values were determined, mean scintillation-background DPM was subtracted from test and control raw data. A test item is regarded as a sensitiser in the LLNA if the following criteria are fulfilled: First, that exposure to at least one concentration of the test item resulted in an incorporation of 3HTdR at least 3-fold or greater than that recorded in control mice, as indicated by the stimulation index.\n\nSecond, that the data are compatible with a conventional dose response, although allowance must be made (especially at high topical concentrations) for either local toxicity or immunological suppression.\n\nOBSERVATIONS\n\nIn addition to the sensitising reactions the following observations and data were recorded during the test and observation period:\n\nMortality / Viability: once daily (week day) from experimental start to necropsy.\n\nBody weights: prior to the first application and prior to treatment with3HTdR.\n\nClinical signs (local / systemic):Â In the pre-test clinical signs were recorded within 1 hour and 24Â±4 hours after each application as well as on day 7. In the main experiment clinical signs were recorded within 1Â hour and 24Â±4 hours after the first and second application (days 1 and 2) as well as on the day of preparation (day 6). Especially the treatment sites were observed carefully.\n\nPositive control substance(s)\n\n* hexyl cinnamic aldehyde (CAS No 101-86-0)\n\nStatistics\n\nThe mean values and standard deviations were calculated in the body weight tables.\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPositive control results\n\nExperiment performend in May 2010, 5, 10, and 25% alpha-Hexylcinnamaldehyde in acetone:olive oil (4+1) yielded a S.I. of 2.04, 3.41, and 6.14, respectively. The EC3 value calculated was 8.5%\n\n### In vitro / in chemico\n\n### Results\n\nOutcome of the prediction model\n\n[Empty]\n\nOther effects / acceptance of results\n\n[Empty]\n\n### In silico\n\n### Results\n\nOutcome of the prediction model\n\n[Empty]\n\n### In vivo (non-LLNA)\n\n### Results\n\n### In vivo (LLNA)\n\n### Results\n\n### #1 - Results\n\nKey result\n\nParameter\n\nSI\n\nValue\n\n1.56\n\nVariability\n\n[Empty]\n\nTest group / Remarks\n\n10% test item concentration (w/v)\n\nRemarks on result\n\nother:\nsee table below\n\n### #2 - Results\n\nKey result\n\nParameter\n\nSI\n\nValue\n\n1.29\n\nVariability\n\n[Empty]\n\nTest group / Remarks\n\n25% test item concentration (w/v)\n\nRemarks on result\n\nother:\nsee table below\n\n### #3 - Results\n\nKey result\n\nParameter\n\nSI\n\nValue\n\n1.32\n\nVariability\n\n[Empty]\n\nTest group / Remarks\n\n50% test item concentration (w/v)\n\nRemarks on result\n\nother:\nsee table below\n\n### #4 - Results\n\nKey result\n\nParameter\n\nother:\ndisintegrations per minute (DPM)\n\nValue\n\n[Empty]\n\nVariability\n\n[Empty]\n\nTest group / Remarks\n\n[Empty]\n\nRemarks on result\n\nother:\nsee table below\n\nCellular proliferation data / Observations\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n## Calculation of Results\n\nSince the lymph nodes of the animals of a dose group were pooled, the number of radioactive disintegrations per minute per lymph node (DPM/node) was determined by dividing the measured DPM-value by the number of lymph nodes pooled (8 lymph nodes). Before DPM/node values were determined, mean scintillation-background DPM was subtracted from test and control raw data. For the control group (vehicle group), a DPM/node value of 336.6 was determined whereas DPM/node values of 523.4, 435.8, and 444.8 were determined for the test item groups with test item concentrations of 10, 25, and 50% (w/v), respectively. The Stimulation Indices calculated for these groups were 1.56 (at a test item concentration of 10%), 1.29 (at a test item concentration of 25%) and 1.32 (at a test item concentration of 50%) (see Table 2). The EC3 value could not be calculated, since none of the tested concentrations induced an S.I. greater than 3.\n\n## Viability / Mortality\n\nNo deaths occurred during the study period.\n\n## Clinical Signs\n\nNo symptoms of local toxicity at the ears of the animals and no systemic findings were observed during the study period.\n\n## Body Weights\n\nThe body weight of the animals, recordedprior to the first application and prior to treatment with3HTdR, was within the range commonly recorded for animals of this strain and age\n\n##### Summary of Results\n\n \n\n|  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- |\n| Test item concentration % (w/v) | Group | Measurement DPM | Calculation | | | Result |\n| DPM-BGa) | number of lymph nodes | DPM per lymph nodeb) | **S.I.** |\n| --- | BG I | 20 | --- | --- | --- | --- |\n| --- | BG II | 17 | --- | --- | --- | --- |\n| --- | 1 | 2711 | 2693 | 8 | 336.6 | **1.00** |\n| 10 | 2 | 4206 | 4188 | 8 | 523.4 | **1.56** |\n| 25 | 3 | 3505 | 3487 | 8 | 435.8 | **1.29** |\n| 50 | 4 | 3577 | 3559 | 8 | 444.8 | **1.32** |\n\nBG =  Background (1 mL 5% trichloroacetic acid) in duplicate\n\n1    =  Control Group\n\n2-4=  Test Groups\n\nS.I. =  Stimulation Index\n\na)   =  The mean value was taken from the figures BG I and BG II\n\nb)   =   Since the lymph nodes of the animals of a dose group were pooled, DPM/node was determined by dividing the measured value by the                number of lymph nodes pooled\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nnot sensitising\n\nMigrated information\n\nConclusions\n\nThe test item was not a skin sensitiser under the described conditions.\n\nExecutive summary\n\nIn order to study the possible contact allergenic potential of the substance, 3 groups each of 4 female mice were treated daily with the test item at concentrations of 10, 25, and 50% (w/v) in dimethylformamide by topical application to the dorsum of each ear (left and right) for 3 consecutive days. A control group of 4 mice was treated with the vehicle (dimethylformamide) only. Five days after the first topical application the mice were injected intravenously into a tail vein with radio-labelled thymidine (3H-methyl thymidine). Approximately 5 hours after intravenous injection, the mice were sacrificed, the draining auricular lymph nodes excised and pooled per group. Single cell suspensions of lymph node cells were prepared from pooled lymph nodes, which were subsequently washed and incubated with trichloroacetic acid overnight. The proliferative capacity of pooled lymph node cells was determined by the incorporation of3H-methyl thymidine measured in ab-scintillation counter.\n\n \n\nAll treated animals survived the scheduled study period and no signs of toxicity were observed.\n\n \n\nA test item is regarded as a sensitiser in the LLNA if the exposure to one or more test concentration resulted in 3-fold or greater increase in incorporation of3HTdR compared with concurrent controls, as indicated by the Stimulation Index (S.I.). The estimated concentration of test item required to produce a S.I. of 3 is referred to as the EC3 value.\n\n \n\nIn this study Stimulation Indices of 1.56, 1.29, and 1.32 were determined with the test item at concentrations of 10, 25, and 50% (w/v) in dimethylformamide. A dose response was not observed.\n\n \n\nThe EC3 value could not be calculated, since none of the tested concentrations induced an S.I. greater than 3.\n\nBack to top",
          "content_length": 14272,
          "status": "success"
        },
        "002 | Disregarded | (Q)SAR": {
          "document_id": "IUC5-3cca6339-8495-4ec7-a285-523f1e7e40c3_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Skin sensitisation\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nskin sensitisation\n\nother: QSAR model\n\nType of information\n\n(Q)SAR\n\nAdequacy of study\n\ndisregarded due to major methodological deficiencies\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nExperimental QSAR model, unvalidated.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\nQSAR prediction: migrated from IUCLID 5.6\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Skin sensitization: Modeling based on skin metabolism simulation and formation of protein conjugates](db2cbc3c-ddf1-3a12-87a8-458ab41d37cb_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nA QSAR was developed to estimate skin sensitisation potency, incorporating potential skin metabolism of the parent molecule. The metabolism simulator contained 203 potential reactions. Approximately 80% of sensitising chemicals and 72% of non-sensitising chemicals in the 96 compound validation set were correctly identified.\n\nGLP compliance\n\nno\n\nType of study\n\nother:\n\nJustification for non-LLNA method\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](834526d1-13b7-379d-910c-910361745517_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### In vitro test system\n\nDetails of test system\n\n[Empty]\n\nDetails on the study design\n\n[Empty]\n\nVehicle / solvent control\n\n[Empty]\n\nNegative control\n\n[Empty]\n\nPositive control\n\n[Empty]\n\n### In chemico test system\n\nDetails of test system\n\n[Empty]\n\nDetails on the study design\n\n[Empty]\n\nVehicle / solvent\n\n[Empty]\n\nPositive control\n\n[Empty]\n\n### In silico test system\n\nDetails of test system\n\n[Empty]\n\nDetails on the study design\n\n[Empty]\n\n### In vivo test system\n\n### Test animals\n\nSpecies\n\nother:\nnot applicable\n\nStrain\n\nother:\nnot applicable\n\nSex\n\nnot specified\n\nDetails on test animals and environmental conditions\n\n[Empty]\n\n### Study design: in vivo (non-LLNA)\n\n### Induction\n\n### Challenge\n\nNo. of animals per dose\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nChallenge controls\n\n[Empty]\n\nPositive control substance(s)\n\n[Empty]\n\n### Study design: in vivo (LLNA)\n\nVehicle\n\n[Empty]\n\nConcentration\n\n[Empty]\n\nNo. of animals per dose\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nPositive control substance(s)\n\n[Empty]\n\nStatistics\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPositive control results\n\n[Empty]\n\n### In vitro / in chemico\n\n### Results\n\nOutcome of the prediction model\n\n[Empty]\n\nOther effects / acceptance of results\n\n[Empty]\n\n### In silico\n\n### Results\n\nOutcome of the prediction model\n\n[Empty]\n\n### In vivo (non-LLNA)\n\n### Results\n\n### In vivo (LLNA)\n\n### Results\n\nCellular proliferation data / Observations\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nPrediction: sensitising\n\nMetabolism reliabilty score: 0.19\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nno data\n\nMigrated information\n\nunvalidated QSAR\n\nConclusions\n\nUnvalidated experimental QSAR model: result not reliable. Quoted source of the experimental result used for comparison does not contain stated data, as a result unverifiable.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 4931,
          "status": "success"
        },
        "003 | Disregarded | (Q)SAR": {
          "document_id": "IUC5-f2b3e0bd-7ad5-40da-8c1d-0dc606e33c77_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Skin sensitisation\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nskin sensitisation\n\nother: QSAR model\n\nType of information\n\n(Q)SAR\n\nAdequacy of study\n\ndisregarded due to major methodological deficiencies\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nExperimental QSAR model, unvalidated.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\nQSAR prediction: migrated from IUCLID 5.6\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Exploring the potential for allergic contact dermatitis via computed heats of reaction of haptens with protein end-groups](2ddbeea6-ca00-3e71-9abc-2e1419d781d2_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nQSAR modelling of the guinea pig maximisation test (GPMT). The identified reaction leading to a positive result in the GPMT is between a hapten and simple protein endgroups at the recognition site of the major histocompatibility complex class 2 on the surface of Langerhans cells. As only the first few atoms of the protein end-group take part in the reaction, methoxide ion and thiomethoxide ions were used as models for activated cysteine and serine.\n\nGLP compliance\n\nno\n\nType of study\n\nother:\n\nJustification for non-LLNA method\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](834526d1-13b7-379d-910c-910361745517_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### In vitro test system\n\nDetails of test system\n\n[Empty]\n\nDetails on the study design\n\n[Empty]\n\nVehicle / solvent control\n\n[Empty]\n\nNegative control\n\n[Empty]\n\nPositive control\n\n[Empty]\n\n### In chemico test system\n\nDetails of test system\n\n[Empty]\n\nDetails on the study design\n\n[Empty]\n\nVehicle / solvent\n\n[Empty]\n\nPositive control\n\n[Empty]\n\n### In silico test system\n\nDetails of test system\n\n[Empty]\n\nDetails on the study design\n\n[Empty]\n\n### In vivo test system\n\n### Test animals\n\nSpecies\n\nother:\nnot applicable\n\nStrain\n\nother:\nnot applicable\n\nSex\n\nnot specified\n\nDetails on test animals and environmental conditions\n\n[Empty]\n\n### Study design: in vivo (non-LLNA)\n\n### Induction\n\n### Challenge\n\nNo. of animals per dose\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nChallenge controls\n\n[Empty]\n\nPositive control substance(s)\n\n[Empty]\n\n### Study design: in vivo (LLNA)\n\nVehicle\n\n[Empty]\n\nConcentration\n\n[Empty]\n\nNo. of animals per dose\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nPositive control substance(s)\n\n[Empty]\n\nStatistics\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPositive control results\n\n[Empty]\n\n### In vitro / in chemico\n\n### Results\n\nOutcome of the prediction model\n\n[Empty]\n\nOther effects / acceptance of results\n\n[Empty]\n\n### In silico\n\n### Results\n\nOutcome of the prediction model\n\n[Empty]\n\n### In vivo (non-LLNA)\n\n### Results\n\n### In vivo (LLNA)\n\n### Results\n\nCellular proliferation data / Observations\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nPredictionfor salicylamide: Class 1: non sensitising or very weekly sensitising. In the absence of enzymatic catalysis, the substance is not predicted to contain functional groups which are reactive towards activated end-groups. Potential methoxide ion adducts are reversible and do not form products.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\nnot sensitising\n\nMigrated information\n\nunvalidated QSAR\n\nConclusions\n\nUnvalidated experimental QSAR model: result not reliable. Quoted source of the experimental result does not contain stated data, as a result unverifiable.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5310,
          "status": "success"
        },
        "004 | No specified study adequacy | No specified result type": {
          "document_id": "55c37d0e-988e-451b-bc58-2c891f90c69d_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Skin sensitisation\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nskin sensitisation: in vitro\n\nType of information\n\n[Empty]\n\nAdequacy of study\n\n[Empty]\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n[Empty]\n\nRationale for reliability incl. deficiencies\n\n[Empty]\n\nData waiving\n\nstudy scientifically not necessary / other information available\n\nJustification for data waiving\n\n* an in vitro skin sensitisation study does not need to be conducted because adequate data from an in vivo skin sensitisation study are available\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n[Empty]\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\n[Empty]\n\nType of study\n\n[Empty]\n\nJustification for non-LLNA method\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Empty]\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### In vitro test system\n\nDetails of test system\n\n[Empty]\n\nDetails on the study design\n\n[Empty]\n\nVehicle / solvent control\n\n[Empty]\n\nNegative control\n\n[Empty]\n\nPositive control\n\n[Empty]\n\n### In chemico test system\n\nDetails of test system\n\n[Empty]\n\nDetails on the study design\n\n[Empty]\n\nVehicle / solvent\n\n[Empty]\n\nPositive control\n\n[Empty]\n\n### In silico test system\n\nDetails of test system\n\n[Empty]\n\nDetails on the study design\n\n[Empty]\n\n### In vivo test system\n\n### Test animals\n\nSpecies\n\n[Empty]\n\nStrain\n\n[Empty]\n\nSex\n\n[Empty]\n\nDetails on test animals and environmental conditions\n\n[Empty]\n\n### Study design: in vivo (non-LLNA)\n\n### Induction\n\n### Challenge\n\nNo. of animals per dose\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nChallenge controls\n\n[Empty]\n\nPositive control substance(s)\n\n[Empty]\n\n### Study design: in vivo (LLNA)\n\nVehicle\n\n[Empty]\n\nConcentration\n\n[Empty]\n\nNo. of animals per dose\n\n[Empty]\n\nDetails on study design\n\n[Empty]\n\nPositive control substance(s)\n\n[Empty]\n\nStatistics\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nPositive control results\n\n[Empty]\n\n### In vitro / in chemico\n\n### Results\n\nOutcome of the prediction model\n\n[Empty]\n\nOther effects / acceptance of results\n\n[Empty]\n\n### In silico\n\n### Results\n\nOutcome of the prediction model\n\n[Empty]\n\n### In vivo (non-LLNA)\n\n### Results\n\n### In vivo (LLNA)\n\n### Results\n\nCellular proliferation data / Observations\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nInterpretation of results\n\n[Empty]\n\nConclusions\n\n[Empty]\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 3994,
          "status": "success"
        }
      },
      "7.4.2 Respiratory sensitisation": {},
      "S-01 | Summary": {
        "document_id": "IUC5-cf1c7009-1cb3-4e16-b11f-41a46d009b8d_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
        "markdown_content": "#### Sensitisation\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Empty]\n\nJustification\n\n[Empty]\n\nUse restricted to selected regulatory programmes\n\n[Empty]\n\n### Description of key information\n\nSkin: not sensitising, LLNA, OECD 429, Vogel 2010\n\n### Key value for chemical safety assessment\n\n### Skin sensitisation\n\nLink to relevant study record(s)\n\n* [001 | Key | Experimental study](IUC5-c7472cd6-8ff6-4f7d-b9b0-86b1eed500ae_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nEndpoint conclusion\n\nno adverse effect observed (not sensitising)\n\n### Respiratory sensitisation\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\n### Justification for classification or non-classification\n\nThe results from a mouse local lymph node assay indicate the substance is not a skin sensitiser. As a result the substance does not meet the criteria for classification according to Regulation (EC) No. 1272/2008, Part 3, 3.4.2.2.\n\n### Additional information\n\nTwo published QSAR results for salicylamide were available, both were unvalidated experimental models. Dimitrov et al (2005) predicted the substance to be sensitising, while Magee et al (2000) predicted it to be non-sensitising. Both results were discarded as being unreliable. However, both studies refer to an experimental result of non-sensitising in Cronin et al. (1994), SAR and QSAR in Environmental Research 2, 159 -179. The original Cronin paper contains no reference to salicylamide (but does refer to salicylanilide - non-sensitising). Therefore this result also had to be discarded as unreliable.\n\nA single experimental study was available which was conducted under GLP and according to OECD guideline 429. The result as non-sensitising is considered to be relevant, reliable, and adequate for risk assessment, classification and labelling.\n\n**Justification for selection of skin sensitisation endpoint:**  \nGLP compliant, guideline study, no restrictions, fully adequate for assessment.\n\n### Attached background material\n\nBack to top",
        "content_length": 2041,
        "status": "success"
      }
    },
    "7.5 Repeated dose toxicity": {
      "7.5.1 Repeated dose toxicity: oral": {
        "001 | Supporting | Experimental study": {
          "document_id": "IUC5-e5c37048-f1ca-4984-8065-7d130ebb7aed_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Repeated dose toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nsub-chronic toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal. Performed before GLP and OECD guidelines were introduced. Experimental details documented, but no data on housing, no individual animal records (body weight, food consumption, mortality, etc.). Maximum dose (200 mg/kg bw) too low for limit test. Sufficient numbers of animals (10 M, 10 F per dose), hematology and histology performed, but not reported in detail. Death rates similar in all dose groups, all deaths attributed to faulty (intratracheal) administration, on the basis of necropsy findings.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Pharmacological and toxicological studies on salicylamide](2707fc48-a1fc-3b9a-ad9c-d13d06ae71dd_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nGavage application 13 weeks, 5 times/week, post mortem examination, hematology and histopathology in some animals, recovery time 3-7 weeks in some animals. No control group; application only five days per week; no data on acclimatization and housing; only summary data on weight development, rudimentary clinical laboratory data; high losses due to intratracheal application.\n\nGLP compliance\n\nno\n\nGLP not available at study time\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](d9154718-77e0-3cf0-8f8e-b6f81727a39e_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrat\n\nStrain\n\nnot specified\n\nDetails on species / strain selection\n\n[Empty]\n\nSex\n\nmale/female\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Source: no data\n\n- Weight at study initiation: 100 - 130 g\n\n- Fasting period before study: no\n\n- Housing, diet, water, acclimation period: no data\n\nENVIRONMENTAL CONDITIONS\n\n- no data\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nDetails on route of administration\n\n[Empty]\n\nVehicle\n\nother:\n0.5% gum tragacanth in water\n\nDetails on oral exposure\n\nVEHICLE\n\n- Justification for use and choice of vehicle (if other than water): stability of test substance, tolerability of vehicle (confounding effect of alcohols)\n\n- Concentration in vehicle: depending on dose\n\n- Amount of vehicle (if gavage): 10 or 20 ml/kg bw\n\nAnalytical verification of doses or concentrations\n\nno\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDuration of treatment / exposure\n\n13 weeks\n\nFrequency of treatment\n\n5 times per week, totally 67 doses\n\n### Doses / concentrations\n\n### #1 - Doses / concentrations\n\nDose / conc.\n\n[Empty]\n\nRemarks\n\nDoses / Concentrations:\n5, 25, 50, 100, and 200 mg/kg bw\nBasis:\nother: applied by gavage\n\nNo. of animals per sex per dose\n\n10 males, 10 females\n\nControl animals\n\n* no\n\nDetails on study design\n\n- Dose selection rationale: 1, 5, 10, 20, and 40 times average human adult dose\n\n- Rationale for animal assignment (if not random): no data\n\n- Rationale for selecting satellite groups: Some animals sacrificed at end of treatment, for hematologic studies; others injected with 4% formaldehyde for histologic examination, 3 - 7 weeks after cessation of treatment\n\n- Post-exposure recovery period in satellite groups: 3 - 7 weeks\n\n- Section schedule rationale (if not random): no data\n\nPositive control\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nObservations and examinations performed and frequency\n\nCAGE SIDE OBSERVATIONS: Yes, but no results reported\n\n- Time schedule: no data\n\nDETAILED CLINICAL OBSERVATIONS: No data\n\nBODY WEIGHT: Yes, but only summary findings reported\n\n- Time schedule for examinations: weekly\n\nFOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):\n\n- Food consumption: No data\n\n- Compound intake: total: 70 mg - 13400 mg / animal, calculated from gavage amounts\n\nFOOD EFFICIENCY:\n\n- No data\n\nWATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data\n\nOPHTHALMOSCOPIC EXAMINATION: No\n\nHAEMATOLOGY: Yes\n\n- Time schedule for collection of blood: sacrifice at end of treatment\n\n- Anaesthetic used for blood collection: No\n\n- Animals fasted: No data\n\n- How many animals: 19 (allocation to dose groups not stated)\n\n- Parameters checked: prothrombin time, coagulation time, hemoglobin, erythrocyte count, leukocyte count (differential count in case of abnormal numbers)\n\nCLINICAL CHEMISTRY: No\n\nURINALYSIS: No\n\nNEUROBEHAVIOURAL EXAMINATION: No\n\nSacrifice and pathology\n\nGROSS PATHOLOGY: Yes\n\n- post-mortem examination on all animals dying on test or sacrificed afterward\n\nHISTOPATHOLOGY: Yes\n\n- 46 treated surviving animals (allocation to dose groups unclear)\n\nOptional endpoint(s)\n\n[Empty]\n\nOther examinations\n\n[Empty]\n\nStatistics\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results of examinations\n\nClinical signs\n\nno effects observed\n\nDescription (incidence and severity)\n\nSignificant, but fully attributed to technical accidents (intratracheal application), not related to test substance\n\nMortality\n\nno mortality observed\n\nDescription (incidence)\n\nSignificant, but fully attributed to technical accidents (intratracheal application), not related to test substance\n\nBody weight and weight changes\n\nno effects observed\n\nDescription (incidence and severity)\n\nWeights: steady increased steadily. No dose effect. Male weight range 200-310 g at end of treatment (EOT), 240-370 g 4 weeks later. Female weight range 160-205 g at EOT, 185-235 g 4 weeks later.\n\nFood consumption and compound intake (if feeding study)\n\nnot examined\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\nnot examined\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\nnot examined\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\nnot examined\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\nno effects observed\n\nDescription (incidence and severity)\n\nProthrombin times normal (29.26 - 36.55 sec); coagulation times relatively high (5-7 min); erythrocytes+hemoglobin: lower normal range. Leucocytes: wide range (300-5300 in 3 animals, >10000 in 2 animals), no influence on differential count\n\nClinical biochemistry findings\n\nnot examined\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\nnot examined\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\nnot examined\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\nnot examined\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\neffects observed, treatment-related\n\nDescription (incidence and severity)\n\nHyperemic hemorrhagic lungs, seropurulent pleurisy, pericarditis in animals dying - fully attributed to accidental intratracheal administration. No significant abnormal changes in rats necropsied at EOT.\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\nno effects observed\n\nDescription (incidence and severity)\n\nNo significant abnormal changes upon microscopical examination of internal organs at any dose.\n\nHistopathological findings: neoplastic\n\nno effects observed\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\n### Effect levels\n\n### #1\n\nKey result\n\nDose descriptor\n\nNOAEL\n\nEffect level\n\n200 \n\n\n \n\nmg/kg bw/day (actual dose received)\n\nBased on\n\ntest mat.\n\nSex\n\nmale/female\n\nBasis for effect level\n\n* other:\n  Maximum dose administered\n\nRemarks on result\n\nnot determinable\n\nno NOAEL identified\n\n### Target system / organ toxicity\n\n### #1\n\nKey result\n\nCritical effects observed\n\nnot specified\n\nLowest effective dose / conc.\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\nTreatment related\n\n[Empty]\n\nDose response relationship\n\n[Empty]\n\nRelevant for humans\n\n[Empty]\n\n### Detailed toxicology results\n\n### Detailed toxicology results\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nNo significant changes were observed at any dose, including the maximum. Non-guideline study, not considered to be reliable.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 10556,
          "status": "success"
        },
        "002 | Supporting | Experimental study": {
          "document_id": "IUC5-b970badc-22d2-420f-9cf9-c901531f4fb7_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Repeated dose toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nsub-chronic toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nMostly a review article on various toxicological and pharmacological properties of salicylamide; however, author cites an own 67-day repeated-dose experiment with mice. No experimental details, little information on clinical symptoms. No guideline followed.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Salicylamid](1a8724f0-b3c1-3a44-90c2-b7b0df88bcb2_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nApplication of 250 mg salicylamide/kg bw in the drinking water for 67 days\n\nGLP compliance\n\nno\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](6167d75d-1a51-33ac-a342-a73f9c861977_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nmouse\n\nStrain\n\nnot specified\n\nDetails on species / strain selection\n\n[Empty]\n\nSex\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\noral: drinking water\n\nDetails on route of administration\n\n[Empty]\n\nVehicle\n\nunchanged (no vehicle)\n\nDetails on oral exposure\n\n[Empty]\n\nAnalytical verification of doses or concentrations\n\nno\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDuration of treatment / exposure\n\n67 days\n\nFrequency of treatment\n\ndaily\n\n### Doses / concentrations\n\n### #1 - Doses / concentrations\n\nDose / conc.\n\n[Empty]\n\nRemarks\n\nDoses / Concentrations:\n250 mg/kg body weight\nBasis:\nnominal in water\n\nNo. of animals per sex per dose\n\nno data\n\nControl animals\n\n* yes, concurrent no treatment\n\nDetails on study design\n\n[Empty]\n\nPositive control\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nObservations and examinations performed and frequency\n\n[Empty]\n\nSacrifice and pathology\n\n[Empty]\n\nOptional endpoint(s)\n\n[Empty]\n\nOther examinations\n\n[Empty]\n\nStatistics\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results of examinations\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\n### Effect levels\n\n### #1\n\nKey result\n\nDose descriptor\n\nNOEL\n\nEffect level\n\n>=\n250 \n\n\n \n\nmg/kg bw/day (nominal)\n\nBased on\n\ntest mat.\n\nSex\n\nnot specified\n\nBasis for effect level\n\n* other:\n  No observable distinction from control animals\n\nRemarks on result\n\n[Empty]\n\n### Target system / organ toxicity\n\n### #1\n\nKey result\n\nCritical effects observed\n\nnot specified\n\nLowest effective dose / conc.\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\nTreatment related\n\n[Empty]\n\nDose response relationship\n\n[Empty]\n\nRelevant for humans\n\n[Empty]\n\n### Detailed toxicology results\n\n### Detailed toxicology results\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nNo detectable difference between treated and control animals at the end of the study (67 days).\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\n[Empty]\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 6671,
          "status": "success"
        },
        "003 | Supporting | Experimental study": {
          "document_id": "IUC5-05ac9672-bfca-476b-8b8d-e5097122e4a9_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Repeated dose toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nrepeated dose toxicity: oral\n\ncombined repeated dose and reproduction / developmental screening\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nNon-guideline study not performed under GLP. Non-standard study design. 3 âgenerations Studied in mice. Only a low level of experimental detail reported. Route of administration was in the diet at 0.1%, 0.5% or 1.0%. No data provided to show achieved concentration, homogeneity or stability in the diet preparations. Purity/composition/origin of test substance not given. Food consumption not shown but achieved doses reported as 143, 688 or 1345 mg/kg/day respectively representing 10%, 70% and 95% of the acute oral LD50. Results do not give detail of the clinical condition of the animals other than a condition percentage that was assessed on a 5 weekly basis. No record of the animal breeding procedures. Reproductive parameters are not measured in detail (44%-45% of all females across all dose groups and generations did not litter. However no dose response and no further data given) â number of females to litter (%) and pups born that were raised to weaning age (%) were reduced in all treated groups with no dose response. Parental survival time was significantly reduced compared with controls for all dose groups. As was percentage of pups raised to weaning age. A NOAEL was not derived.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Chronic toxicity studies of analgesic and antipyretic drugs and congeners](d431f89d-3491-3260-b56e-ce602805413e_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nMale and female mice in mated and unmated groups of five were powder-fed with 0.1, 0.5, and 1.0% of the test substance in the diet, starting at weaning in each generation. The condition of the mice was recorded at 5-week intervals. Food consumption and animal weight (weekly) were recorded for 50 weeks. Litters and survival of pups, as well as neoplasm formation and deaths (survival times) are reported as averages.\n\nGLP compliance\n\nno\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](e42c0357-66dd-30ec-9a55-45a3a4138a98_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nmouse\n\nStrain\n\nother:\nABC-A, albino, inbred for 25 generations\n\nDetails on species / strain selection\n\n[Empty]\n\nSex\n\nmale/female\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Source: developed in author's laboratory, derived from ABC mice (Dr. J.J. Bittner)\n\n- Age at study initiation: weanling\n\n- Weight at study initiation: no data\n\n- Fasting period before study: no\n\n- Housing: cages of 5, mated groups: 2 males and 3 females\n\n- Diet (ad libitum): Purina Labeena, Ralston-Purina Co., St. Louis, USA\n\n- Water (ad libitum): tap water\n\n- Acclimation period: none\n\nENVIRONMENTAL CONDITIONS\n\n- Temperature (Â°C), humidity (%), air changes (per hr): no data\n\n- Photoperiod (hrs dark / hrs light): 14 hours dark, 10 hours light\n\n### Administration / exposure\n\nRoute of administration\n\noral: feed\n\nDetails on route of administration\n\n[Empty]\n\nVehicle\n\nunchanged (no vehicle)\n\npowder feeding\n\nDetails on oral exposure\n\nDIET PREPARATION\n\n- Rate of preparation of diet (frequency): twice weekly\n\n- Mixing appropriate amounts with (Type of food): commercial food (Purina Labeena), finely ground\n\n- Storage temperature of food: room temperature\n\nVEHICLE\n\n- none\n\nAnalytical verification of doses or concentrations\n\nno\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDuration of treatment / exposure\n\nlifetime (averages 45.6 to 50.0 weeks in first generation) , start at weaning\n\nFrequency of treatment\n\ncontinuous, daily\n\n### Doses / concentrations\n\n### #1 - Doses / concentrations\n\nDose / conc.\n\n[Empty]\n\nRemarks\n\nDoses / Concentrations:\n0.1, 0.5, and 1.0% in feed\nBasis:\nnominal in diet\n\n### #2 - Doses / concentrations\n\nDose / conc.\n\n[Empty]\n\nRemarks\n\nDoses / Concentrations:\n143, 688, and 1345 mg/kg bw/day\nBasis:\nother: mean uptake calculated for whole dose groups, from food intake\n\nNo. of animals per sex per dose\n\n52-54 in first generation (both sexes, no details on sex)\n35-54 in second generation (both sexes, no details on sex)\n9-21 in third generation (both sexes, no details on sex)\n\nControl animals\n\n* yes, concurrent no treatment\n\nDetails on study design\n\n- Dose selection rationale: 2, 10, and 20 times the expected maximal human therapeutic dosage\n\n- Rationale for animal assignment (if not random): no data\n\n- Rationale for selecting satellite groups: mated and unmated groups, not further specified\n\n- Post-exposure recovery period in satellite groups: none\n\n- Section schedule rationale (if not random): animals maintained until spontaneous death\n\nPositive control\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nObservations and examinations performed and frequency\n\nCAGE SIDE OBSERVATIONS: Yes\n\n- Time schedule: daily (for mortality, litters)\n\nDETAILED CLINICAL OBSERVATIONS: Yes\n\n- Time schedule: 5-week intervals\n\nBODY WEIGHT: Yes\n\n- Time schedule for examinations: weekly\n\nFOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):\n\n- Food consumption for groups of animals determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes\n\n- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes\n\nFOOD EFFICIENCY:\n\n- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data\n\nWATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No\n\nOPHTHALMOSCOPIC EXAMINATION: No\n\nHAEMATOLOGY: No\n\nCLINICAL CHEMISTRY: No\n\nURINALYSIS: No\n\nNEUROBEHAVIOURAL EXAMINATION: No\n\nOTHER:\n\n- number of litters born\n\n-number of young raised to weaning age\n\nSacrifice and pathology\n\nGROSS PATHOLOGY: Yes (no table): probably limited to observation of mammary carcinoma\n\nHISTOPATHOLOGY: No\n\nOptional endpoint(s)\n\n[Empty]\n\nOther examinations\n\n[Empty]\n\nStatistics\n\nSurvival time per dose group (mean and standard error), with significant differences at p <= 0.01\nMean condition percentage for a 60-week period: average of 6 observations (at 10 week intervals), with gradings good (10), fair (5), poor (3), very poor (1), dead (0)\n% of mated females having no litters\n% of litters not raised to weaning\nMean number of pups born per female\nMean number of pups weaned per female\n% of females developing neoplasms\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results of examinations\n\nClinical signs\n\neffects observed, treatment-related\n\nDescription (incidence and severity)\n\nmean survival times in first generation: significantly shortened: 60.5 weeks in control, 50.0 weeks at dose 0.1%, 46.1 weeks at dose 0.5%, 45.6 weeks at dose 1.0%. No difference in survival times between generations.\n\nMortality\n\nmortality observed, treatment-related\n\nDescription (incidence)\n\nmean survival times in first generation: significantly shortened: 60.5 weeks in control, 50.0 weeks at dose 0.1%, 46.1 weeks at dose 0.5%, 45.6 weeks at dose 1.0%. No difference in survival times between generations.\n\nBody weight and weight changes\n\nnot specified\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\neffects observed, treatment-related\n\nDescription (incidence and severity)\n\n0.1% diet: 143 mg/kg/day, 0.5% diet: 688 mg/kg/day, 1.0 % diet: 1345 mg/kg/day\n\nFood efficiency\n\nnot specified\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\nnot examined\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\nnot examined\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\nnot examined\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\nnot examined\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\nnot examined\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\nnot examined\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\nnot examined\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\nno effects observed\n\nDescription (incidence and severity)\n\nno increase in % females with neoplasms\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\nnot examined\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\nnot examined\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\nCLINICAL SIGNS AND MORTALITY\n\n- condition maintenance percentage, with gradings good (10), fair (5), poor (3), very poor (1), dead (0): similar to controls after 10 weeks, 79% of controls after 20 weeks, steady decline to 29% of controls at 60 weeks (dose 1.0% of diet, first generation)\n\n### Effect levels\n\n### #1\n\nKey result\n\nDose descriptor\n\nNOAEL\n\nEffect level\n\n<\n1,000 \n\nmg/kg diet\n\nBased on\n\ntest mat.\n\nSex\n\nmale/female\n\nBasis for effect level\n\n* other:\n  Significant shortening of mean survival times\n\nRemarks on result\n\nnot determinable\n\nno NOAEL identified\n\n### Target system / organ toxicity\n\n### #1\n\nKey result\n\nCritical effects observed\n\nnot specified\n\nLowest effective dose / conc.\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\nTreatment related\n\n[Empty]\n\nDose response relationship\n\n[Empty]\n\nRelevant for humans\n\n[Empty]\n\n### Detailed toxicology results\n\n### Detailed toxicology results\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nRepeated doses of 10%, 70%, and 95% of the acute LD50 decreased the mean survival time up to 1/3 (dose-dependent); the effect was highly significant at all doses. No influence of the test substance on the incidence of mammary carcinoma was observed at any concentration.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nThe study is considered to be relevant, but not reliable or suitable for risk assessment or classification and labeling purposes with regard to repeat dose toxicology.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 12540,
          "status": "success"
        },
        "004 | Disregarded | Experimental study": {
          "document_id": "IUC5-e6f8e9bb-e4ab-467d-8ef7-4d5688c20a8b_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Repeated dose toxicity: oral\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nshort-term repeated dose toxicity: oral\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\ndisregarded due to major methodological deficiencies\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nNon-standard repeated-dose application with dose levels close to oral LD50. No guideline followed. High mortality rate, approc. 30% of the animals dying as a result of faulty (intrapulmonary) application. No reasonable interpretation possible.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [The toxicity and analgetic potency of salicylamide and certain of its derivatives as compared with established analgetic-antipyretic drugs](e8fe096b-45d4-3b83-a459-c0edc904d9a1_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nRepetitive daily gavage application of 35-65% of the oral LD50, 6 days per week for a maximumof 36 doses. Microscopic examination of animals dying on test\n\nGLP compliance\n\nno\n\nLimit test\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Test material information](6167d75d-1a51-33ac-a342-a73f9c861977_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrat\n\nStrain\n\nnot specified\n\nDetails on species / strain selection\n\n[Empty]\n\nSex\n\nnot specified\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\noral: gavage\n\nDetails on route of administration\n\n[Empty]\n\nVehicle\n\nother:\n1-1.5 % gum tragacanth in water\n\nDetails on oral exposure\n\nVEHICLE\n\n- Concentration in vehicle: 5 or 10 % suspension\n\n- Amount of vehicle (if gavage): no data\n\n- Justification for choice of vehicle: No appropriate solvents found to produce a true solution under physiological conditions. Suspensions satisfactorily stable.\n\nMAXIMUM DOSE VOLUME APPLIED: no data\n\nAnalytical verification of doses or concentrations\n\nno\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDuration of treatment / exposure\n\n36 doses, equal to 6 weeks\n\nFrequency of treatment\n\ndaily, 6 days per week\n\n### Doses / concentrations\n\n### #1 - Doses / concentrations\n\nDose / conc.\n\n[Empty]\n\nRemarks\n\nDoses / Concentrations:\n0.7 g/kg bw/day\nBasis:\nother: nominal, gavaged\n\n### #2 - Doses / concentrations\n\nDose / conc.\n\n[Empty]\n\nRemarks\n\nDoses / Concentrations:\n0.9 g/kg bw/day\nBasis:\nother: nominal, gavaged\n\nNo. of animals per sex per dose\n\n15 (no data for sex)\n\nControl animals\n\n* no\n\nDetails on study design\n\n- Dose selection rationale: 35-65% of single-dose oral LD50\n\nPositive control\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nObservations and examinations performed and frequency\n\nCAGE SIDE OBSERVATIONS: Yes\n\n- Time schedule: daily\n\n- Only mortality reported\n\nSacrifice and pathology\n\nGROSS PATHOLOGY: No data\n\nHISTOPATHOLOGY: Yes, only on animaly dying on test\n\nOptional endpoint(s)\n\n[Empty]\n\nOther examinations\n\n[Empty]\n\nStatistics\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results of examinations\n\nClinical signs\n\neffects observed, treatment-related\n\nDescription (incidence and severity)\n\n0.7 mg/kg bw/d: of 13 rats, 1 died after 19th dose, 6 survived all 36 doses, 6 died from intrapulmonary administration; 0.9 mg/kg bw/d: of 15 rats, 4 died after the 9th, 12th, and 19th dose, 6 survived all 36 doses, 5 died from faulty gavage\n\nMortality\n\nmortality observed, treatment-related\n\nDescription (incidence)\n\n0.7 mg/kg bw/d: of 13 rats, 1 died after 19th dose, 6 survived all 36 doses, 6 died from intrapulmonary administration; 0.9 mg/kg bw/d: of 15 rats, 4 died after the 9th, 12th, and 19th dose, 6 survived all 36 doses, 5 died from faulty gavage\n\nBody weight and weight changes\n\nnot specified\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\nnot specified\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\nnot specified\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\nnot specified\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\nnot specified\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\nnot specified\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\nnot specified\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\nnot specified\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\nnot specified\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\nnot specified\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\nnot specified\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\neffects observed, treatment-related\n\nDescription (incidence and severity)\n\nhyperemia throughout tissues, edema and alveolar hemorrhages of the lungs. One animal showed multiple foci of necrosis / cellular infiltration in liver and spleen.\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\n### Effect levels\n\n### #1\n\nKey result\n\nDose descriptor\n\nNOAEL\n\nEffect level\n\n[Empty]\n\nBased on\n\n[Empty]\n\nSex\n\n[Empty]\n\nBasis for effect level\n\n[Empty]\n\nRemarks on result\n\nnot determinable\n\nno NOAEL identified\n\n### Target system / organ toxicity\n\n### #1\n\nKey result\n\nCritical effects observed\n\nnot specified\n\nLowest effective dose / conc.\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\nTreatment related\n\n[Empty]\n\nDose response relationship\n\n[Empty]\n\nRelevant for humans\n\n[Empty]\n\n### Detailed toxicology results\n\n### Detailed toxicology results\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nNon-guideline study, compromised by too high doses and high accidental mortalities (intratracheal application). As a result, the study was discarded.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 8332,
          "status": "success"
        }
      },
      "7.5.2 Repeated dose toxicity: inhalation": {},
      "7.5.3 Repeated dose toxicity: dermal": {},
      "7.5.4 Repeated dose toxicity: other routes": {},
      "S-01 | Summary": {
        "document_id": "IUC5-06926879-579d-4b3d-b3f3-7e084a8db82e_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
        "markdown_content": "#### Repeated dose toxicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Empty]\n\nJustification\n\n[Empty]\n\nUse restricted to selected regulatory programmes\n\n[Empty]\n\n### Description of key information\n\n```\n13-week oral-gavage study, rat, highest dose 200 mg/kg bw, no guideline, Ichniowski 1946. No signs of toxicity or histopathological changes. Leucopenia suspected, but not reproducible in second, specific hematology study.  \n67-day drinking water study, mouse, 250mg/kg, no guideline, Drebinger 1952. No signs of toxicity  \nCombined 3-generation study, mouse, no guideline, non-standard method, Wright 1967. Depression of physical condition, shortening of survival time, no increase in mammary carcinoma.\n```\n\n### Key value for chemical safety assessment\n\nToxic effect type\n\n[Empty]\n\nEndpoint conclusion â systemic effects, oral route\n\nno adverse effect observed\n\nEndpoint conclusion â systemic effects, dermal\n\nno information available\n\nEndpoint conclusion â systemic effects, inhalation\n\nno information available\n\n### Short-term repeated dose toxicity â systemic effects\n\n### Oral route\n\nLink to relevant study record(s)\n\n[Empty]\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Dermal\n\nLink to relevant study record(s)\n\n[Empty]\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Inhalation\n\nLink to relevant study record(s)\n\n[Empty]\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Sub-chronic toxicity â systemic effects\n\n### Oral route\n\nLink to relevant study record(s)\n\n* [001 | Supporting | Experimental study](IUC5-e5c37048-f1ca-4984-8065-7d130ebb7aed_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n* [002 | Supporting | Experimental study](IUC5-b970badc-22d2-420f-9cf9-c901531f4fb7_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n* [003 | Supporting | Experimental study](IUC5-05ac9672-bfca-476b-8b8d-e5097122e4a9_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\nrat\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Dermal\n\nLink to relevant study record(s)\n\n[Empty]\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Inhalation\n\nLink to relevant study record(s)\n\n[Empty]\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Chronic toxicity â systemic effects\n\n### Oral route\n\nLink to relevant study record(s)\n\n[Empty]\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Dermal\n\nLink to relevant study record(s)\n\n[Empty]\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Inhalation\n\nLink to relevant study record(s)\n\n[Empty]\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\nSystem\n\n[Empty]\n\nOrgan\n\n[Empty]\n\n### Repeated dose toxicity â local effects\n\n### Dermal\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nStudy duration\n\nsubchronic\n\nSpecies\n\n[Empty]\n\n### Inhalation\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nStudy duration\n\n[Empty]\n\nSpecies\n\n[Empty]\n\n### Repeated dose toxicity: other routes\n\nLink to relevant study record(s)\n\n[Empty]\n\n### Mode of Action Analysis / Human Relevance Framework\n\n[Empty]\n\n### Justification for classification or non-classification\n\nOn the basis of the available data, salicylamide does not meet the criteria for classification and labelling according to Regulation (EC) No. 1272/2008, Annex I, Part 3, 3.9. The available data are not conclusive.\n\n### Additional information\n\nThe 13 -week rat study of Ichniowski (1946), though not conforming to any guideline, and compromised by high accidental mortalities (intratracheal application), is nevertheless considered relevant, although not reliable. It suggests that the subchronic NOAEL of salicylamide is >200 mg/kg bw, since no adverse effects were observed in the examined parameters, including histopathology and haematology.\n\n \n\nThe 67-day mouse study (Drebinger 1952), though inadequately documented, supports this finding, since no signs of toxicity were found at 250 mg/kg.\n\n \n\nIn contrast, the combined 3-generation mouse lifetime feeding study (Wright 1967) used far higher doses (up to 1345 mg/kg bw/day), at which depression of physical condition (not further specified) and shortening of survival time were observed. A consistent interpretation and comparison is not possible.\n\n \n\nNo study identified a NOAEL for repeated-dose toxicity for salicylamide and none are regarded as adequate for use in risk assessment and classification and labelling.\n\n**Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:**   \nThe 13 -week rat study of Ichniowski (1946), though not conforming to any guideline, and compromised by high accidental mortalities (intratracheal application), is nevertheless considered relevant, although not reliable. It suggests that the subchronic NOAEL of salicylamide is >200 mg/kg bw, since no adverse effects were observed in the examined parameters, including histopathology and haematology.\n\n### Attached background material\n\nBack to top",
        "content_length": 5898,
        "status": "success"
      }
    },
    "7.6 Genetic toxicity": {
      "7.6.1 Genetic toxicity in vitro": {
        "001 | Weight of evidence | Experimental study": {
          "document_id": "IUC5-37e7b1cc-1ed5-42ee-932a-905402afcac8_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Genetic toxicity in vitro\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nin vitro gene mutation study in bacteria\n\nType of genotoxicity: gene mutation\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nweight of evidence\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards. Experimental details well documented, no explicit reference to guideline. Strains tested: S. typhimurium TA1535, TA100, TA1538, TA98, TA1537; E. coli K12/343/113. The strains TA102 (S. typhimurium) or WP2 uvrA (E. coli) requested by the guideline OECD 471 were not tested. Highest tested dose 9600 micrograms/plate with S. Typhimurium, but only 3700 micrograms/plate with E.coli. No individual data on treated plates and positive/negative controls reported; significance of differences in mutant frequencies assessed by chi square test.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Mutagenicity studies with X-ray-contrast media, analgesics, antipyretics, antirheumatics and some other pharmaceutical drugs in bacterial, Drosophila and mammalian test systems](aac49774-40b5-357e-b59a-7f6cf5d50805_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nOECD Guideline 471 (Bacterial Reverse Mutation Assay)\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\nyes\n\nStrains TA102 and/or WP2 uvrA lacking; E.coli: tested only up to 3600 microgram/plate\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nType of assay\n\nbacterial reverse mutation assay\n\n### Test material\n\nTest material information\n\n[Test material information](0d8f64df-0581-30c1-957c-4a54aa8c1deb_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Method\n\nTarget gene\n\nhis G46, D3052, C3076\nE. coli K12/343/113: mutations to 5-methyltryptophane resistance, galactose utilization, arginine independence tested\n\n### Species / strain\n\n### #1 - Species / strain\n\nSpecies / strain / cell type\n\nS. typhimurium TA 1535, TA 1537, TA 98 and TA 100\n\nDetails on mammalian cell type (if applicable)\n\n[Empty]\n\nAdditional strain / cell type characteristics\n\n[Empty]\n\n### #2 - Species / strain\n\nSpecies / strain / cell type\n\nS. typhimurium TA 1538\n\nDetails on mammalian cell type (if applicable)\n\n[Empty]\n\nAdditional strain / cell type characteristics\n\n[Empty]\n\n### #3 - Species / strain\n\nSpecies / strain / cell type\n\nE. coli, other:\nK12/343/113\n\nDetails on mammalian cell type (if applicable)\n\n[Empty]\n\nAdditional strain / cell type characteristics\n\n[Empty]\n\nCytokinesis block (if used)\n\n[Empty]\n\nMetabolic activation\n\nwith and without\n\nMetabolic activation system\n\nS9 liver fraction (Sprague-Dawley SIV-50 rats) induced with Aroclor 1254\n\nTest concentrations\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\ngenerally: at least 5 concentrations up to 3600 microgram/plate\n\nhighest tested dose from table of experimental results: S. typhimurium 70 micromoles/plate = 9600 microgram/plate; E.coli: 10 mM = 3600 microgram/plate\n\nVehicle / solvent\n\n- Vehicle(s)/solvent(s) used: DMSO 30 microliter\n\n- Justification for choice of solvent/vehicle: solubility of test substance\n\n### Controls\n\n### #1 - Controls\n\nUntreated negative controls\n\nnot specified\n\nNegative solvent / vehicle controls\n\nyes\n\nTrue negative controls\n\nno\n\nPositive controls\n\nyes\n\nPositive control substance\n\n* benzo(a)pyrene\n\nRemarks\n\nMigrated to IUCLID6: MNNG (N-methyl-N'-nitro-N-nitrosoguanidine), 2-aminoanthracene, N-nitrosomorpholine\n\nDetails on test system and experimental conditions\n\nMETHOD OF APPLICATION: S. typhimurium: in agar (plate incorporation); sometimes also with preincubation; E. coli: in suspension\n\nDURATION\n\n- Preincubation period: 30 min at 37Â°C\n\n- Exposure duration: not explicitly stated (routine test according to Ames BN et al, Mutation Research 31: 347-364 (1975))\n\nNUMBER OF REPLICATIONS: no explicit data (sufficient to perform chi square test)\n\nNUMBER OF CELLS EVALUATED: no data\n\nDETERMINATION OF CYTOTOXICITY\n\n- No details given\n\n- Probably none observed, since concentrations up to 9600 micrograms/plate were reported\n\nRationale for test conditions\n\n[Empty]\n\nEvaluation criteria\n\n[Empty]\n\nStatistics\n\nChi square test to assess significance of differences between absolute mutant frequencies in the control and the test series\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Test results\n\n### #1 - Test results\n\nKey result\n\nSpecies / strain\n\nS. typhimurium TA 100\n\nMetabolic activation\n\nwith and without\n\nGenotoxicity\n\nnegative\n\n9600 micrograms/plate\n\nCytotoxicity / choice of top concentrations\n\nnot specified\n\nprobably none, max. dose 9600 micrograms/plate reported\n\nVehicle controls validity\n\nnot specified\n\nUntreated negative controls validity\n\nnot specified\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\nnot specified\n\n### #2 - Test results\n\nKey result\n\nSpecies / strain\n\nS. typhimurium TA 98\n\nMetabolic activation\n\nwith and without\n\nGenotoxicity\n\nnegative\n\n9600 micrograms/plate\n\nCytotoxicity / choice of top concentrations\n\nnot specified\n\nprobably none, max. dose 9600 micrograms/plate reported\n\nVehicle controls validity\n\nnot specified\n\nUntreated negative controls validity\n\nnot specified\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\nnot specified\n\n### #3 - Test results\n\nKey result\n\nSpecies / strain\n\nS. typhimurium TA 1537\n\nMetabolic activation\n\nwith and without\n\nGenotoxicity\n\nnegative\n\n9600 micrograms/plate\n\nCytotoxicity / choice of top concentrations\n\nnot specified\n\nprobably none, max. dose 9600 micrograms/plate reported\n\nVehicle controls validity\n\nnot specified\n\nUntreated negative controls validity\n\nnot specified\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\nnot specified\n\n### #4 - Test results\n\nKey result\n\nSpecies / strain\n\nS. typhimurium TA 1535\n\nMetabolic activation\n\nwith and without\n\nGenotoxicity\n\nnegative\n\n9600 micrograms/plate\n\nCytotoxicity / choice of top concentrations\n\nnot specified\n\nprobably none, max. dose 9600 micrograms/plate reported\n\nVehicle controls validity\n\nnot specified\n\nUntreated negative controls validity\n\nnot specified\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\nnot specified\n\n### #5 - Test results\n\nKey result\n\nSpecies / strain\n\nS. typhimurium TA 1538\n\nMetabolic activation\n\nwith and without\n\nGenotoxicity\n\nnegative\n\nup to 9600 micrograms/plate\n\nCytotoxicity / choice of top concentrations\n\nnot specified\n\nprobably none, max. dose 9600 micrograms/plate reported\n\nVehicle controls validity\n\nnot specified\n\nUntreated negative controls validity\n\nnot specified\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\nnot specified\n\n### #6 - Test results\n\nKey result\n\nSpecies / strain\n\nE. coli, other:\nK12/343/113\n\nMetabolic activation\n\nwith and without\n\nGenotoxicity\n\nnegative\n\nup to 3600 micrograms/plate\n\nCytotoxicity / choice of top concentrations\n\nnot specified\n\nprobably none, max. dose 3600 micrograms/plate reported\n\nVehicle controls validity\n\nnot specified\n\nUntreated negative controls validity\n\nnot specified\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\nnot specified\n\nAdditional information on results\n\n[Empty]\n\nRemarks on result\n\nother:\nall strains/cell types tested\n\nMigrated from field 'Test system'.\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nIntrasanguineous host mediated test (Mohn G, Ellenberger J, The use of Escherichia coli K12/343/113 as a multipurpose indicator strain in various mutagenicity testing procedures, in Kilbey M, Legator W, Nichols W & Ramel C, Handbook of mutagenicity test procedures, Elsevier Amsterdam (1977), 95 -118) in female NMRI mice injected with 8000'000'000 cells E. coli K12/343/113 and treated with salicylamide, 550 mg/kg i.p.:\n\nNegative\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nInterpretation of results (migrated information):\n\nnegative\n\nThe study is considered to be reliable with some restrictions and suitable for use as part of a weight-of-evidence assessment.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 9930,
          "status": "success"
        },
        "002 | Weight of evidence | Experimental study": {
          "document_id": "IUC5-522e27ec-8dea-4544-bb4f-a7fc5729977e_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Genetic toxicity in vitro\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nin vitro gene mutation study in bacteria\n\nType of genotoxicity: gene mutation\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nweight of evidence\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards. Experimental details well documented, no explicit reference to guideline. Strains tested: S. typhimurium TA98 and TA100. The strains TA 1535, TA1537, TA102 (S. typhimurium) or WP2 uvrA (E. coli) requested by the guideline OECD 471 were not tested. Highest tested dose 100 micrograms/plate.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Mutagenicity of analgesics, their derivatives, and anti-inflammatory drugs with S-9 mix of several animal species](fce339d8-e338-3ab1-838f-05a313930f05_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nOECD Guideline 471 (Bacterial Reverse Mutation Assay)\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\nyes\n\nOnly strains TA98 and TA100; maximum dose 100 microgram/plate\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nType of assay\n\nbacterial reverse mutation assay\n\n### Test material\n\nTest material information\n\n[Test material information](9753512f-637f-320c-8175-d5f82e1d6251_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Method\n\nTarget gene\n\nhis D3052, G46\n\n### Species / strain\n\n### #1 - Species / strain\n\nSpecies / strain / cell type\n\nS. typhimurium TA 98\n\nDetails on mammalian cell type (if applicable)\n\n[Empty]\n\nAdditional strain / cell type characteristics\n\n[Empty]\n\n### #2 - Species / strain\n\nSpecies / strain / cell type\n\nS. typhimurium TA 100\n\nDetails on mammalian cell type (if applicable)\n\n[Empty]\n\nAdditional strain / cell type characteristics\n\n[Empty]\n\nCytokinesis block (if used)\n\n[Empty]\n\nMetabolic activation\n\nwith and without\n\nMetabolic activation system\n\nS9 liver mix from male rats (SD strain), male mice (ddy strain), male guinea pigs (Hartley strain) and male golden hamsters; all induced with 500 mg/kg polychlorobiphenyl i.p.\n\nTest concentrations\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n0.1 mg / plate\n\nVehicle / solvent\n\nDMSO 0.1 ml / plate\n\n### Controls\n\n### #1 - Controls\n\nUntreated negative controls\n\nno\n\nNegative solvent / vehicle controls\n\nyes\n\nTrue negative controls\n\nno\n\nPositive controls\n\nyes\n\nPositive control substance\n\n* 4-nitroquinoline-N-oxide\n\nRemarks\n\nMigrated to IUCLID6: AF-2 (furyl furamide, 2-(furan-2-yl)-3-(5-nitrofuran-2-yl)prop-2-enamide), benzopyrene\n\nDetails on test system and experimental conditions\n\nMETHOD OF APPLICATION: preincubation\n\nDURATION\n\n- Preincubation period: 30 min at 37Â°\n\n- Exposure duration: 48 h at 37Â°\n\nNUMBER OF REPLICATIONS: 5\n\nNUMBER OF CELLS EVALUATED: no data\n\nRationale for test conditions\n\n[Empty]\n\nEvaluation criteria\n\nnumber of his+ revertants more than twice the number of spontaneous revertants considered to be mutagenic\n\nStatistics\n\nmean and standard deviation for 5 plates\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Test results\n\n### #1 - Test results\n\nKey result\n\nSpecies / strain\n\nS. typhimurium TA 98\n\nMetabolic activation\n\nwith and without\n\nGenotoxicity\n\nnegative\n\nMost revertant numbers below those of DMSO control\n\nCytotoxicity / choice of top concentrations\n\nnot specified\n\nVehicle controls validity\n\nvalid\n\nUntreated negative controls validity\n\nnot examined\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\nvalid\n\n### #2 - Test results\n\nKey result\n\nSpecies / strain\n\nS. typhimurium TA 100\n\nMetabolic activation\n\nwith and without\n\nGenotoxicity\n\nnegative\n\nMaximum ratio of revertant numbers (treated / DMSO control) = 1.27\n\nCytotoxicity / choice of top concentrations\n\nnot specified\n\nVehicle controls validity\n\nvalid\n\nUntreated negative controls validity\n\nnot examined\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\nvalid\n\nAdditional information on results\n\n[Empty]\n\nRemarks on result\n\nother:\nall strains/cell types tested\n\nMigrated from field 'Test system'.\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nInterpretation of results (migrated information):\n\nnegative\n\nThe study is considered to be reliable with some restrictions and suitable for use as part of a weight-of-evidence assessment.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 6317,
          "status": "success"
        },
        "003 | Weight of evidence | Experimental study": {
          "document_id": "IUC5-3646958b-9bcf-4b23-93b2-6d63448a71c3_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Genetic toxicity in vitro\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nin vitro gene mutation study in bacteria\n\nType of genotoxicity: gene mutation\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nweight of evidence\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards, within the National Toxicology Program's mutagenicity program. Two independent tests were performed at different laboratories.Experimental details well documented, no explicit reference to guideline. Strains tested: S. typhimurium TA100, TA1535, TA97, TA98. The strains TA102 (S. typhimurium) or WP2 uvrA (E. coli) requested by the guideline OECD 471 were not tested.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Salmonella mutagenicity tests: V. Results from the testing of 311 chemicals](c13fd690-f46a-3373-abdd-3ef821b0b686_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nOECD Guideline 471 (Bacterial Reverse Mutation Assay)\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\nyes\n\nStrains TA102 and/or WP2 uvrA lacking\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nType of assay\n\nbacterial reverse mutation assay\n\n### Test material\n\nTest material information\n\n[Test material information](5bd347d2-df84-3965-ba03-44be0bb9e165_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Method\n\nTarget gene\n\nhis G46, C3076, D3052\n\n### Species / strain\n\n### #1 - Species / strain\n\nSpecies / strain / cell type\n\nS. typhimurium TA 100\n\nDetails on mammalian cell type (if applicable)\n\n[Empty]\n\nAdditional strain / cell type characteristics\n\n[Empty]\n\n### #2 - Species / strain\n\nSpecies / strain / cell type\n\nS. typhimurium TA 1535\n\nDetails on mammalian cell type (if applicable)\n\n[Empty]\n\nAdditional strain / cell type characteristics\n\n[Empty]\n\n### #3 - Species / strain\n\nSpecies / strain / cell type\n\nS. typhimurium TA 97\n\nDetails on mammalian cell type (if applicable)\n\n[Empty]\n\nAdditional strain / cell type characteristics\n\n[Empty]\n\n### #4 - Species / strain\n\nSpecies / strain / cell type\n\nS. typhimurium TA 98\n\nDetails on mammalian cell type (if applicable)\n\n[Empty]\n\nAdditional strain / cell type characteristics\n\n[Empty]\n\nCytokinesis block (if used)\n\n[Empty]\n\nMetabolic activation\n\nwith and without\n\nMetabolic activation system\n\n10% and 30% S-9 fraction of male Syrian hamster liver, Aroclor 1254 induced, 10% and 30% S-9 fraction of male Sprague-Dawley rat liver, Aroclor 1254 induced\n\nTest concentrations\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\nLaboratory MIC (Microbiological Associates, Rockville MD): 100, 333, 1000, 3334, 6667 microgram/plate\n\nLaboratory SRI (SRI International, Menlo Park, CA): 33, 100, 333, 1000, 1666, 3334 microgram/plate\n\nVehicle / solvent\n\n- Vehicle(s)/solvent(s) used: DMSO\n\n- Justification for choice of solvent/vehicle: Solubility of test substance\n\n### Controls\n\n### #1 - Controls\n\nUntreated negative controls\n\nyes\n\nwater, in test for acetic acid and others\n\nNegative solvent / vehicle controls\n\nyes\n\nTrue negative controls\n\nno\n\nPositive controls\n\nyes\n\nPositive control substance\n\n* sodium azide\n\nRemarks\n\nwithout metabolic activation\nMigrated to IUCLID6: 9-aminoacridine, 4-nitro-o-phenylenediamine\n\n### #2 - Controls\n\nUntreated negative controls\n\nyes\n\nwater, in test for acetic acid and others\n\nNegative solvent / vehicle controls\n\nyes\n\nTrue negative controls\n\nno\n\nPositive controls\n\nyes\n\nPositive control substance\n\n* other:\n  2-aminoanthracene\n\nRemarks\n\nwith metabolic activation\n\nDetails on test system and experimental conditions\n\nMETHOD OF APPLICATION: preincubation\n\nDURATION\n\n- Preincubation period: 20 min. at 37Â°C\n\n- Exposure duration: 2 days at 37Â°C\n\nNUMBER OF REPLICATIONS:\n\n- triplicate per trial and dose\n\n- repeat trial at least one week following the initial trial\n\nNUMBER OF CELLS EVALUATED:\n\n- no data\n\n- plates machine-counted (New Brunswick; Artek) unless precipitate present\n\nDETERMINATION OF CYTOTOXICITY\n\n- Method: Initial toxicity assay with TA100; toxic concentrations defined as those producing a decrease in number of his+ colonies, a clearing of the density of the background lawn, or both\n\nRationale for test conditions\n\n[Empty]\n\nEvaluation criteria\n\nIndividual trials judged mutagenic (+), weakly mutagenic (+W), questionable (?), or non-mutagenic (-), depending on magnitude of increase in his+ revertants, and the shape of the dose-response. Questionable (?) applied, if only a single dose elevated, or a weak increase not dose-related. It was not necessary for a response to reach two-fold over background to be judged mutagenic.\nA chemical was judged mutagenic, if it produced a reproducible, dose-related response over solvent control in replicate trial, under a single metabolic activation condition.\n\nStatistics\n\nMean and SEM (standard error of mean)\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Test results\n\n### #1 - Test results\n\nKey result\n\nSpecies / strain\n\nS. typhimurium TA 100\n\nMetabolic activation\n\nwith and without\n\nGenotoxicity\n\nnegative\n\nCytotoxicity / choice of top concentrations\n\ncytotoxicity\n\nslight clearing of background lawn at 6667 microgram/plate\n\nVehicle controls validity\n\nvalid\n\nUntreated negative controls validity\n\nvalid\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\nvalid\n\n### #2 - Test results\n\nKey result\n\nSpecies / strain\n\nS. typhimurium TA 1535\n\nMetabolic activation\n\nwith and without\n\nGenotoxicity\n\nnegative\n\nCytotoxicity / choice of top concentrations\n\nno cytotoxicity nor precipitates, but tested up to recommended limit concentrations\n\nVehicle controls validity\n\nvalid\n\nUntreated negative controls validity\n\nvalid\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\nvalid\n\n### #3 - Test results\n\nKey result\n\nSpecies / strain\n\nS. typhimurium TA 97\n\nMetabolic activation\n\nwith and without\n\nGenotoxicity\n\nnegative\n\nCytotoxicity / choice of top concentrations\n\ncytotoxicity\n\nslight clearing of background lawn at 6667 microgram/plate\n\nVehicle controls validity\n\nvalid\n\nUntreated negative controls validity\n\nvalid\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\nvalid\n\n### #4 - Test results\n\nKey result\n\nSpecies / strain\n\nS. typhimurium TA 98\n\nMetabolic activation\n\nwith and without\n\nGenotoxicity\n\nnegative\n\nCytotoxicity / choice of top concentrations\n\ncytotoxicity\n\nslight clearing of background lawn at 6667 microgram/plate\n\nVehicle controls validity\n\nvalid\n\nUntreated negative controls validity\n\nvalid\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\nvalid\n\nAdditional information on results\n\n[Empty]\n\nRemarks on result\n\nother:\nall strains/cell types tested\n\nMigrated from field 'Test system'.\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nGood consistence between results from two laboratories. Maximum increase of revertant count over solvent control in any single dose: 30 % (TA 100, 30% hamster liver S-9, in only one laboratory). No dose-related increase in any trial.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nInterpretation of results (migrated information):\n\nnegative\n\nThe study is considered to be reliable with some restrictions and suitable for use as part of a weight-of-evidence assessment.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 9039,
          "status": "success"
        },
        "004 | Weight of evidence | Experimental study": {
          "document_id": "IUC5-7611b63a-4913-4c59-adbe-e37d6ee2e881_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Genetic toxicity in vitro\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nin vitro chromosome aberration study in mammalian cells\n\nType of genotoxicity: chromosome aberration\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nweight of evidence\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a data book by the National Institute of Hygienic Sciences, Tokyo, Japan, containing chromosome aberration data on 779 chemicals. Study performed according to scientific standards, experimental details well documented, explicit reference to guidelines OECD 473 and US EPA OPPTS \"In vitro mammalian cytogenetics\". Deficiencies: No replications indicated; only 100 metaphases per concentration counted.\n\nPositive results for salicylamide (including polyploidy) were only observed at a cytotoxic concentration (>50% inhibition) of 3.6 mM.\n\nA secondary source (Ishidate et al, Mutation Research 195: 151-213 (1988) quotes the original result without any further information.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Reference](ef503d48-26bf-3a37-8086-bbaeb3122196_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n* [A comparative analysis of data on the clastogenicity of 951 chemical substances tested in mammalian cell cultures](512fd5d1-5adf-3172-a55c-06ca934a8d4f_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\naccording to guideline\n\nGuideline\n\nOECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)\n\nVersion / remarks\n\nadopted 1983\n\nDeviations\n\nyes\n\nNo replications indicated, only 100 metaphases per concentration counted\n\n### #2 - Test guideline\n\nQualifier\n\naccording to guideline\n\nGuideline\n\nEPA OPPTS 870.5375 - In vitro Mammalian Chromosome Aberration Test\n\nVersion / remarks\n\nAugust 1982\n\nDeviations\n\nyes\n\nNo replications indicated, only 100 metaphases per concentration counted\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nType of assay\n\nin vitro mammalian chromosome aberration test\n\n### Test material\n\nTest material information\n\n[Test material information](834526d1-13b7-379d-910c-910361745517_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Method\n\nTarget gene\n\n[Empty]\n\n### Species / strain\n\n### #1 - Species / strain\n\nSpecies / strain / cell type\n\nChinese hamster lung fibroblasts (V79)\n\nDetails on mammalian cell type (if applicable)\n\n- Fibroblast cell line from the lung of a newborn female Chinese hamster, established in 1970\n\n- Type and identity of media: Eagle's MEM (Gibco) with 10% inactivated calf serum\n\n- Properly maintained: yes (single-cell subclone 1973-1987)\n\n- Periodically checked for Mycoplasma contamination: no data\n\n- Periodically checked for karyotype stability: yes (25 chromosomes, compared with 22 for Chinese hamster)\n\n- Periodically \"cleansed\" against high spontaneous background: no data\n\n- Doubling time: approx. 15 hours\n\n- Cells proliferate in monolayers\n\nAdditional strain / cell type characteristics\n\n[Empty]\n\nCytokinesis block (if used)\n\n[Empty]\n\nMetabolic activation\n\nwith and without\n\nMetabolic activation system\n\nRat (Wistar or Fisher) liver S9 fraction, after induction with 500 mg/kg polychlorinated biphenyls i.p.\n\nTest concentrations\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n0.125, 0.25, 0.5 mg/ml\n\nVehicle / solvent\n\nEthanol\n\n### Controls\n\n### #1 - Controls\n\nUntreated negative controls\n\nyes\n\nNegative solvent / vehicle controls\n\nyes\n\nTrue negative controls\n\nyes\n\n414/779 substances tested negative\n\nPositive controls\n\nyes\n\n313/779 substances tested positive\n\nPositive control substance\n\n[Empty]\n\nRemarks\n\npositive controls not explicitly mentioned as such\n\nDetails on test system and experimental conditions\n\nMETHOD OF APPLICATION: in medium\n\nDURATION\n\n- Preincubation period: 3 days\n\n- Exposure duration: 24 and 48 hours\n\n- Expression time (cells in growth medium): 24 and 48 hours\n\n- Fixation time (start of exposure up to fixation or harvest of cells): 24 and 48 hours\n\nNUMBER OF REPLICATIONS:\n\n- none mentioned\n\nNUMBER OF CELLS EVALUATED: 100 metaphases\n\nDETERMINATION OF CYTOTOXICITY\n\n- Method: relative total growth: Cell proliferation after 2 days of exposure assessed indirectly by rate of staining (0.1% crystal violet after formalin fixation), proliferation of solvent control set to 100%. A concentration with approximately 50% inhibition was used as standard.\n\nOTHER EXAMINATIONS:\n\n- Determination of polyploidy: yes\n\n- Determination of endoreplication: no data\n\nRationale for test conditions\n\n[Empty]\n\nEvaluation criteria\n\nStructural aberrations classified as chromatid gaps, breaks, and exchanges, or chromosome gaps, breaks, and exchanges. A cell having any of these was recorded as aberrant.\nNegative: <5% aberrant cells, inconclusive 5 - <10%, positive 10% and more\n\nStatistics\n\nLeast-square regression lines incl. solvent control points (linear or semi-logarithmic) used to interpolate or extrapolate to D20 (concentration in mg/ml inducing any aberration in 20% of the metaphases).\nTR values in experiments with positive results were calculated as E/D (with E= number of cells with exchanges, D = concentration in mg/ml). The highest TR value was reported for the substance.\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Test results\n\n### #1 - Test results\n\nKey result\n\nSpecies / strain\n\nChinese hamster lung fibroblasts (V79)\n\nMetabolic activation\n\nwithout\n\nGenotoxicity\n\npositive\n\n10% incidence of aberrant cells (exactly at threshold) after 48 hours; 7% after 24 hours (inconclusive)\n\nCytotoxicity / choice of top concentrations\n\ncytotoxicity\n\nVehicle controls validity\n\nvalid\n\nUntreated negative controls validity\n\nvalid\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\nvalid\n\nAdditional information on results\n\n[Empty]\n\nRemarks on result\n\nother:\nall strains/cell types tested\n\nMigrated from field 'Test system'.\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nIt must be noted that gaps are included in the score of cells with structural chromosome aberrations, although they should generally not be included in the total aberration frequency, according to OECD 473. Their frequency is 3% (of a total of 7%) after 24 hours, and 2% (of a total of 10%) after 48 hours.\n\nDetailed results show that chromosome aberration occurs only at the highest concentration (3.6 mM); the frequency is 7% (inconclusive) after 24 hours and just reaches the margin of \"positive\" (10%) after 48 hours. Polyploidy also occurs only at the highest concentration. \n\nSample selection in this study was based on cytotoxicity preliminary screening; a concentration with approx. 50 % inhibition was used as a standard, and usually 3 concentrations above and below this standard were included in the CA test. In case of no cytotoxicity , about 10 mM were tested.\n\nNo details on cytotoxicity are reported for salicylamide, but from the highest tested concentration of 0.5 mg/mL = 3.6 mM we conclude that\n\n1. there was cytotoxicity observed (without cytotox, the testing limit would be about 10 mM)\n\n2. the second highest concentration tested (0.25 mg/mL) would be the standard with approximately 50% inhibition, and the highest concentration was probably more inhibitory.\n\nIt cannot be derived from the data whether a high degree of cytotoxicity influenced the results of the chromosome aberration test.\n\n|  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| Treatment time | Concen- tration | Meta- phases | Polyploid | |  | Chromatid changes % |  |  | Chromo- some changes % |  |  | Judge- ment |\n| hrs | mg/mL | number | % | Judge | Gaps | Breaks | Exch. | Gaps | Breaks | Exch. | Total |  |\n| 24 | None | 100 | 1 |  | 2 | 0 | 0 | 0 | 0 | 0 | 2 |  |\n| 24 | 0.125 | 100 | 0 | - | 3 | 0 | 0 | 0 | 0 | 0 | 3 | - |\n| 24 | 0.25 | 100 | 2 | - | 3 | 1 | 0 | 0 | 0 | 0 | 4 | - |\n| 24 | 0.5 | 100 | 1 | - | 3 | 5 | 0 | 0 | 0 | 0 | 7 | +/- |\n| 48 | Ethanol | 100 | 0 |  | 0 | 0 | 1 | 0 | 0 | 0 | 1 |  |\n| 48 | 0.125 | 100 | 1 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |\n| 48 | 0.25 | 100 | 4 | - | 1 | 1 | 2 | 0 | 0 | 0 | 3 | - |\n| 48 | 0.5 | 100 | 12 | + | 2 | 7 | 3 | 0 | 0 | 0 | 10 | + |\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nInterpretation of results (migrated information):\n\npositive without metabolic activation after 24 hours: ambiguous (7% aberrations), after 48 hours: positive (10% aberrations, including gaps, borderline)\n\nThe study is considered to be reliable with some restrictions and suitable for use as part of a weight-of-evidence assessment. The result is considered to be borderline.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 10314,
          "status": "success"
        },
        "005 | Supporting | Experimental study": {
          "document_id": "IUC5-9a1ad02c-6cd8-4200-90d2-ed5acf17f03f_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Genetic toxicity in vitro\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nin vitro gene mutation study in bacteria\n\nType of genotoxicity: gene mutation\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nQuotation of National Toxicity Program database for experimental results. No experimental data; strains etc. given. Reporting of various QSAR predictions. No validation of QSARs.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Prediction of Salmonella mutagenicity](1f8f9d98-c889-38a5-adf7-2f9ba08c8d67_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nNo details in publication\n\nGLP compliance\n\nnot specified\n\nType of assay\n\nbacterial reverse mutation assay\n\n### Test material\n\nTest material information\n\n[Test material information](c9f12405-8ed0-34fc-83e1-0e5c0ec0bde4_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Method\n\nTarget gene\n\n[Empty]\n\n### Species / strain\n\n### #1 - Species / strain\n\nSpecies / strain / cell type\n\nS. typhimurium, other:\nTA97, TA98, TA100, TA1535\n\nDetails on mammalian cell type (if applicable)\n\n[Empty]\n\nAdditional strain / cell type characteristics\n\n[Empty]\n\nCytokinesis block (if used)\n\n[Empty]\n\nMetabolic activation\n\nwith and without\n\nMetabolic activation system\n\nAroclor 1254-induced rat and hamster liver S9\n\nTest concentrations\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\nno data\n\nVehicle / solvent\n\n[Empty]\n\n### Controls\n\n### #1 - Controls\n\nUntreated negative controls\n\nnot specified\n\nNegative solvent / vehicle controls\n\nnot specified\n\nTrue negative controls\n\nnot specified\n\nPositive controls\n\nnot specified\n\nPositive control substance\n\n* not specified\n\nRemarks\n\n[Empty]\n\nDetails on test system and experimental conditions\n\nMETHOD OF APPLICATION: preincubation\n\nRationale for test conditions\n\n[Empty]\n\nEvaluation criteria\n\n[Empty]\n\nStatistics\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Test results\n\n### #1 - Test results\n\nKey result\n\nSpecies / strain\n\nS. typhimurium, other:\nTA97, TA98, TA100, TA1535\n\nMetabolic activation\n\nwith and without\n\nGenotoxicity\n\nnegative\n\nCytotoxicity / choice of top concentrations\n\nnot specified\n\nVehicle controls validity\n\nnot specified\n\nUntreated negative controls validity\n\nnot specified\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\nnot specified\n\nAdditional information on results\n\n[Empty]\n\nRemarks on result\n\nother:\nall strains/cell types tested\n\nMigrated from field 'Test system'.\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nSeveral SAR and QSAR methods were applied:\n\nSA (structural alert; Ashby, J., Environ. Mutagen., 1985, 7, 919 -921)\n\nSA+ (structural alert with intervention of expert judgement; Ashby)\n\nCASE (Computer Automated Structure Evaluator, with learning sets from NTP and US-EPA)\n\nTOPKAT\n\nAll gave consistent negative (non-mutagenic) predictions for 2 -hydroxybenzamide.\n\nThe ke procedure (Bakale G., et al, Carcinogenesis, 1987, 8, 253 -264) gave a questionable result, ke = 3.1\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nInterpretation of results (migrated information):\n\nnegative\n\nThe study is considered to be suitable for use as supporting information.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5077,
          "status": "success"
        },
        "006 | Supporting | Experimental study": {
          "document_id": "IUC5-8ed68848-9e74-4d96-bb04-989e5c492037_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Genetic toxicity in vitro\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nin vitro DNA damage and/or repair study\n\nType of genotoxicity: DNA damage and/or repair\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nStudy published in a peer-reviewed journal, according to scientific standards. Experimental details well documented. No guideline for Rec-assay available.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Mutagenicity of analgesics, their derivatives, and anti-inflammatory drugs with S-9 mix of several animal species](fce339d8-e338-3ab1-838f-05a313930f05_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline available\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nCold-incubation method (Kada T & Sadaie Y (1972), In vitro and host-mediated \"Rec-assay\" procedures for screening chemical mutagens, and phloxine, a mutagenic red dye detected, Mutation Res. 16: 165 - 174). Rec+ and Rec- strains of B. subtilis used to assess length of inhibition zone.\n\nGLP compliance\n\nno\n\nType of assay\n\nBacillus subtilis recombination assay\n\n### Test material\n\nTest material information\n\n[Test material information](ff8ee903-08ef-3a04-83bc-675789ec01d9_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Method\n\nTarget gene\n\nRec+ and Rec-\n\n### Species / strain\n\n### #1 - Species / strain\n\nSpecies / strain / cell type\n\nbacteria, other:\nBacillus subtilis, strains H17 and M45\n\nDetails on mammalian cell type (if applicable)\n\n[Empty]\n\nAdditional strain / cell type characteristics\n\n[Empty]\n\nCytokinesis block (if used)\n\n[Empty]\n\nMetabolic activation\n\nwithout\n\nMetabolic activation system\n\n[Empty]\n\nTest concentrations\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n5 mg/disc\n\nVehicle / solvent\n\nDMSO\n\n### Controls\n\n### #1 - Controls\n\nUntreated negative controls\n\nno\n\nNegative solvent / vehicle controls\n\nyes\n\nDMSO\n\nTrue negative controls\n\nno\n\nPositive controls\n\nyes\n\nPositive control substance\n\n* 4-nitroquinoline-N-oxide\n\nRemarks\n\nMigrated to IUCLID6: mitomycin C\n\nDetails on test system and experimental conditions\n\nMETHOD OF APPLICATION: as impregnation on paper disk\n\nDURATION\n\n- Cold incubation period: 24 h at 4Â°C\n\n- Incubation period: 24 h at 37Â°C\n\nNUMBER OF REPLICATIONS: 5\n\nRationale for test conditions\n\n[Empty]\n\nEvaluation criteria\n\nLength of inhibition zone of cellular growth: difference between Rec+ and Rec- strains >= 2mm considered positive (damaging effect on cellular DNA)\n\nStatistics\n\nmean and standard deviation for 5 plates\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Test results\n\n### #1 - Test results\n\nKey result\n\nSpecies / strain\n\nbacteria, other:\nBacillus subtilis, strains H17 and M45\n\nMetabolic activation\n\nwithout\n\nGenotoxicity\n\nnegative\n\nCytotoxicity / choice of top concentrations\n\nnot determined\n\nVehicle controls validity\n\nvalid\n\nUntreated negative controls validity\n\nnot specified\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\nvalid\n\nAdditional information on results\n\n[Empty]\n\nRemarks on result\n\nother:\nall strains/cell types tested\n\nMigrated from field 'Test system'.\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nLength of inhibition zone 0.0 +/- 0.0 mm both with Rec+ and Rec-\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nInterpretation of results (migrated information):\n\nnegative\n\nThe study is considered to be suitable for use as supporting information.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5385,
          "status": "success"
        },
        "007 | Disregarded | Experimental study": {
          "document_id": "IUC5-075bc53d-86f8-4e4c-b3ec-15119542aae2_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Genetic toxicity in vitro\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nin vitro DNA damage and/or repair study\n\nType of genotoxicity: DNA damage and/or repair\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\ndisregarded due to major methodological deficiencies\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nFocus is on two early screening tests, Vitotox and RadarScreen, which are currently unvalidated. Ames data (only Y/N for mutagenicity of salicylamide) come from an unidentified source (possibly in-house testing, not specified).\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Evaluation of the VitotoxTM and RadarScreen assays for the rapid assessment of genotoxicity in the early research phase of drug development](15728359-bef4-3731-b4fb-128469fe40f8_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline available\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nVitotox: Bacterial reporter assay based on the SOS-response system; luciferase gene under control of recN promoter, which is de-repressed by SOS-response in the presence of a DNA-damaging genotoxic compound. Quantification by measurement of luminescence after addition of luciferin.\n\nGLP compliance\n\nno\n\nType of assay\n\nSOS/umu assay\n\n### Test material\n\nTest material information\n\n[Test material information](994b8e2e-4e14-3e1d-a584-275378cd07a9_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Method\n\nTarget gene\n\nany (DNA damage assessed by SOS-response system)\n\n### Species / strain\n\n### #1 - Species / strain\n\nSpecies / strain / cell type\n\nS. typhimurium, other:\nTA104 recN2-4\n\nDetails on mammalian cell type (if applicable)\n\n[Empty]\n\nAdditional strain / cell type characteristics\n\nother:\nfor detection of induction of SOS repair\n\n### #2 - Species / strain\n\nSpecies / strain / cell type\n\nS. typhimurium, other:\nTA104 pr1\n\nDetails on mammalian cell type (if applicable)\n\n[Empty]\n\nAdditional strain / cell type characteristics\n\nother:\nfor detection of cytotoxicity\n\nCytokinesis block (if used)\n\n[Empty]\n\nMetabolic activation\n\nwith and without\n\nMetabolic activation system\n\nS9 mixture (liver homogenate from Aroclor-induced Wistar rats)\n\nTest concentrations\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\nmaximum 0.1 mM, lower concentrations spaced by square-root(10), lowest efficient concentration 0.1 mM\n\nVehicle / solvent\n\nDMSO\n\n### Controls\n\n### #1 - Controls\n\nUntreated negative controls\n\nno\n\nNegative solvent / vehicle controls\n\nyes\n\nDMSO\n\nTrue negative controls\n\nno\n\nPositive controls\n\nyes\n\nPositive control substance\n\n* 4-nitroquinoline-N-oxide\n\nRemarks\n\nMigrated to IUCLID6: benzo[a]pyrene\n\nDetails on test system and experimental conditions\n\nMETHOD OF APPLICATION: in suspension (384-well plates)\n\nDURATION\n\n- Exposure duration: 3 hours\n\n- Luminescence read every five min\n\n- Results up to 45 min not used, since SOS response does not occur that quickly\n\nNUMBER OF REPLICATIONS: 2\n\nDETERMINATION OF CYTOTOXICITY\n\n- Luminescence of pr1 strain assessed in parallel\n\nRationale for test conditions\n\n[Empty]\n\nEvaluation criteria\n\nSignal to noise ratio (S/N) > 1.3 in recN2-4 strain\nand S/N of recN2-4 divided by S/N of pr1 greater than 1.5\n\nStatistics\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Test results\n\n### #1 - Test results\n\nKey result\n\nSpecies / strain\n\nS. typhimurium, other:\nTA104 recN2-4\n\nMetabolic activation\n\nwith\n\nGenotoxicity\n\npositive\n\nlowest effective concentration 0.1 mM\n\nCytotoxicity / choice of top concentrations\n\nno cytotoxicity\n\nVehicle controls validity\n\nvalid\n\nUntreated negative controls validity\n\nnot specified\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\nvalid\n\nAdditional information on results\n\n[Empty]\n\nRemarks on result\n\nother:\nall strains/cell types tested\n\nMigrated from field 'Test system'.\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nLowest effective concentration (0.1 mM) is equal to the highest concentration tested. Quantitative results not presented (neither for genotoxicity nor for cytotoxicity). The reliability of this test has not yet been validated.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nInterpretation of results (migrated information):\n\npositive Vitotox assay, lowest (and only) efficient concentration 0.1 mM\n\nThe study was not conducted to a guideline and used an unvalidated in vitro method, intented for screening level purposes. The Ames result reported originated from an undocumented source. As a result the study results were considered to be unreliable and discarded.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 6461,
          "status": "success"
        },
        "008 | Disregarded | Experimental study": {
          "document_id": "IUC5-71659e3f-044d-447b-a812-4c8d795c4eaf_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Genetic toxicity in vitro\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nin vitro DNA damage and/or repair study\n\nType of genotoxicity: DNA damage and/or repair\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\ndisregarded due to major methodological deficiencies\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nFocus is on two early screening tests, Vitotox and RadarScreen, which are currently unvalidated. Ames data (only Y/N for mutagenicity of salicylamide) come from an unidentified source (possibly in-house testing, not specified).\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Evaluation of the VitotoxTM and RadarScreen assays for the rapid assessment of genotoxicity in the early research phase of drug development](15728359-bef4-3731-b4fb-128469fe40f8_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline available\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nRAD54 promoter-linked beta-galactosidase reporter assay in yeast. The beta-galactosidase gene is under transcriptional\n\ncontrol of the RAD54 promoter and is expressed after DNA damage to repair double-strand breaks by homologous recombination.\n\nQuantification by d-luciferin-o-beta-galactopyranoside, which is converted into galactose and luciferin that can be measured luminometrically.\n\nClastogenic and aneugenic compounds that cause chromosomal aberrations, micronucleus formation and improper chromatid exchange may also be detected.\n\nGLP compliance\n\nno\n\nType of assay\n\nyeast cytogenetic assay\n\n### Test material\n\nTest material information\n\n[Test material information](994b8e2e-4e14-3e1d-a584-275378cd07a9_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Method\n\nTarget gene\n\nany (DNA double-strand breaks assessed by RAD54 beta-galactosidase reporter construct)\n\n### Species / strain\n\n### #1 - Species / strain\n\nSpecies / strain / cell type\n\nyeast, other:\nstrain SKAM4\n\nDetails on mammalian cell type (if applicable)\n\n[Empty]\n\nAdditional strain / cell type characteristics\n\nother:\ncontaining RAD54 beta-galactosidase reporter construct\n\nCytokinesis block (if used)\n\n[Empty]\n\nMetabolic activation\n\nwith and without\n\nMetabolic activation system\n\nS9 mixture (liver homogenate from Aroclor-induced Wistar rats)\n\nTest concentrations\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\nmaximum 1 mM, lower concentrations spaced by square-root(10), lowest efficient concentration 0.1 mM\n\nVehicle / solvent\n\nDMSO\n\n### Controls\n\n### #1 - Controls\n\nUntreated negative controls\n\nno\n\nNegative solvent / vehicle controls\n\nyes\n\nDMSO\n\nTrue negative controls\n\nno\n\nPositive controls\n\nyes\n\nPositive control substance\n\n* methylmethanesulfonate\n\nRemarks\n\nMigrated to IUCLID6: benzo[a]pyrene\n\nDetails on test system and experimental conditions\n\nMETHOD OF APPLICATION: in suspension (96-well plates)\n\nDURATION\n\n- Exposure duration: 6 hours\n\n- Luminescence read after addition of Beta-Glo substrate and 45-60 min shaking to allow cell lysis\n\nNUMBER OF REPLICATIONS: 2\n\nDETERMINATION OF CYTOTOXICITY AND PRECIPITATION\n\n- Absorbance measurement at 590 nm after 6 h, OD values for 1 mM methylmethanesulfonate set as 100% cytotoxicity\n\n- Concurrent blank plates checked visually for precipitation\n\nRationale for test conditions\n\n[Empty]\n\nEvaluation criteria\n\nInduction of a response by factor 1.5 (50% increase = 5.4 times the standard deviation of the background: yeast cells with DMSO)\n\nStatistics\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Test results\n\n### #1 - Test results\n\nKey result\n\nSpecies / strain\n\nyeast, other:\nstrain SKAM4\n\nMetabolic activation\n\nwith and without\n\nGenotoxicity\n\nnegative\n\nCytotoxicity / choice of top concentrations\n\nno cytotoxicity\n\nVehicle controls validity\n\nvalid\n\nUntreated negative controls validity\n\nnot specified\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\nvalid\n\nAdditional information on results\n\n[Empty]\n\nRemarks on result\n\nother:\nall strains/cell types tested\n\nMigrated from field 'Test system'.\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nInterpretation of results (migrated information):\n\nnegative\n\nThe study was not conducted to a guideline and used an unvalidated in vitro method, intented for screening level purposes. The Ames result reported originated from an undocumented source. As a result the study results were considered to be unreliable and discarded.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 6355,
          "status": "success"
        },
        "009 | No specified study adequacy | Justification/conclusion (weight of evidence)": {
          "document_id": "c637ba05-1cbf-4a14-8c42-a157f56b6a09_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Genetic toxicity in vitro\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\ngenetic toxicity in vitro, other\n\nType of information\n\nweight of evidence justification/conclusion\n\nAdequacy of study\n\n[Empty]\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n[Empty]\n\nRationale for reliability incl. deficiencies\n\n[Empty]\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\nThe substance demonstrated negative results in several in vitro bacterial gene mutation tests (Ames), and tested positive in a single in vitro chromosome aberration test with mammalian cells. A positive result in only one in vitro mutagenicity assay is generally not sufficient to lead to classification for mutagenicity. Furthermore, four in vivo mutagenicity tests, including somatic cell bone-marrow metaphase analysis and micronucleus tests, gave consistently negative results. As a result, and in accordance with Regulation (EC) No. 1272/2008, Annex I, Part 3, 3.5.2, salicylamide is not considered to be classified for germ cell mutagenicity.\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nweight of evidence source\n\nRelated information\n\n[004 | Weight of evidence | Experimental study](IUC5-7611b63a-4913-4c59-adbe-e37d6ee2e881_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nRemarks\n\n[Not publishable]\n\n### #2 - Cross-reference\n\nReason / purpose for cross-reference\n\nweight of evidence source\n\nRelated information\n\n[003 | Weight of evidence | Experimental study](IUC5-3646958b-9bcf-4b23-93b2-6d63448a71c3_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nRemarks\n\n[Not publishable]\n\n### #3 - Cross-reference\n\nReason / purpose for cross-reference\n\nweight of evidence source\n\nRelated information\n\n[002 | Weight of evidence | Experimental study](IUC5-522e27ec-8dea-4544-bb4f-a7fc5729977e_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nRemarks\n\n[Not publishable]\n\n### #4 - Cross-reference\n\nReason / purpose for cross-reference\n\nweight of evidence source\n\nRelated information\n\n[001 | Weight of evidence | Experimental study](IUC5-37e7b1cc-1ed5-42ee-932a-905402afcac8_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n[Empty]\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\n[Empty]\n\nType of assay\n\n[Empty]\n\n### Test material\n\nTest material information\n\n[Empty]\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Method\n\nTarget gene\n\n[Empty]\n\n### Species / strain\n\nCytokinesis block (if used)\n\n[Empty]\n\nMetabolic activation\n\n[Empty]\n\nMetabolic activation system\n\n[Empty]\n\nTest concentrations\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Empty]\n\nVehicle / solvent\n\n[Empty]\n\n### Controls\n\nDetails on test system and experimental conditions\n\n[Empty]\n\nRationale for test conditions\n\n[Empty]\n\nEvaluation criteria\n\n[Empty]\n\nStatistics\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Test results\n\n### #1 - Test results\n\nKey result\n\nSpecies / strain\n\nS. typhimurium TA 1535\n\nMetabolic activation\n\nwith and without\n\nGenotoxicity\n\nnegative\n\nCytotoxicity / choice of top concentrations\n\nnot specified\n\nprobably none, max. dose 9600 micrograms/plate reported\n\nVehicle controls validity\n\nnot specified\n\nUntreated negative controls validity\n\nnot specified\n\nTrue negative controls validity\n\n[Empty]\n\nPositive controls validity\n\nnot specified\n\nAdditional information on results\n\nNegative, Ames test, S. typhimurium TA1535, TA100, TA1538, TA98, TA1537; E. coli K12/343/113, King 1979\n\nNegative, Ames test, S. typhimurium TA98, TA100; Kuboyama 1992\n\nNegative, Ames test, S. typhimurium TA100, TA1535, TA97, TA98; Zeiger 1992\n\nPositive, chromosome aberration test - in vitro, CHL cells, Ishidate 1988\n\nRemarks on result\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\n[Empty]\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5337,
          "status": "success"
        }
      },
      "7.6.2 Genetic toxicity in vivo": {
        "001 | Key | Experimental study": {
          "document_id": "IUC5-5e5798eb-ce20-465d-807f-0453299dadbb_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Genetic toxicity in vivo\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nin vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus\n\nType of genotoxicity: chromosome aberration\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nkey study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards. Experimental details well documented, no explicit reference to guideline. Only four animals / dose, male and female (number per sex not specified). No information on housing conditions, diet.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Mutagenicity studies with X-ray-contrast media, analgesics, antipyretics, antirheumatics and some other pharmaceutical drugs in bacterial, Drosophila and mammalian test systems](aac49774-40b5-357e-b59a-7f6cf5d50805_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nOECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\nyes\n\nOnly 4 mice per dose\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nType of assay\n\nmicronucleus assay\n\n### Test material\n\nTest material information\n\n[Test material information](e8593aeb-0aa6-3aab-8d30-40ce2e5bdc8b_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nmouse\n\nStrain\n\nNMRI\n\nDetails on species / strain selection\n\n[Empty]\n\nSex\n\nmale/female\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Supplier:S. Ivanovas GmbH, Kisslegg, Germany\n\n- Weight at study initiation: about 30 g\n\n- Fasting period before study: no data\n\n- Housing: no data\n\n- Diet / Water / Acclimation period: no data\n\nENVIRONMENTAL CONDITIONS\n\n- Temperature (Â°C) / Humidity (%) / Air changes (per hr) / Photoperiod (hrs dark / hrs light): no data\n\n### Administration / exposure\n\nRoute of administration\n\nintraperitoneal\n\nVehicle\n\n- Vehicle(s)/solvent(s) used: not precisely specified: probably dispersion in 3% gum arabic (the two alternative solvents stated in the article, 0.9% NaCl and olive oil, are unlikely to dissolve the test substance)\n\nDetails on exposure\n\n[Empty]\n\nDuration of treatment / exposure\n\n30 hours (two i.p. injections 24 hours apart, sacrifice 6 hours after the second injection)\n\nFrequency of treatment\n\nTwice\n\nPost exposure period\n\n6 hours after the second injection\n\n### Doses / concentrations\n\n### #1 - Doses / concentrations\n\nDose / conc.\n\n[Empty]\n\nRemarks\n\nDoses / Concentrations:\n5 mmoles/kg, 685 mg/kg\nBasis:\nnominal conc.\nHighest tested dose\n\nNo. of animals per sex per dose\n\nusually 4 mice, number per sex not specified\n\nControl animals\n\n* yes\n\nPositive control(s)\n\nno specific data (various mutagens were administered, representative data reported in Wild D (1978) Mutation Res. 56: 319-327)\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nTissues and cell types examined\n\nBone marrow smears; polychromatic erythrocytes\n\nDetails of tissue and slide preparation\n\nCRITERIA FOR DOSE SELECTION:\n\n- non-toxic to approximately lethal, based on previous toxicity experiments\n\nDETAILS OF SLIDE PREPARATION:\n\n- bone-marrow smears, stained with May-Gruenwald and Giemsa stains\n\nMETHOD OF ANALYSIS:\n\n- 1000 polychromatic erythrocytes analyzed per animal\n\nEvaluation criteria\n\nAccording to Schmid W (1976) in Hollaender A, Ed., Chemical Mutagens, Vol 4: 31-53, Plenum New York\n\nStatistics\n\nCalculation of significance of results according to tables by Kastenbaum MA & Bowman KO (1976), Mutation Res. 9: 527-549\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Test results\n\n### #1 - Test results\n\nKey result\n\nSex\n\nmale/female\n\nGenotoxicity\n\nnegative\n\nToxicity\n\nnot specified\n\nVehicle controls validity\n\nother:\ncontrol group mentioned, but no data given\n\nNegative controls validity\n\nnot specified\n\nPositive controls validity\n\nother:\ncontrol groups with various mutagens mentioned, but no data given\n\nRemarks on result\n\n[Empty]\n\nAdditional information on results\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nInterpretation of results (migrated information): negative\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 6142,
          "status": "success"
        },
        "002 | Key | Experimental study": {
          "document_id": "IUC5-9f166403-0e82-4087-b11f-f4358d09e839_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Genetic toxicity in vivo\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nin vivo mammalian somatic cell study: cytogenicity / bone marrow chromosome aberration\n\nType of genotoxicity: chromosome aberration\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nkey study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nStudy published in a peer-reviewed journal, according to scientific standards. Experimental details well documented, no explicit reference to guideline.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Comparative genotoxicity of six salicylic acid derivatives in bone marrow cells of mice](4183bc80-cac0-35ad-bab4-dd82f392781a_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nOECD Guideline 475 (Mammalian Bone Marrow Chromosome Aberration Test)\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\nyes\n\nHousing temperature (28+-2Â°C) too high. Only male mice tested (5 per dose) - no justification given.\n\n### #2 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nEPA OPPTS 870.5385 (In Vivo Mammalian Cytogenetics Tests: Bone Marrow Chromosomal Analysis)\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\nyes\n\nOnly male mice tested (4 per dose i.p., 5 for oral gavage----) - no justification given.\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nType of assay\n\nchromosome aberration assay\n\n### Test material\n\nTest material information\n\n[Test material information](f098789a-251d-363e-8bf2-5750b3c0b370_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nmouse\n\nStrain\n\nSwiss\n\nDetails on species / strain selection\n\n[Empty]\n\nSex\n\nmale\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Source: Division of Laboratory animals, Central Drug Res. Institute, Lucknow, India\n\n- Age at study initiation: 10-12 weeks\n\n- Weight at study initiation: 30 g\n\n- Assigned to test groups randomly: no data\n\n- Fasting period before study: no\n\n- Housing: five per cage, husk bedding\n\n- Diet: Standard rodent pellet diet, Gold Mohor, Lipton India Ltd, Chandigarh, India (ad libitum)\n\n- Water: ad libitum\n\n- Acclimation period: no data\n\nENVIRONMENTAL CONDITIONS\n\n- Temperature (Â°C): 28 +/- 2 Â°C\n\n- Humidity (%): 60 +/- 5 %\n\n- Air changes (per hr): no data\n\n- Photoperiod (hrs dark / hrs light): 12 / 12 hours\n\nIN-LIFE DATES: no data\n\n### Administration / exposure\n\nRoute of administration\n\nother:\nintraperitoneal (3 dose levels); or oral (gavage) 1 dose level\n\nVehicle\n\n- Vehicle(s)/solvent(s) used: DMSO (for i.p. application), suspension in 2% gum acacia in distilled water (for gavage application)\n\n- Justification for choice of solvent/vehicle: solubility of the test substance\n\n- Concentration of test material in vehicle: dose-dependent: approx. 20, 40, and 80 mg/mL (i.p.), 35 mg/mL (gavage)\n\n- Amount of vehicle (if gavage or dermal): DMSO 75 microliter/mouse for i.p., 2% gum acacia in water 0.3 mL per mouse for gavage\n\n- Type and concentration of dispersant aid (if powder): 2% gum acacia\n\n- Lot/batch no. (if required): no data\n\n- Purity: no data\n\nDetails on exposure\n\n[Empty]\n\nDuration of treatment / exposure\n\ni.p. administration: 24 hours, gavage administration: 24 hours\ncolchicine: 2 hours before sacrifice\n\nFrequency of treatment\n\nsingle treatment\n\nPost exposure period\n\nnone (time between administration and sacrifice: i.p. 24 hours, gavage 24 hours)0\n\n### Doses / concentrations\n\n### #1 - Doses / concentrations\n\nDose / conc.\n\n[Empty]\n\nRemarks\n\nDoses / Concentrations:\ni.p. 50, 100, 200 mg/kg body weight\nBasis:\nnominal conc.\n\n### #2 - Doses / concentrations\n\nDose / conc.\n\n[Empty]\n\nRemarks\n\nDoses / Concentrations:\noral (gavage) 350 mg/kg body weight\nBasis:\nnominal conc.\n\nNo. of animals per sex per dose\n\n4 males per dose, i.p. administration\n5 males, oral administration\n\nControl animals\n\n* yes, concurrent vehicle\n\nPositive control(s)\n\ncyclophosphamide:\n\n- Justification for choice of positive control(s): no data\n\n- Route of administration: i.p. only\n\n- Doses / concentrations: 25 mg/kg\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nTissues and cell types examined\n\nBone marrow cells\n\nDetails of tissue and slide preparation\n\nCRITERIA FOR DOSE SELECTION:\n\ni.p.: based on the results of the Sister Chromatid Exchange (SCE) dose-response study: one higher dose was selected, since chromosome aberration is less sensitive than SCE\n\noral/gavage: 1/3 of approx. oral LD50\n\nTREATMENT AND SAMPLING TIMES ( in addition to information in specific fields):\n\n- i.p. injection and gavage 22 h before colchicine, 24 hours before sacrifice\n\n- colchicine (2 mg/kg) 2 h before sacrifice\n\n- sacrifice and expelling of bone marrow 24 hours after treatment\n\nDETAILS OF SLIDE PREPARATION:\n\n- bone marrow chromosomes prepared according to Preston RJ et al (1987) Mutation Res. 198: 157-165\n\n- staining of chromosomes on slide with Giemsa\n\nMETHOD OF ANALYSIS:\n\n- 100 well-spread metaphase cells scored per animal\n\n- mitotic indices (MI) calculated from 1000 cells / animal, expressed as percentage\n\n- chromosome aberrations (CA) scored according to WHO method (Preston et al, see above)\n\n- aberration frequencies of chromatid and chromosome type per cell calculated\n\n- gaps recorded but not included in the frequency of aberrations per cell\n\nEvaluation criteria\n\nSignificant increase in chromosome aberration\nGaps recorded but not included in the frequency of aberrations per cell\n\nStatistics\n\nStatistical calculations carried out from percentages of aberrant cells\nStudent's t-test, to compare results at each dose with control\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Test results\n\n### #1 - Test results\n\nKey result\n\nSex\n\nmale\n\nGenotoxicity\n\nnegative\n\nToxicity\n\nno effects\n\nno mortality\n\nVehicle controls validity\n\nvalid\n\nNegative controls validity\n\nnot examined\n\nPositive controls validity\n\nvalid\n\nRemarks on result\n\n[Empty]\n\nAdditional information on results\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nNo significant increase in aberrations / cell and aberrant cells (%) for all doses tested, when compared to solvent control.\n\nNo significant difference in mitotic indices, when compared to control.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nInterpretation of results (migrated information): negative\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 8238,
          "status": "success"
        },
        "003 | Key | Experimental study": {
          "document_id": "IUC5-ebcf9397-ef8d-4e98-a8fb-70fe5249f120_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Genetic toxicity in vivo\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nin vivo mammalian cell study: DNA damage and/or repair\n\nType of genotoxicity: DNA damage and/or repair\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nkey study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nStudy published in a peer-reviewed journal, according to scientific standards. Experimental details well documented, no OECD guideline, no explicit reference to EPA OPPTS 870.5915.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Comparative genotoxicity of six salicylic acid derivatives in bone marrow cells of mice](4183bc80-cac0-35ad-bab4-dd82f392781a_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nEPA OPPTS 870.5915 (In Vivo Sister Chromatid Exchange Assay)\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\nyes\n\nBrdU tablets implanted 1 h before (not after) test substance administration. Only male mice tested (5 per dose) - no justification given. Room temperature of animal facilities unusually high (28Â°C).\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nType of assay\n\nsister chromatid exchange assay\n\n### Test material\n\nTest material information\n\n[Test material information](f098789a-251d-363e-8bf2-5750b3c0b370_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nmouse\n\nStrain\n\nSwiss\n\nDetails on species / strain selection\n\n[Empty]\n\nSex\n\nmale\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Source: Division of Laboratory animals, Central Drug Res. Institute, Lucknow, India\n\n- Age at study initiation: 10-12 weeks\n\n- Weight at study initiation: 30 g\n\n- Assigned to test groups randomly: no data\n\n- Fasting period before study: no\n\n- Housing: five per cage, husk bedding\n\n- Diet: Standard rodent pellet diet, Gold Mohor, Lipton India Ltd, Chandigarh, India (ad libitum)\n\n- Water: ad libitum\n\n- Acclimation period: no data\n\nENVIRONMENTAL CONDITIONS\n\n- Temperature (Â°C): 28 +/- 2 Â°C\n\n- Humidity (%): 60 +/- 5 %\n\n- Air changes (per hr): no data\n\n- Photoperiod (hrs dark / hrs light): 12 / 12 hours\n\nIN-LIFE DATES: no data\n\n### Administration / exposure\n\nRoute of administration\n\nother:\nintraperitoneal (3 dose levels); or oral (gavage) 1 dose level\n\nVehicle\n\n- Vehicle(s)/solvent(s) used: DMSO (for i.p. application), suspension in 2% gum acacia in distilled water (for gavage application)\n\n- Justification for choice of solvent/vehicle: solubility of the test substance\n\n- Concentration of test material in vehicle: dose-dependent: approx. 10, 20, 40 mg/mL (i.p.), 35 mg/mL (gavage)\n\n- Amount of vehicle (if gavage or dermal): DMSO 75 microliter/mouse for i.p., 2% gum acacia in water 0.3 mL per mouse for gavage\n\n- Type and concentration of dispersant aid (if powder): 2% gum acacia\n\n- Lot/batch no. (if required): no data\n\n- Purity: no data\n\nDetails on exposure\n\n[Empty]\n\nDuration of treatment / exposure\n\ni.p. administration: 23 hours, gavage administration: 23.5 hours\nBrdU: 24 hours before sacrifice\ncolchicine: 2 hours before sacrifice\n\nFrequency of treatment\n\nsingle treatment\n\nPost exposure period\n\nnone (time between administration and sacrifice: i.p. 23 hours, gavage 23.5 hours\n\n### Doses / concentrations\n\n### #1 - Doses / concentrations\n\nDose / conc.\n\n[Empty]\n\nRemarks\n\nDoses / Concentrations:\ni.p. 25, 50, 100 mg/kg body weight\nBasis:\nnominal conc.\n\n### #2 - Doses / concentrations\n\nDose / conc.\n\n[Empty]\n\nRemarks\n\nDoses / Concentrations:\noral (gavage) 350 mg/kg body weight\nBasis:\nnominal conc.\n\nNo. of animals per sex per dose\n\n5 males per dose\n\nControl animals\n\n* yes, concurrent vehicle\n\nPositive control(s)\n\nmitomycin C\n\n- Justification for choice of positive control(s): Preston RJ et al (1987) Mutation Res. 198: 157-165\n\n- Route of administration: i.p. only\n\n- Doses / concentrations: 1.5 mg/kg\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nTissues and cell types examined\n\nBone marrow cells\n\nDetails of tissue and slide preparation\n\nCRITERIA FOR DOSE SELECTION:\n\ni.p.: 1/10 of approx. oral LD50, since no i.p. LD50 available\n\noral/gavage: 1/3 of approx. oral LD50\n\nTREATMENT AND SAMPLING TIMES ( in addition to information in specific fields):\n\n- BrdU tablet (paraffin-coated, 80% of surface) implanted subcutaneously under anesthesia\n\n- i.p. injection 1 h after tablet implantation, or gavage 1/2 h after tablet implantation\n\n- colchicine (4 mg/kg) 22 h after tablet implantation\n\n- sacrifice and expelling of bone marrow 2 hours later, i.e. 24 hours after tablet implantation\n\nDETAILS OF SLIDE PREPARATION:\n\n- hypotonic treatment: 20 min, 0.075 M KCl at 37Â°\n\n- three times fixing with methanol / acetic acid 3:1\n\n- differential staining of chromosomes on slide with fluorescence-plus-Giemsa technique\n\nMETHOD OF ANALYSIS:\n\n- 30 second division metaphase cells (40 +/- 2 chromosomes) per animal scored for sister chromatid exchange SCE\n\n- this is a total of 150 cells per dose scored\n\n- randomly selected metaphase cells scored for replicative indices RI by staining pattern as first (M1), second (M2) and third (M3) division metaphases\n\n- RI = (1\\*M1 + 2\\*M2 + 3\\*M3) / 100\n\nEvaluation criteria\n\nSignificant increase of SCE over control\ndose-related increase\nchange in replicative index\n\nStatistics\n\nStudent's t-test, to compare results at each dose with control\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Test results\n\n### #1 - Test results\n\nKey result\n\nSex\n\nmale\n\nGenotoxicity\n\nnegative\n\nToxicity\n\nno effects\n\nno mortality\n\nVehicle controls validity\n\nvalid\n\nNegative controls validity\n\nnot examined\n\nPositive controls validity\n\nvalid\n\nRemarks on result\n\n[Empty]\n\nAdditional information on results\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nNo significant increase in sister chromatid exchange (SCE) for all doses tested, when compared to solvent control.\n\nNo significant differences in replicative index (RI), when compared to control.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nInterpretation of results (migrated information): negative\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 7986,
          "status": "success"
        },
        "004 | Key | Experimental study": {
          "document_id": "IUC5-56e1f7f0-efbb-4f67-a4be-9a5a0b806cd9_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Genetic toxicity in vivo\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\nin vivo mammalian germ cell study: gene mutation\n\nType of genotoxicity: gene mutation\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nkey study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nStudy published in a peer-reviewed journal, according to scientific standards. Experimental details well documented, no explicit reference to guideline. DMSO (2% in glucose solutuion) used as vehicle. No individual data on the number of chromosomes tested, the number of nonfertile males and the number of lethal chromosomes per exposure concentration and mating period. No confirmatory second experiment reported.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Mutagenicity studies with X-ray-contrast media, analgesics, antipyretics, antirheumatics and some other pharmaceutical drugs in bacterial, Drosophila and mammalian test systems](aac49774-40b5-357e-b59a-7f6cf5d50805_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nequivalent or similar to guideline\n\nGuideline\n\nOECD Guideline 477 (Genetic Toxicology: Sex-linked Recessive Lethal Test in Drosophila melanogaster)\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\nyes\n\nNo individual data reported\n\nPrinciples of method if other than guideline\n\n[Empty]\n\nGLP compliance\n\nnot specified\n\nType of assay\n\nDrosophila SLRL assay\n\n### Test material\n\nTest material information\n\n[Test material information](0d8f64df-0581-30c1-957c-4a54aa8c1deb_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nDrosophila melanogaster\n\nStrain\n\nother:\nBerlin K (wild type) males, Basc females (In(1)sc S1L sc 8R + S, sc S1 sc 8 w a B)\n\nDetails on species / strain selection\n\n[Empty]\n\nSex\n\nmale/female\n\nDetails on test animals or test system and environmental conditions\n\nMales Berlin K, age 1-2 days\n\n### Administration / exposure\n\nRoute of administration\n\noral: feed\n\nVehicle\n\n5% sucrose solution containing 2% DMSO\n\nDetails on exposure\n\n[Empty]\n\nDuration of treatment / exposure\n\n3 days\n\nFrequency of treatment\n\ncontinuous feeding\n\nPost exposure period\n\n3 broods, each of 3 days duration\n\n### Doses / concentrations\n\n### #1 - Doses / concentrations\n\nDose / conc.\n\n[Empty]\n\nRemarks\n\nDoses / Concentrations:\n20 mM = 2740 mg/L\nBasis:\nnominal in diet\nHighest tested dose\n\nNo. of animals per sex per dose\n\n> 1000 F1 females per brood\n\nControl animals\n\n* yes, historical\n\nPositive control(s)\n\nno data\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nTissues and cell types examined\n\nSex-linked recessive lethal chromosomes\n\nDetails of tissue and slide preparation\n\nCRITERIA FOR DOSE SELECTION:\n\n- maximally tolerated dose (up to the LD50)\n\nEvaluation criteria\n\nSex-linked recessive lethals scored in F2 generation and confirmed in F3 generation\n\nStatistics\n\nProbability of significance , by test of Kastenbaum MA & Bowman KO (1976), Mutation Res. 9: 527-549\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Test results\n\n### #1 - Test results\n\nKey result\n\nSex\n\nmale/female\n\nGenotoxicity\n\nnegative\n\nToxicity\n\nnot specified\n\nVehicle controls validity\n\nnot specified\n\nNegative controls validity\n\nnot specified\n\nPositive controls validity\n\nnot specified\n\nRemarks on result\n\n[Empty]\n\nAdditional information on results\n\nNo individual data on the number of chromosomes tested, the number of nonfertile males and the number of lethal chromosomes per exposure concentration and mating period. However, for the only positive test substance in this article, 1,2-dichloroethane, the number of X-chromosomes tested, the number of lethals, the recessive lethal mutation (%), and the probability of significance are tabulated per brood. It is very likely that the same data were also collected for the negative test substances, although they are not shown in the publication.\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n[Empty]\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nInterpretation of results (migrated information): negative\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 5903,
          "status": "success"
        }
      },
      "S-01 | Summary": {
        "document_id": "IUC5-b1452b11-761b-435a-8e17-8d414f9d3af9_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
        "markdown_content": "#### Genetic toxicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Empty]\n\nJustification\n\n[Empty]\n\nUse restricted to selected regulatory programmes\n\n[Empty]\n\n### Description of key information\n\nNegative, Ames test, S. typhimurium TA1535, TA100, TA1538, TA98, TA1537; E. coli K12/343/113, King 1979\n\nNegative, Ames test, S. typhimurium TA98, TA100; Kuboyama 1992\n\nNegative, Ames test, S. typhimurium TA100, TA1535, TA97, TA98; Zeiger 1992\n\nPositive, chromosome aberration test - in vitro, CHL cells, Ishidate 1988\n\nNegative, sister chromatid exchange - in vivo, mouse, Giri 1996\n\nNegative, chromosome aberration test - in vivo, mouse, Giri 1996\n\nNegative, micronucleus test - in vivo, mouse, King 1979\n\nNegative, sex-linked recessive lethal test, drosophila, King 1979\n\n### Key value for chemical safety assessment\n\n### Genetic toxicity in vitro\n\nLink to relevant study record(s)\n\n* [001 | Weight of evidence | Experimental study](IUC5-37e7b1cc-1ed5-42ee-932a-905402afcac8_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n* [002 | Weight of evidence | Experimental study](IUC5-522e27ec-8dea-4544-bb4f-a7fc5729977e_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n* [003 | Weight of evidence | Experimental study](IUC5-3646958b-9bcf-4b23-93b2-6d63448a71c3_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n* [004 | Weight of evidence | Experimental study](IUC5-7611b63a-4913-4c59-adbe-e37d6ee2e881_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nEndpoint conclusion\n\nadverse effect observed (positive)\n\n### Genetic toxicity in vivo\n\nLink to relevant study record(s)\n\n* [002 | Key | Experimental study](IUC5-9f166403-0e82-4087-b11f-f4358d09e839_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n* [001 | Key | Experimental study](IUC5-5e5798eb-ce20-465d-807f-0453299dadbb_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n* [003 | Key | Experimental study](IUC5-ebcf9397-ef8d-4e98-a8fb-70fe5249f120_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n* [004 | Key | Experimental study](IUC5-56e1f7f0-efbb-4f67-a4be-9a5a0b806cd9_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nEndpoint conclusion\n\nno adverse effect observed (negative)\n\n### Mode of Action Analysis / Human Relevance Framework\n\n[Empty]\n\n### Justification for classification or non-classification\n\nThe substance demonstrated negative results in several in vitro bacterial gene mutation tests (Ames), and tested positive in a single in vitro chromosome aberration test with mammalian cells. A positive result in only one in vitro mutagenicity assay is generally not sufficient to lead to classification for mutagenicity. Furthermore, four in vivo mutagenicity tests, including somatic cell bone-marrow metaphase analysis and micronucleus tests, gave consistently negative results. As a result, and in accordance with Regulation (EC) No. 1272/2008, Annex I, Part 3, 3.5.2, salicylamide is not considered to be classified for germ cell mutagenicity.\n\n### Additional information\n\n**Additional information from genetic toxicity in vitro:**\n\n**Ames test (bacterial reverse mutation in vitro)**: Negative\n\nThe study by King (1979) is probably the best-documented report on Ames testing, with the maximum number of strains tested (S. typhimurium TA1535, TA100, TA1538, TA98, TA1537; E. coli K12/343/113), which all show negative results, with and without metabolic activation. However, being published in 1979, it provides no data on E. coli WP2 uvrA, or E. coli WP2 uvrA (pKM101), or S. typhimurium TA102, as requested by newer versions of the guideline OECD 471. It is known that the strains tested by King may not detect certain oxidising mutagens, cross-linking agents and hydrazines, but since the test substance salicylamide has neither of these properties, we believe that the missing strain does not disqualify the negative result obtained by King.\n\nThe study by Zeiger (1992) is also well-documented and shows negative results for S. typhimurium TA100, TA1535, TA98, and additionally TA97, which supports the King result, as does the study by Kuboyama (1991), who tested only S. typhimurium TA98 and TA100, both negative with and without metabolic activation. The second paper by Zeiger (1996) is probably a quotation of their 1992 results.\n\nBased on a weight-of-evidence approach, according to Regulation (EC) No. 1907/2006, Annex XI, section 1.2., it is concluded that salicylamide is non-mutagenic in the Ames test.\n\n**Chromosome aberration test in vitro**: Positive\n\nIshidate (1988, Data Book) reports a large number of chromosome aberration (CA) tests (for 779 substances) and explicitly refers to guidelines OECD 473 and EPA OPPTS \"In-vitro mammalian cytogenetics\". Ishidate (1988, Mutation research, 951 substances), refers to the same experimental data. A positive chromosome aberration result is reported for salicylamide, albeit with the following caveats:\n\n- The number of metaphases evaluated is only 100, although the present-day OECD guideline asks for at least 200 well-spread metaphases.\n\n- Gaps (3 out of 7% after 24 h, 2 out of 10 % after 48 h) are counted as chromosomal aberrations, although OECD 473 advises: Gaps or achromatic lesions are recorded separately and not included in the total aberration frequency.\n\n- The result at the usual screening harvest time (24 hours) is ambiguous (7% cells with structural CAs, thereof 3% gaps).\n\n- The 48-hour result is just at the edge of the \"positive\" definition (10% or more): 10% CA, thereof 2% gaps. If gaps were not counted, the result would be \"ambiguous\".\n\n- The middle concentration, 0.25 mg/mL, intended to cause approximately 50% inhibition of cell proliferation, yields negative results at 24 h (4% CA, thereof 3% gaps) and 48 h (3% CA, thereof 1% gaps). An ambiguous or positive effect is only seen at 0.5 mg/mL, which is assumed to be above the 50% inhibitory level. Although not numerically specified, a relatively high cytotoxicity may have interfered with normal metaphase formation.\n\nAlthough this study reports a positive result in vitro, it is overrun by negative results in vivo (section 7.6.2, Giri 1996: chromosome aberration, and King 1979: mouse micronucleus test).\n\n**Other in vitro tests**: Inconclusive\n\nKuboyama (1992) reports a negative Rec-assay (Bacillus subtilis, strains H17 and M45). Since there is no guideline for this type of test, this was only considered supporting information for the conclusion that salicylamide is not mutagenic in bacterial test systems.\n\nVitotox assay (Westerink 2009), which is a bacterial reporter screen in S. typhimurium designed as a faster alternative to the Ames test, but not yet validated, gave a positive result for salicylamide (with metabolic activation, lowest, and only, effective concentration 0.1 mM). The same article lists a positve result in an Ames test, without giving a source or any further detail. Since the Vitotox test is not validated, and the Ames result not documented, and both contradict all other Ames results quoted above, it was decided to disregard this study.\n\nRadarScreen assay (Westerink 2009), a yeast reporter screen designed as a faster alternative to established clastogenicity tests, but not yet validated and accepted by authorities, gave a negative result for salicylamide. The positive chromosome aberration result listed in the same paper is correctly quoted from Ishidate (1988).\n\n**Additional information from genetic toxicity in vivo:**\n\n**In vivo tests**: Negative\n\nAll in-vivo studies were considered key studies, since they were published in peer-reviewed journals, were well-documented, and followed pertinent guidelines with only minor deviations.\n\nSister chromatid exchange in vivo (Giri 1996) gave a negative result in the mouse.\n\nSex-linked recessive lethal test (King 1979) also produced a negative result (Drosophila melanogaster).\n\nThe two in vivo tests recommended (in case of positive in-vitro mutagenicity findings) to decide whether a genotoxic potential can be expressed in vivo, yielded clear negative results:\n\nA rodent (mouse) bone marrow clastogenicity study (chromosome aberration in vivo, Giri 1996) showed no genotoxicity for salicylamide.\n\nA mouse bone marrow micronucleus test in vivo (King 1979) also gave a negative result.\n\nSince salicylamide is used as an analgetic, and has proven pharmacological effects in mice and rats, there is no doubt as to its bioavailability.\n\nTherefore the results of the four in vivo tests indicate that salicylamide is not genotoxic in vivo.\n\n**Justification for selection of genetic toxicity endpoint**   \nThe two in vivo tests recommended (in case of positive in-vitro mutagenicity findings) to decide whether a genotoxic potential can be expressed in vivo, yielded clear negative results:   \nA rodent (mouse) bone marrow clastogenicity study (chromosome aberration in vivo, Giri 1996) showed no genotoxicity for salicylamide.   \nA mouse bone marrow micronucleus test in vivo (King 1979) also gave a negative result.\n\n### Attached background material\n\nBack to top",
        "content_length": 8896,
        "status": "success"
      }
    },
    "7.7 Carcinogenicity": {},
    "7.8 Toxicity to reproduction": {
      "7.8.1 Toxicity to reproduction": {},
      "7.8.2 Developmental toxicity / teratogenicity": {
        "001 | Supporting | Experimental study": {
          "document_id": "IUC5-f3b74473-bb82-4d6b-9e3b-fc2338c414d3_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Developmental toxicity / teratogenicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\ndevelopmental toxicity\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nNon-guideline study not performed under GLP. Non-standard study design.\n\nLow level of experimental detail reported. No data on purity, stability or origin of the test item. The route of administration was the diet. Dose levels of 0, 2% salicylamide in the diet. No data provided to show achieved concentration, homogeneity in the diet preparations. Animals were dosed from either day 5 to 11 of gestation or day 12 to 18 and all dams were terminated on day 18 of gestation.\n\nCritical elements of the study design were missing including, number of dams per dose group, therefore it is difficult to interpret the data as where means were calculated the number in each group is not shown, there are often very large standard deviations and the suitability of the statistical analysis is not clear.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Effects of salicylamide and protein restriction on the skeletal development of the rat fetus](16578315-2985-301b-803e-e20e479bb8c6_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nPregnant Holtzman rats were fed a diet supplemented with 2% salicylamide either from day 5-11 or from day 12-18 of gestation. Weight gain of the dams was recoded throughout the feeding period. Dams were killed on gestation day 18 and fetuses and placentas were extracted and counted; placentas were weighted and examined on resorption sites. Fetuses were weighted, examined for gross malformations, and stained with Alizarin Red S.Stained fetuses were examined on skeletal abnormalities and centers of ossifications were counted.\n\nGLP compliance\n\nno\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](a9dc8c7d-b296-3bb0-9f69-958b4c30cb52_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrat\n\nStrain\n\nother:\nHoltzman\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Weight at study initiation: approximately 200-210 g\n\n- Acclimation period: 1 day\n\n### Administration / exposure\n\nRoute of administration\n\noral: feed\n\nType of inhalation exposure (if applicable)\n\n[Empty]\n\nVehicle\n\nunchanged (no vehicle)\n\nMass median aerodynamic diameter (MMAD)\n\n[Empty]\n\nGeometric standard deviation (GSD)\n\n[Empty]\n\nRemarks on MMAD\n\n[Empty]\n\nDetails on exposure\n\n[Empty]\n\nAnalytical verification of doses or concentrations\n\nnot specified\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDetails on mating procedure\n\n- Impregnation procedure: purchased pregnant\n\nDuration of treatment / exposure\n\nOne group fed 2% salicylamide on gestation day 5-11.\nOne group fed 2% salicylamide on gestation day 12-18\n\nFrequency of treatment\n\ndaily\n\nDuration of test\n\ngestation day 5-18\n\n### Doses / concentrations\n\nNo. of animals per sex per dose\n\nno data\n\nControl animals\n\n* yes, plain diet\n\nDetails on study design\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nMaternal examinations\n\nBODY WEIGHT: Yes\n\nOvaries and uterine content\n\nThe ovaries and uterine content was examined after termination: Yes\n\nExaminations included:\n\n- number of placentas\n\n- placental weight\n\n- number of resorptions\n\nBlood sampling\n\n[Empty]\n\nFetal examinations\n\n- Number of fetuses\n\n- Viability\n\n- External examinations\n\n- Skeletal examinations\n\nStatistics\n\nDifferences in the outcome of gestation, the incidence of fetal skeletal defects and skeletal maturity were examined by ANOVA. Three factor interactions were analyzed by the G-test. Analysis of covariance was used to examine data on fetuses from individual dams.\n\nIndices\n\n[Empty]\n\nHistorical control data\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results: maternal animals\n\n### General toxicity (maternal animals)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\n### Maternal developmental toxicity\n\nNumber of abortions\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nPre- and post-implantation loss\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nTotal litter losses by resorption\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEarly or late resorptions\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDead fetuses\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in pregnancy duration\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in number of pregnant\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on maternal toxic effects\n\nMaternal toxic effects:no effects\n\nDetails on maternal toxic effects:\n\nAt start of drug administration on gestation day 5 or 12, a transient decline in weight of the dams was visible. Subsequently, the drug-treated dams showed normal weight gain which, however, was less than weight gain of control animals.\n\n### Effect levels (maternal animals)\n\n### Maternal abnormalities\n\n### Results (fetuses)\n\nFetal body weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReduction in number of live offspring\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in sex ratio\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in litter size and weights\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nAnogenital distance of all rodent fetuses\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in postnatal survival\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nExternal malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nSkeletal malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nVisceral malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on embryotoxic / teratogenic effects\n\nEmbryotoxic / teratogenic effects:yes\n\nDetails on embryotoxic / teratogenic effects:\n\nCompared to the control group, mean placental and fetal weights were significantly lower in the group treated with salicylamide. This effect was more pronounced in animals receiving salicylamide from gestation day 12-18 than in animals receiving the compound on gestation day 5-11.\n\nThe percentage of resorptions was significantly increased by treatment with salicylamide.\n\nExternal malformations were found in fetuses of dams receiving salicylamide from gestation day 5-11, and in some fetuses in the groups receiving salicylamide from gestation day 12-18.\n\nMalformations included micromelia of the hind legs, phocomelia, syndactyly and short or absent tails. Skeletal malformations included missing and abnormal ribs, fused ileum, lordosis and absence of lumbar arches with number of malformations being higher in fetuses from rats receiving the drug from the fifth to eleventh days of gestation.\n\nNo malformed fetuses were observed in control rats.\n\nDrug treatment during early gestation (days 5-11) significantly decreased the number of ossification centers; when the drug was administered in the late gestational period (days 12-18) no significant effect on the development of ossification centers was noticed.\n\n### Effect levels (fetuses)\n\n### Fetal abnormalities\n\n### #1\n\nKey result\n\nAbnormalities\n\nnot specified\n\nLocalisation\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Overall developmental toxicity\n\n### #1\n\nKey result\n\nDevelopmental effects observed\n\nnot specified\n\nLowest effective dose / conc.\n\n[Empty]\n\nTreatment related\n\n[Empty]\n\nRelation to maternal toxicity\n\n[Empty]\n\nDose response relationship\n\n[Empty]\n\nRelevant for humans\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nTable 1: Effect of salicylamide on placental and fetal weight\n\n|  |  |  |  |\n| --- | --- | --- | --- |\n| Treatment period | Drug level [%] | Placental weight [g] | Fetal weight [g] |\n| gestation day 5-11 | 0 | 0.5421  Â±0.09 | 1.4570  Â±0.14 |\n| 2 | 0.5012 \\*  Â±0.09 | 1.4100  Â±0.28 |\n| gestation day 12-18 | 0 | 0.5205  Â±0.09 | 1.5460  Â±0.2 |\n| 2 | 0.480 \\*  Â±0.04 | 1.3450 \\*\\*  Â±0.09 |\n\nSignificant difference to untreated control: \\* p< 0.05 \\*\\* p < 0.001\n\n \n\nTable 3: External and skeletal malformations of fetuses\n\n|  |  |  |  |\n| --- | --- | --- | --- |\n|  | No. of fetuses examined | Malformed | Not malformed |\n| External malformations | | | |\n| Control (no treatment) | 90 | 0 | 90 |\n| 2% salicylamide on gestation day 5-11 | 31 | 4 | 27 |\n| 2% salicylamide on gestation day 12-18 | 52 | 1 | 51 |\n| Skeletal malformations | | | |\n| Control (no treatment) | 59 | 0 | 59 |\n| 2% salicylamide on gestation day 5-11 | 23 | 4 | 19 |\n| 2% salicylamide on gestation day 12-18 | 32 | 1 | 31 |\n\n \n\nTable 4: Effect of salicylamide on number of fetal ossification centers\n\n|  |  |  |\n| --- | --- | --- |\n| Treatment period [gestation day] | Drug level [%] | Average number of ossification centers |\n| 5-18 | 0 | 22.72Â±5.0 |\n| 5-11 | 2 | 17.26Â±8.0 |\n| 12-18 | 2 | 21.00Â±2.1 |\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nThe study is considered to be relevant, but not reliable or suitable for risk assessment or classification and labeling purposes with regard to developmental or reproductive toxicology.\n\nExecutive summary\n\nThe effect of oral salicylamide administration on fetal development was assessed in a feeding study with rats. Salicylamide (2% in feed) was administered to pregnant Holtzman rats either during gestation day 5 -11 or during gestation day 12 -18. Parameters under investigation were maternal body weight, number and weight of placentas, number of resorptions and of fetuses, external and skeletal malformations.\n\nThere are serious shortcomings in study design as well as in reporting (e.g. feed consumption not measured, no information on the number of fetuses total/per litter, and so on); therefore, the study was deemed to be not reliable.\n\nResults indicate that oral administration of salicylamide during gestation resulted in reduced placental and fetal weight. Salicylamide was found to be teratogenic, especially when administered during early organogenesis (gestation day 5-11). Malformations included especially abnormalities of the limbs but also short or missing tail, lordosis, or fused ileum. The number of ossification centers was reduced mainly in fetuses of dams receiving salicylamide during early organogenesis.\n\nBack to top",
          "content_length": 14091,
          "status": "success"
        },
        "002 | Supporting | Experimental study": {
          "document_id": "IUC5-01147252-a82c-4036-bb46-1f07998b9f4b_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Developmental toxicity / teratogenicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\ndevelopmental toxicity\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nNon-guideline study not performed under GLP. Non-standard study design. Low level of experimental detail reported. No data on purity, stability or origin of the test item. No data provided to show achieved concentration, homogeneity in the diet preparations. Doses exceed maximum dose for a guideline developmental toxicology study of 1000mg/kg/day. Maternal bodyweights were recorded but data is not given and clinical observations were not recorded. In the first phase of the study foetal malformations and resorptions were recorded as percentage of total fetuses and number of litters affected was not recorded. Placental weights were recorded. In the second phase of the study no foetal malformations or resorption rate were recorded. A dose related increase in malformations and resorptions were reported in the first phase (% of total fetuses). Malformations included micromelia and shortened tails however the incidence of these individual findings is not reported. A dose related decrease in mean foetal weight is reported for dams terminated at day 18 of gestation â individual foetal data is not given. In the second phase of the study foetal examinations for malformations are not reported.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Effect of salicylamide on the placental transfer and fetal tissue distribution of sodium-35S-sulfate in the rat](884d82e4-f2c8-3092-9012-014f1f1b7d7b_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nPregnant Holtzman rats were fed a diet supplemented with 1 or 2% salicylamide from gestation day 6-18. Weight gain of the dams was recoded throughout the feeding period. Dams were killed on gestation day 18 and blood samples were obtained. The maternal liver, the fetuses and placentas were extracted and weighted. Fetuses were also examined for gross malformations.\n\nGLP compliance\n\nno\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](8405c188-9e88-3356-b905-18d9c445d882_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrat\n\nStrain\n\nother:\nHoltzman\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Weight at study initiation: 230-250 g\n\n- Housing: individually\n\n- Diet (e.g. ad libitum): ad libitum\n\n### Administration / exposure\n\nRoute of administration\n\noral: feed\n\nType of inhalation exposure (if applicable)\n\n[Empty]\n\nVehicle\n\nunchanged (no vehicle)\n\nMass median aerodynamic diameter (MMAD)\n\n[Empty]\n\nGeometric standard deviation (GSD)\n\n[Empty]\n\nRemarks on MMAD\n\n[Empty]\n\nDetails on exposure\n\nDIET PREPARATION\n\n- Mixing appropriate amounts with: diet containing 25% casein, 15% hydrogenated vegetable oil, 52.7% glucose, 2% B-Vitamin mix (Thiamin HCl 0.40 mg, pyridoxine HCl 0.40 mg, riboflavin 0.80 mg, niacin 4.00 mg, inositol 20,00 mg, DL-calcium pantothenate 4.00 mg, biotin 0.02 mg, vitamin-B 11 0.003 mg, folic acid 0.20 mg and menadione 1.00 mg in 2.00 g glucose monohydrate), 1% fat soluble vitamins (retinyl acetate 310.0 mg, cholecalciferol 4.5 mg, a-tocopheryl acetate 5.0 g, corn oil to 1 kg), 4% salt mix, 0.3% choline\n\nAnalytical verification of doses or concentrations\n\nno\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDetails on mating procedure\n\n- Proof of pregnancy: sperm in vaginal smear referred to as day 0 of pregnancy\n\nDuration of treatment / exposure\n\nfrom gestation day 6 to gestation day 18\n\nFrequency of treatment\n\nfeed was offered ad libitum\n\nDuration of test\n\n[Empty]\n\n### Doses / concentrations\n\nNo. of animals per sex per dose\n\n24 dams per dose group\n\nControl animals\n\n* yes, plain diet\n\nDetails on study design\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nMaternal examinations\n\nBODY WEIGHT: Yes\n\n- Time schedule for examinations: daily\n\nPOST-MORTEM EXAMINATIONS: Yes\n\n- Sacrifice on gestation day #18\n\n- Organs examined: liver, uterus\n\nOvaries and uterine content\n\nThe ovaries and uterine content was examined after termination: Yes\n\nExaminations included:\n\n- Number of resorptions\n\n- Number of placentas\n\n- Placental weight\n\n- Number of fetuses\n\nBlood sampling\n\n[Empty]\n\nFetal examinations\n\n- External examinations: gross malformations\n\n- Fetal weight\n\nStatistics\n\nStatistical differences were examined by ANOVA.\n\nIndices\n\n[Empty]\n\nHistorical control data\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results: maternal animals\n\n### General toxicity (maternal animals)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\n### Maternal developmental toxicity\n\nNumber of abortions\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nPre- and post-implantation loss\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nTotal litter losses by resorption\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEarly or late resorptions\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDead fetuses\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in pregnancy duration\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in number of pregnant\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on maternal toxic effects\n\nMaternal toxic effects:no effects\n\nDetails on maternal toxic effects:\n\nNo significant differences were detected in the body weight gain of animals receiving control diet or diet containing salicylamide (table 1), although in the first two days of the study period, food intake of animals receiving the drug was lower compared to control animals.\n\n### Effect levels (maternal animals)\n\n### Maternal abnormalities\n\n### Results (fetuses)\n\nFetal body weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReduction in number of live offspring\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in sex ratio\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in litter size and weights\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nAnogenital distance of all rodent fetuses\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in postnatal survival\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nExternal malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nSkeletal malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nVisceral malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on embryotoxic / teratogenic effects\n\nEmbryotoxic / teratogenic effects:yes\n\nDetails on embryotoxic / teratogenic effects:\n\nThe average fetal body weights ranged from 0.85-1.42 g in control animals; from 0.83-1.30 g in the 1% salicylamide group, and from 0.83-1.29 g in the 2% salicylamide group. Salicylamide-induced reduction of fetal body weight was indicative in animals examined on gestation day 17 and significant at the 0.01 level in fetuses extracted on gestation day 18. Placental weights on gestation day 18 were not significantly different from one another.\n\nFetal malformations were observed in the offspring of drug-treated animals with a distinct dose-response relationship (table 2). Malformations observed included micromelia and short tails. A significant effect of the drug was found on the number of resorption sites in the high-dose group (table 2).\n\n### Effect levels (fetuses)\n\n### Fetal abnormalities\n\n### #1\n\nKey result\n\nAbnormalities\n\nnot specified\n\nLocalisation\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Overall developmental toxicity\n\n### #1\n\nKey result\n\nDevelopmental effects observed\n\nnot specified\n\nLowest effective dose / conc.\n\n[Empty]\n\nTreatment related\n\n[Empty]\n\nRelation to maternal toxicity\n\n[Empty]\n\nDose response relationship\n\n[Empty]\n\nRelevant for humans\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nTable 1: Food intake and body weights of pregnant rats receiving salicylamide by feed and control animals.\n\n|  |  |  |\n| --- | --- | --- |\n| Diet group | Mean food intake [g/day] | Mean body weight [g/day] |\n| Control | 18.57Â±0.39 | 280.09Â±6.75 |\n| 1% Salicylamide | 19.43Â±0.50 | 268.22Â±6.46 |\n| 2% Salicylamide | 19.66Â±0.60 | 272.40Â±6.86 |\n\nValues given are mean Â± SEM (n = 24)\n\n \n\nTable 2: Teratogenic and embryotoxic effects of salicylamide in the rat\n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| Diet group | No. of fetuses | Malformations | | Resorptions | |\n| No. | % | No. | % |\n| Control | 108 | 0 | 0 | 6 | 5.55 |\n| 1% Salicylamide | 92 | 7 \\* | 7.6 | 5 | 5.43 |\n| 2% Salicylamide | 139 | 16 \\*# | 11.5 | 13 \\*# | 9.35 |\n\n\\* Significantly different from control (p < 0.01)\n\n#Significantly different from other dose group (p < 0.01)\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nThe study is considered to be relevant, but not reliable or suitable for risk assessment or classification and labeling purposes with regard to developmental or reproductive toxicology.\n\nExecutive summary\n\nThe effect of oral salicylamide administration on fetal development was assessed in a feeding study with rats. Salicylamide (1 and 2% in feed) was administered to pregnant Holtzman rats on gestation day 6 - 18. Parameters under investigation were maternal body weight, placental weight, number of resorptions and fetuses, fetal body weight and external malformations.\n\nThere are serious shortcomings in study design as well as in reporting (e.g. feed consumption not measured, no information on the number of fetuses per litter); therefore, the study was deemed to be not assessable.\n\nResults indicate that oral administration of salicylamide during gestation had no influence on maternal body weight gain. However, salicylamide administration resulted in reduced fetal body weight. Salicylamide was also found to be teratogenic, causing malformations (micromelia and short tails) with a clear dose-dependence.\n\nBack to top",
          "content_length": 13746,
          "status": "success"
        },
        "003 | Supporting | Experimental study": {
          "document_id": "IUC5-14ae4d5c-f5f7-4e62-9033-3c5b1f2acdf4_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Developmental toxicity / teratogenicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\ndevelopmental toxicity\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nNon-guideline study, a mechanistic study rather than a developmental toxicology study. Not performed under GLP. Non-standard study design. No data on purity, stability or origin of the test item. The route of administration was the diet. Dose levels of 0, 2% salicylamide in the diet. No data provided to show achieved concentration, homogeneity in the diet preparations. Animals were dosed from either day 6 to day 17 or 18 of gestation. Dams were terminated on day 17 or 18 of gestation respectively. There were no external, visceral or skeletal examinations of the fetuses â instead the fetuses were used for quantitative analysis of radio-labeled sulfate into skeletal glycosaminoglycans and the calcium content in limb bones.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Effect of salicylamide on skeletal glycosaminoglycan sulfation and calcification in fetal rat limbs](bf4bda0d-ae1b-32da-9b67-8b7f38015d7e_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nPregnant Holtzman rats were fed a diet supplemented with 2% salicylamide from gestation day 6 to 17 or 19. Body weight gain and food intakes of the dams were recoded daily throughout the study period. Dams were killed on gestation day 17 or 19 and blood samples were obtained. Placentas were removed and weighted. Fetuses were weighted; subsequently, limbs were removed, pooled, and digfested with papain. In the remaining mixture, glycosaminoglycane (GAG) and chondroitin sulfate levels were determined.\n\nIn a second study under the same conditions (pregnant Holtzman rats receiving 2% salicylamide in feed from gestation day 6-19), the fetal calcium content was determined by AAS.\n\nGLP compliance\n\nno\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](ddcbef69-fda3-3f17-9fd8-3dc15afb6567_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrat\n\nStrain\n\nother:\nHoltzman albino\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Housing: individually\n\n- Diet (e.g. ad libitum): ad libitum\n\n### Administration / exposure\n\nRoute of administration\n\noral: feed\n\nType of inhalation exposure (if applicable)\n\n[Empty]\n\nVehicle\n\nunchanged (no vehicle)\n\nMass median aerodynamic diameter (MMAD)\n\n[Empty]\n\nGeometric standard deviation (GSD)\n\n[Empty]\n\nRemarks on MMAD\n\n[Empty]\n\nDetails on exposure\n\nDIET PREPARATION\n\n- Mixing appropriate amounts with: diet containing 25% casein, 15% hydrogenated vegetable oil, 52.7% glucose, 2% B-Vitamin mix (Thiamin HCl 0.40 mg, pyridoxine HCl 0.40 mg, riboflavin 0.80 mg, niacin 4.00 mg, inositol 20,00 mg, DL-calcium pantothenate 4.00 mg, biotin 0.02 mg, vitamin-B 11 0.003 mg, folic acid 0.20 mg and menadione 1.00 mg in 2.00 g glucose monohydrate), 1% fat soluble vitamins (retinyl acetate 310.0 mg, cholecalciferol 4.5 mg, a-tocopheryl acetate 5.0 g, corn oil to 1 kg), 4% salt mix, 0.3% choline\n\nAnalytical verification of doses or concentrations\n\nno\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDetails on mating procedure\n\n- Proof of pregnancy sperm in vaginal smear referred to as day 0 of pregnancy\n\nDuration of treatment / exposure\n\nfrom gestation day 6 to gestation days 17 and 19\n\nFrequency of treatment\n\nSalicylamide was offered in feed\n\nDuration of test\n\nfrom gestation day 6 to gestation days 17 and 19\n\n### Doses / concentrations\n\nNo. of animals per sex per dose\n\n12 rats per group\n\nControl animals\n\n* yes, plain diet\n\nDetails on study design\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nMaternal examinations\n\nBODY WEIGHT: Yes\n\n- Time schedule for examinations: daily\n\n.\n\nFOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes\n\n- Food consumption for each animal determined and mean daily diet consumption calculated as g food/animal/day: Yes\n\nPOST-MORTEM EXAMINATIONS: Yes\n\n- Sacrifice on gestation day 17 or 19\n\n- Organs examined: blood (serum), uterus\n\nOTHER:\n\n- Two days before sacrifice, dams received an intramuscular injection of radiolabelled Na2(35)SO4. Aliquots of maternal serum and liver were assayed for radioactive sulphate.\n\n- Maternal serum calcium level was quantified by AAS\n\nOvaries and uterine content\n\nThe ovaries and uterine content was examined after termination: Yes\n\n- placental weight\n\n- number of resorptions\n\n- litter size\n\nBlood sampling\n\n[Empty]\n\nFetal examinations\n\n- Fetal weight\n\n- radioactive sulphate was assayed in pooled and digested fetal limbs\n\n- glycoaminoglycans (GAG), chondroitin 4- and 6- sulphate (Ch-4-S and Ch-6-S) were quantified\n\n- fetal limb bone calcium level was quantified by AAS\n\nStatistics\n\nValues are reported as mean Â± standard error of the mean (SEM). Statistical significant differences were assessed by Student's t-test.Analysis of covariance was used to measure treatment effects after adjustment for correlating variables.\n\nIndices\n\n[Empty]\n\nHistorical control data\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results: maternal animals\n\n### General toxicity (maternal animals)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\n### Maternal developmental toxicity\n\nNumber of abortions\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nPre- and post-implantation loss\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nTotal litter losses by resorption\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEarly or late resorptions\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDead fetuses\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in pregnancy duration\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in number of pregnant\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on maternal toxic effects\n\nMaternal toxic effects:no effects\n\nDetails on maternal toxic effects:\n\nFood intake and body weight gain of the dams were significantly decreased by salycylamide administration (table 1).\n\nOral administration of 2% salicylamide did not affect litter size or the number of resorptions (table 1).\n\nThe level of serum sulfate was significantly decreased by salicylamide treatment. This may be caused by maternal metabolism, producing salicylamide-sulfate conjugates for excretion. Maternal serum calcium was not affected by salicylamide treatment.\n\n### Effect levels (maternal animals)\n\n### Maternal abnormalities\n\n### Results (fetuses)\n\nFetal body weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReduction in number of live offspring\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in sex ratio\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in litter size and weights\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nAnogenital distance of all rodent fetuses\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in postnatal survival\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nExternal malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nSkeletal malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nVisceral malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on embryotoxic / teratogenic effects\n\nEmbryotoxic / teratogenic effects:yes\n\nDetails on embryotoxic / teratogenic effects:\n\nOral administration of 2% salicylamide resulted in a reduction of fetal but not of placental weight (table 2).\n\nAdministration of 2% salicylamide to pregnant rats decreased incorporation of radiosulfate into fetal skeletal GAG.\n\nThe bone weight of fetal limbs was significantly lower in the salicylamide treated group, compared to the control animals. Salicylamide treatment also significantly decreased calcification of fetal limbs.\n\n### Effect levels (fetuses)\n\n### Fetal abnormalities\n\n### #1\n\nKey result\n\nAbnormalities\n\nnot specified\n\nLocalisation\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Overall developmental toxicity\n\n### #1\n\nKey result\n\nDevelopmental effects observed\n\nnot specified\n\nLowest effective dose / conc.\n\n[Empty]\n\nTreatment related\n\n[Empty]\n\nRelation to maternal toxicity\n\n[Empty]\n\nDose response relationship\n\n[Empty]\n\nRelevant for humans\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nTable 1: Effect of salicylamide on maternal body weight, food intake, litter size, and resorptions.\n\n|  |  |  |  |  |\n| --- | --- | --- | --- | --- |\n| Sacrifice on gestation day | 17 | 19 | 17 | 19 |\n| Salicylamide | 0% (control) | 2% | 0% (control) | 2% |\n| Body weight gain [g/animal/day] | 8.4Â±0.3 | 6.1Â±0.3 \\*\\* | 9.2Â±0.2 | 7.7Â±0.2 \\*\\* |\n| Final body weight [g] | 364.5Â±4.7 | 342.4Â±4.3 \\*\\* | 396.6Â±6.5 | 371.5Â±4.6 \\*\\* |\n| Food intake [g/rat/day] | 19.7Â±0.6 | 18.3Â±0.5 \\* | 20.9Â±0.4 | 19.1Â±0.3 \\*\\* |\n| Serum35S-sulfate [1000 dpm/ml] | 23Â±1.6 | 15Â±1.2 \\*\\* | 21Â±1.0 | 12Â±0.7 \\*\\* |\n| Serum calcium [mg/100 ml] | n.t. | n.t. | 10.0Â±0.5a) | 9.8Â±0.8b) |\n| Litter size | 11.2Â±0.5 | 9.5Â±1.2 | 10.3Â±0.3 | 10.3Â±0.7 |\n| Number of resorptions | 0.6Â±0.4 | 0.8Â±0.4 | 0.3Â±0.1 | 0.1Â±0.1 |\n\nValues are mean Â± SEM for 12 rats/group, excepta)13 dams,b)14 dams\n\nn.t.: not tested\n\nValue significantly different from control: \\* p<0.05 \\*\\* p<0.01\n\n \n\n \n\nTable 2: Effect of salicylamide on fetal and placental weight.\n\n|  |  |  |  |  |\n| --- | --- | --- | --- | --- |\n| Sacrifice on gestation day | 17 | 19 | 17 | 19 |\n| Salicylamide | 0% (control) | 2% | 0% (control) | 2% |\n| Placental weight [g] | 0.30Â±0.01  (134) | 0.28Â±0.01  (114) | 0.54Â±0.01  (124) | 0.53Â±0.01  (123) |\n| Fetal weight [g] | 0.83Â±0.01  (134) | 0.78Â±0.01 \\*\\*  (114) | 2.58Â±0.02  (124) | 2.29Â±0.02 \\*\\*  (123) |\n| 35S in fetal skeletal GAG [1000 dpm/Âµmol uronic acid] | 56Â±3.3 | 46Â±4.2 \\* | 51Â±1.8 | 36Â±1.6 \\*\\* |\n| Bone weight / fetal limb pool [mg dry weight] | n.t. | n.t. | 6.4Â±0.1  (138) | 5.5Â±0.1 \\*\\*\\*  (143) |\n| Total calcium/fetal limb pool [Âµg] | n.t. | n.t. | 388.7Â±5.3  (138) | 311.3Â±3.7 \\*\\*\\*  (143) |\n| Calcium content of fetal limb bones [Âµg/mg dry weight] | n.t. | n.t. | 60.9Â±0.4  (138) | 56.3Â±0.4 \\*\\*\\*  (143) |\n\nValues are mean Â± SEM for 12 rats/group\n\nValues in parentheses represent the number of placentas/fetuses per group\n\nn.t.: not tested\n\nValue significantly different from control: \\* p<0.05 \\*\\* p<0.01 \\*\\*\\* p<0.001\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nThe study is considered to be relevant, but not suitable for risk assessment or classification and labeling purposes with regard to developmental or reproductive toxicology.\n\nExecutive summary\n\nThe effect of oral salicylamide administration on fetal development was assessed in a feeding study with rats. Salicylamide (2% in feed) was administered to pregnant Holtzman rats on gestation day 6 to 17 or 19. Parameters under investigation were maternal body weight, placental weight, number of resorptions and fetuses, fetal body weight and external malformations. Additionally, maternal serum and fetal bone sulphate levels were measured as well as fetal bone calcium content and bone weight.\n\nThe study shows several methodological shortcomings; above all, only limited data on maternal and fetal toxicity as well as teratogenicity were assessed.\n\nResults indicate that oral administration of salicylamide during gestation decreased maternal body weight gain, final body weight and maternal sulfate sulfate level by conjugate formation. Furthermore, fetal weights were reduced in the salicylamide treated group as were fetal limb bone sulfate, bone weights and calcification.\n\nBack to top",
          "content_length": 15478,
          "status": "success"
        },
        "004 | Supporting | Experimental study": {
          "document_id": "IUC5-8c8e23cf-b50c-47e5-ae03-00b9e9c7e2bf_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Developmental toxicity / teratogenicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\ndevelopmental toxicity\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nNon-guideline study not performed under GLP. Non-standard study design. Only a low level of experimental detail reported. Route of administration was in the diet at only 1 dose level 1.3% (~13000ppm)(~800-1000 mg/kg/day which is about 160 times the average human adult dose). No data provided to show achieved concentration, homogeneity or stability in the diet preparations. Purity/composition/origin of test substance not given. Achieved doses not reported. Animals were dosed from gestation day 5 to gestation day 17 or 19. It is reported there were no foetal abnormalities or resorptions, and there was no effect of treatment on foetal bodyweight and crown rump length â although no data is given. Results do not give detail of the clinical condition of the dams. The main focus of the study was not assessing the developmental toxicity of salicylamide in rats. A dose relationship was not investigated and a NOAEL or LOAEL was not determined. However, from the available data it was inferred that in the rat salicylamide was well tolerated during the period of gestation.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Development of sulfur depletion in pregnant and fetal rats: interaction of protein restriction and indole or salicylamide administration](23526752-7d01-3d38-9bac-e7ce3bfb862c_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nPregnant Holtzman rats were fed a diet supplemented with 1.33 % salicylamide from gestation day 5 to day 17 and 19. Food intake, body weight gain, and feed efficiency were determined throughout the study period. On gestation day 15 and 17, respectively, animals received a dose of radiolabelled 35S-sodium sulfate by intramuscular injection. After sacrifice, maternal livers and blood were collected. Fetal and placental weights and fetal length were measured. Each of them was assayed for total radioactivity by liquid scintillation counting. Urine samples taken after sulfate injection were analyzed for total and inorganic sulfate.\n\nGLP compliance\n\nno\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](ddcbef69-fda3-3f17-9fd8-3dc15afb6567_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nrat\n\nStrain\n\nother:\nHoltzman\n\nDetails on test animals or test system and environmental conditions\n\n[Empty]\n\n### Administration / exposure\n\nRoute of administration\n\noral: feed\n\nType of inhalation exposure (if applicable)\n\n[Empty]\n\nVehicle\n\nunchanged (no vehicle)\n\nMass median aerodynamic diameter (MMAD)\n\n[Empty]\n\nGeometric standard deviation (GSD)\n\n[Empty]\n\nRemarks on MMAD\n\n[Empty]\n\nDetails on exposure\n\nDIET PREPARATION\n\n- Mixing appropriate amounts with: diet containing 25% casein, 15% hydrogenated vegetable oil, 52.7% glucose, 2% B-Vitamin mix (Thiamin HCl 0.40 mg, pyridoxine HCl 0.40 mg, riboflavin 0.80 mg, niacin 4.00 mg, inositol 20,00 mg, DL-calcium pantothenate 4.00 mg, biotin 0.02 mg, vitamin-B 11 0.003 mg, folic acid 0.20 mg and menadione 1.00 mg in 2.00 g glucose monohydrate), 1% fat soluble vitamins (retinyl acetate 310.0 mg, cholecalciferol 4.5 mg, a-tocopheryl acetate 5.0 g, corn oil to 1 kg), 4% salt mix, 0.3% choline\n\nAnalytical verification of doses or concentrations\n\nno\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDetails on mating procedure\n\n- Proof of pregnancy: sperm in vaginal smear\n\nDuration of treatment / exposure\n\nfrom gestation day 5 to gestation day 17 and 19\n\nFrequency of treatment\n\nthe test item was offered in feed\n\nDuration of test\n\nfrom gestation day 5 to gestation day 17 and 19\n\n### Doses / concentrations\n\nNo. of animals per sex per dose\n\n6 animals per dose group\n\nControl animals\n\n* yes, plain diet\n\nDetails on study design\n\n- Rationale for animal assignment: equalisation of body weight per group\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nMaternal examinations\n\nBODY WEIGHT: Yes\n\nFOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes\n\n- Food consumption for each animal determined and mean daily diet consumption calculated as g food/animal/day: Yes\n\n- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No\n\nPOST-MORTEM EXAMINATIONS: Yes / No / No data\n\n- Sacrifice on gestation day 17 and 19\n\n- Organs examined: blood, liver, uterus\n\nOTHER:\n\n- Two days before sacrifice, dams received an intramuscular injection of radiolabelled Na2(35)SO4. Aliquots of maternal serum and liver were assayed for radioactive sulphate.\n\nOvaries and uterine content\n\nThe ovaries and uterine content was examined after termination: Yes\n\nExaminations included:\n\n- Number of resorptions\n\n- Placental weight\n\nBlood sampling\n\n[Empty]\n\nFetal examinations\n\n- Fetal weight\n\n- Fetal length\n\nStatistics\n\nData were evaluated by ANOVA and Student's t-test\n\nIndices\n\n[Empty]\n\nHistorical control data\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results: maternal animals\n\n### General toxicity (maternal animals)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\n### Maternal developmental toxicity\n\nNumber of abortions\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nPre- and post-implantation loss\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nTotal litter losses by resorption\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEarly or late resorptions\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDead fetuses\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in pregnancy duration\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in number of pregnant\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on maternal toxic effects\n\nMaternal toxic effects:no effects\n\nDetails on maternal toxic effects:\n\nBody weight gain of maternal rats were not influenced by salicylamide intake as can be seen from studies with other feed. Only the control group receiving standard feed had a significantly lower food intake. This is deemed to be an artefact with no correlation to any form of toxicity. Body weight gain and feed efficacy were not affected by this finding (table 1).\n\nRelative liver weights were significantly greater among salicylamide treated rats (table 1).\n\nWhen feeding salicylamide to pregnant rats, retention of sulfate in liver was non-significantly reduced compared to control diet fed rats; reduction of serum sulfate, however, was significant (table 2).\n\nSalicylamide administration significantly increased urinary sulfate excretion (table 3). The amount of inorganic sulfate was distinctly lowered from 41 to 0.4% showing an increase of ester sulfate excretion.\n\nRelative liver weights were significantly greater among salicylamide treated rats (table 1).\n\nWhen feeding salicylamide to pregnant rats, retention of sulfate in liver was non-significantly reduced compared to control diet fed rats; reduction of serum sulfate, however, was significant (table 2).\n\nSalicylamide administration significantly increased urinary sulfate excretion (table 3)\n\n### Effect levels (maternal animals)\n\n### Maternal abnormalities\n\n### Results (fetuses)\n\nFetal body weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReduction in number of live offspring\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in sex ratio\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in litter size and weights\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nAnogenital distance of all rodent fetuses\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in postnatal survival\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nExternal malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nSkeletal malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nVisceral malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on embryotoxic / teratogenic effects\n\nEmbryotoxic / teratogenic effects:no effects\n\nDetails on embryotoxic / teratogenic effects:\n\nOral administration of salicylamide to pregnant rats doesn't induce fetal abnormalities or fetal resorptions. Also fetal weights and lengths and placental weight was not affected by salicylamide treatment.\n\nFetal and placental sulfate levels were significantly reduced when dams were fed with salicylamide (table 4).\n\n### Effect levels (fetuses)\n\n### Fetal abnormalities\n\n### #1\n\nKey result\n\nAbnormalities\n\nnot specified\n\nLocalisation\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Overall developmental toxicity\n\n### #1\n\nKey result\n\nDevelopmental effects observed\n\nnot specified\n\nLowest effective dose / conc.\n\n[Empty]\n\nTreatment related\n\n[Empty]\n\nRelation to maternal toxicity\n\n[Empty]\n\nDose response relationship\n\n[Empty]\n\nRelevant for humans\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nTable 1: Food intake, body weight gain, feed efficiency and relative liver weights of dams receiving either control or salicylamide-supplemented diet.\n\n|  |  |  |\n| --- | --- | --- |\n| Group | I | II |\n| Salicylamide [%] | 0 | 1.33 |\n| Food intake [g/rat/d] | 15.0Â±0.9 \\*a) | 19.4Â±2.5 |\n| Body weight gain [g/rat/d] | 5.1Â±0.2 | 5.5Â±0.6 |\n| Feed efficiency ratio | 0.4Â±0.04 | 0.29Â±0.02 |\n| relative liver weight [g/100 g bw] | 3.8Â±0.1 | 4.1Â±0.1 \\* |\n\nValues are expressed as mean Â± SEM (6 rats/group)\n\nSignificant difference among groups: \\* p<0.05\n\na)food intake of control group significantly reduced compared to food intake of rats receiving a low-protein diet with (19.8Â±0.7 g/rat/d) or without salicylamide (20.2Â±1.9 g/rat/d) and group II rats\n\n \n\nTable 2: Retention of35S-sulfate by maternal liver and serum\n\n|  |  |  |\n| --- | --- | --- |\n| Group | I | II |\n| Salicylamide [%] | 0 | 1.33 |\n| 35S sulfate in liver [dpm/g wet wt] | 2894Â±496 | 1661Â±130 |\n| 35S sulfate in serum [dpm/ml] | 4749Â±933 | 1854Â±456 \\*\\* |\n\nValues are expressed as mean Â± SEM (pooled data from 4 livers/serum samples from rats receiving35S on day 15 and 17 of gestation)\n\nSignificant difference among groups: \\*\\* p<0.01\n\n \n\nTable 3: Urinary excretion of35S-sulfate\n\n|  |  |  |\n| --- | --- | --- |\n| Group | I | II |\n| Salicylamide [%] | 0 | 1.33 |\n| Total excreted35S-sulfate/48 h  % injected dose | 4770Â±350  43 | 5730Â±620 \\*  53 |\n| Inorganic35S-sulfate excreted/48 h  % injected dose | 4600Â±370  41 | 50Â±12 \\*  0.40 |\n\nValues are expressed as mean Â± SEM (pooled data from 4 urine samples from rats receiving35S on day 15 and 17 of gestation)\n\nSignificant difference among groups: \\* p<0.05\n\n \n\nTable 4: retention of35S-sulfate by fetus and placenta, in [dpm/100 mg]\n\n|  |  |  |\n| --- | --- | --- |\n| Group | I | II |\n| Salicylamide [%] | 0 | 1.33 |\n| Day 17 | | |\n| No. of fetuses/placentas | 20 | 17 |\n| Fetal retention | 500Â±46 | 200Â±0 \\*\\*\\* |\n| Placental retention | 400Â±10 | 200Â±8 \\*\\*\\* |\n| Day 19 | | |\n| No. of fetuses/placentas | 20 | 14 |\n| Fetal retention | 1400Â±60 | 800 \\*\\*\\* |\n| Placental retention | 400Â±17 | 300Â±16 |\n\nValues are expressed as mean Â± SEM\n\nSignificant difference among groups: \\*\\*\\* p<0.001\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nThe study is considered to be relevant, but not reliable or suitable for risk assessment or classification and labeling purposes with regard to developmental or reproductive toxicology.\n\nExecutive summary\n\nThe effect of oral salicylamide administration on fetal development was assessed in a feeding study with rats. Salicylamide (1.33% in feed) was administered to pregnant Holtzman rats on gestation day 5 to 17 and 19. Parameters under investigation were maternal body weight, food consumption, food efficiency, and liver weight. Placental weight, number of resorptions and fetuses, fetal length and body weight and external malformations were also assessed. Additionally, maternal liver and serum, fetal and placental sulphate levels were measured as well as maternal urinary sulfate excretion.\n\nThe study shows several methodological shortcomings; above all, only limited data on maternal and fetal toxicity as well as teratogenicity were assessed.\n\nResults indicate that oral administration of salicylamide during gestation has no effect on maternal rats were observed except for increased liver weight and reduction of liver and serum sulfate. Urinary sulfate excretion slightly increased and distinctly shifted towards excretion of organic (i.e. ester bound) sulfate.\n\nIn the offspring of salicylamide-treated rats, neither growth retardation nor malformations were registered; fetal and placental sulfate levels were significantly reduced by salicylamide administration.\n\nBack to top",
          "content_length": 16572,
          "status": "success"
        },
        "005 | Supporting | Experimental study": {
          "document_id": "IUC5-0a0cae66-6e34-423a-a46b-c3ab2a262bfa_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Developmental toxicity / teratogenicity\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\ndevelopmental toxicity\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nNon-guideline study. Non-GLP. Non-standard species and strain. Dose level not clearly stated and only one dose level tested (4 doses of 0.5 grains (2.0 grains total dose) of salicylamide in the liquid carrier of the commercial preparation âLiquiprinâ orally at 12 hour intervals). No information on purity, composition, origin. Animals were window dosed (either days 6 to 7 or 9 -10 of gestation) and terminated on day 14 of gestation. Data for control animals reported but these do not appear to be concurrent controls (does not report whether control animals were sham dosed). Only a low level of experimental detail reported. Only a summary of the data is provided with no statistical analysis. Effects of treatment on the parental animals is not reported including survival rate however it is stated that the dose tested is close to the lethal dose for the mothers. Incidence of reported malformations in fetuses is given as a percentage of the corpora lutea per dose group with no indication of number of litters effected (the unit of analysis for a developmental toxicity study). No dose response relationship reported.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### Data source\n\nReference\n\n* [Salicylamide-induced anomalies in hamster embryos](8f8a9428-b75f-335f-b3a0-133219749a52_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nPregnant hamsters were administered salicylamide either on gestation day 6-7.5 (primitive streak to somite stage) or on gestation day 9-10.5 (limb bud stage).\n\nGLP compliance\n\nno\n\nLimit test\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](ddcbef69-fda3-3f17-9fd8-3dc15afb6567_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nhamster, Syrian\n\nStrain\n\n[Empty]\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Source: local breeder\n\n- Weight at study initiation: 160-160 g\n\n- Acclimation period: 3-4 weeks\n\n### Administration / exposure\n\nRoute of administration\n\noral: unspecified\n\nType of inhalation exposure (if applicable)\n\n[Empty]\n\nVehicle\n\nother:\nliquid carrier of the drug \"Liquiprin\"\n\nMass median aerodynamic diameter (MMAD)\n\n[Empty]\n\nGeometric standard deviation (GSD)\n\n[Empty]\n\nRemarks on MMAD\n\n[Empty]\n\nDetails on exposure\n\n[Empty]\n\nAnalytical verification of doses or concentrations\n\nno\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDetails on mating procedure\n\n[Empty]\n\nDuration of treatment / exposure\n\n2 days: on gestation day 6 and 7 or on gestation day 9 and 10, respectively\n\nFrequency of treatment\n\ntwice a day\n\nDuration of test\n\nfrom gestation day 6 or 9 to gestation day 14 (sacrifice)\n\n### Doses / concentrations\n\nNo. of animals per sex per dose\n\nControl: 32 preganant animals\nTest item groups: 17-18 pregnant animals\n\nControl animals\n\n* yes\n\nDetails on study design\n\n[Empty]\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Examinations\n\nMaternal examinations\n\nPOST-MORTEM EXAMINATIONS: No\n\n- Sacrifice on gestation day: 14\n\nOvaries and uterine content\n\nThe ovaries and uterine content was examined after termination: Yes\n\nExaminations included:\n\n- Number of corpora lutea\n\n- Number of implantations\n\n- Number of resorptions\n\nBlood sampling\n\n[Empty]\n\nFetal examinations\n\n- Fetal weight\n\n- External examinations: Yes: all per litter\n\nStatistics\n\n[Empty]\n\nIndices\n\n[Empty]\n\nHistorical control data\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Results: maternal animals\n\n### General toxicity (maternal animals)\n\nClinical signs\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDermal irritation (if dermal study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nMortality\n\n[Empty]\n\nDescription (incidence)\n\n[Empty]\n\nBody weight and weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood consumption and compound intake (if feeding study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nFood efficiency\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nWater consumption and compound intake (if drinking water study)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOphthalmological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHaematological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nClinical biochemistry findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEndocrine findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nUrinalysis findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nBehaviour (functional findings)\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nImmunological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOrgan weight findings including organ / body weight ratios\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nGross pathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nNeuropathological findings\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: non-neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nHistopathological findings: neoplastic\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on results\n\n[Empty]\n\n### Maternal developmental toxicity\n\nNumber of abortions\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nPre- and post-implantation loss\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nTotal litter losses by resorption\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nEarly or late resorptions\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDead fetuses\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in pregnancy duration\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in number of pregnant\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on maternal toxic effects\n\nMaternal toxic effects:not examined\n\n### Effect levels (maternal animals)\n\n### Maternal abnormalities\n\n### Results (fetuses)\n\nFetal body weight changes\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nReduction in number of live offspring\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in sex ratio\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in litter size and weights\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nAnogenital distance of all rodent fetuses\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nChanges in postnatal survival\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nExternal malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nSkeletal malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nVisceral malformations\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nOther effects\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\nDetails on embryotoxic / teratogenic effects\n\nEmbryotoxic / teratogenic effects:yes\n\nDetails on embryotoxic / teratogenic effects:\n\nNumber of implantation sites was comparable in all three groups. Number of resorptions following salicylamide treatment was higher in the first group (receiving the drug on gestation days 6-7) than in the second group or in the control (see Table 1).\n\nThe frequency of abnormal fetuses was markedly higher in animals on gestation days 9-10 compared to the treatment early in pregnancy or control. Abundance of a certain form of malformation after salicylamide treatment early or late in pregnancy was not visible (Table 2).\n\n### Effect levels (fetuses)\n\n### Fetal abnormalities\n\n### #1\n\nKey result\n\nAbnormalities\n\nnot specified\n\nLocalisation\n\n[Empty]\n\nDescription (incidence and severity)\n\n[Empty]\n\n### Overall developmental toxicity\n\n### #1\n\nKey result\n\nDevelopmental effects observed\n\nnot specified\n\nLowest effective dose / conc.\n\n[Empty]\n\nTreatment related\n\n[Empty]\n\nRelation to maternal toxicity\n\n[Empty]\n\nDose response relationship\n\n[Empty]\n\nRelevant for humans\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nTable 1: Effect of 2-day treatment of pregnant hamsters with salicylamide (64.8 mg/kg bw/day) on fetal development.\n\n|  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| Treatment days | Females | | | | Embryos | | Viable fetuses | | | | | |\n| Pregnant No. | Corpora lutea No. | Implant sites | | Resorptions | | Total | | Normal | | Abnormal | |\n| No. | % | No. | % | No. | % | No. | % | No. | % |\n| 6-7 | 17 | 215 | 172 | 80 | 33 | 19 | 139 | 66 | 85 | 59 | 54 | 39 |\n| 9-10 | 18 | 207 | 170 | 82 | 8 | 4 | 162 | 78 | 52 | 32 | 110 | 68 |\n| Control | 32 | 409 | 327 | 80 | 27 | 7 | 306 | 75 | 306 | 100 | 0 | 0 |\n\nTable 2: Classification and frequency of growth abnormalities induced by 2-day treatment of pregnant hamsters with salicylamide (64.8 mg/kg bw/day)\n\n|  |  |  |  |\n| --- | --- | --- | --- |\n|  | Treatment on gestation day | | Control |\n| 6-7 | 9-10 |\n| Viable fetuses | | | |\n| Total | 139 | 162 | 306 |\n| Abnormal  in % | 54  39 | 110  68 | 0  0 |\n| Classification and frequency of growth abnormalities | | | |\n| Cranial blister  in % | 22  16 | 48  30 | 0  0 |\n| Subdermal hemmorhage  in % | 23  16 | 20  12 | 0  0 |\n| Generalized edema  in % | 23  16 | 35  22 | 0  0 |\n| Umbilical hernia  in % | 13  9 | 13  8 | 0  0 |\n| White skin (albinism)  in % | 4  3 | 7  4 | 0  0 |\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nThe study is considered to be relevant, but not reliable or suitable for risk assessment or classification and labeling purposes.\n\nExecutive summary\n\nThe effect of salicylamide on fetal development was assessed in pregnant hamsters receiving 360-405 mg/kg bw/day the drug for two consecutive days. Salicylamide was administered either on gestation days 6-7 (primitive streak to somite stage) or on gestation days 9-10 (limb bud stages). On gestation day 14, dams were sacrificed, ovaries were removed and the corpora lutea were counted. Uterus was opened and implantation sites and fetuses were counted. Fetuses were subsequently weighted and checked for macroscopic abnormalities which were classified and counted. Number of resorptions following salicylamide treatment was higher in dams receiving the drug on gestation days 6-7 than in the other treatment group or in the control group. The frequency of abnormal fetuses was markedly higher in animals on gestation days 9-10 compared to the treatment early in pregnancy or control. Abundance of a certain form of malformation after salicylamide treatment early or late in pregnancy was not visible. Taken together, salicylamide, when administered at doses of 360-405 mg/kg bw/day to pregnant hamsters during fetal development can cause abnormalities in fetuses.\n\nBack to top",
          "content_length": 12952,
          "status": "success"
        }
      },
      "7.8.3 Toxicity to reproduction: other studies": {
        "001 | Supporting | Experimental study": {
          "document_id": "IUC5-ea83bf47-eb16-47ee-8d97-4e91aaabb67d_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Toxicity to reproduction: other studies\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\ntoxicity to reproduction: other studies\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n3 (not reliable)\n\nRationale for reliability incl. deficiencies\n\nother:\nsee 'Remark'\n\nNon-guideline study not performed under GLP. Non-standard study design. 3 âgenerations Studied in mice. Only a low level of experimental detail reported. Route of administration was in the diet at 0.1%, 0.5% or 1.0%. No data provided to show achieved concentration, homogeneity or stability in the diet preparations. Purity/composition/origin of test substance not given. Food consumption not shown but achieved doses reported as 143, 688 or 1345 mg/kg/day respectively representing 10%, 70% and 95% of the acute oral LD50. Results do not give detail of the clinical condition of the animals other than a condition percentage that was assessed on a 5 weekly basis. No record of the animal breeding procedures. Reproductive parameters are not measured in detail (44%-45% of all females across all dose groups and generations did not litter. However no dose response and no further data given) â number of females to litter (%) and pups born that were raised to weaning age (%) were reduced in all treated groups with no dose response. Parental survival time was significantly reduced compared with controls for all dose groups. As was percentage of pups raised to weaning age. A NOAEL was not derived.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Chronic toxicity studies of analgesic and antipyretic drugs and congeners](d431f89d-3491-3260-b56e-ce602805413e_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nMale and female mice in mated groups of five (2 males, 3 females) were powder-fed with 0.1, 0.5, and 1.0% of the test substance in the diet, starting at weaning in each generation. The condition of the mice was recorded at 5-week intervals. Numbers of litters born and numbers of young raised to weaning age, as well as gross abnormalities, were recorded. Number of mated females, % having no litters, litters not raised, and numbers of pups per female (born, raised to weaning) are reported per dose.\n\nGLP compliance\n\nno\n\nType of method\n\nin vivo\n\n### Test material\n\nTest material information\n\n[Test material information](e42c0357-66dd-30ec-9a55-45a3a4138a98_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Test animals\n\nSpecies\n\nmouse\n\nStrain\n\nother:\nABC-A, albino, inbred for 25 generations\n\nSex\n\nmale/female\n\nDetails on test animals or test system and environmental conditions\n\nTEST ANIMALS\n\n- Source: developed in author's laboratory, derived from ABC mice (Dr. J.J. Bittner)\n\n- Age at study initiation: weanling\n\n- Weight at study initiation: no data\n\n- Fasting period before study: no\n\n- Housing: cages of 5, mated groups: 2 males and 3 females\n\n- Diet (ad libitum): Purina Labeena, Ralston-Purina Co., St. Louis, USA\n\n- Water (ad libitum): tap water\n\n- Acclimation period: none\n\nENVIRONMENTAL CONDITIONS\n\n- Temperature (Â°C), humidity (%), air changes (per hr): no data\n\n- Photoperiod (hrs dark / hrs light): 14 hours dark, 10 hours light\n\n### Administration / exposure\n\nRoute of administration\n\noral: feed\n\nType of inhalation exposure (if applicable)\n\n[Empty]\n\nVehicle\n\nunchanged (no vehicle)\n\npowder feeding\n\nDetails on exposure\n\nROUTE:\n\n- oral: powder feeding\n\nDIET PREPARATION\n\n- Rate of preparation of diet (frequency): twice weekly\n\n- Mixing appropriate amounts with (Type of food): commercial food (Purina Labeena), finely ground\n\n- Storage temperature of food: room temperature\n\nVEHICLE\n\n- none\n\nAnalytical verification of doses or concentrations\n\nno\n\nDetails on analytical verification of doses or concentrations\n\n[Empty]\n\nDuration of treatment / exposure\n\nlifetime (averages 45.6 to 50.0 weeks in first generation) , start at weaning\n\nFrequency of treatment\n\ncontinuous, daily\n\nDuration of test\n\n45.6 to 50.0 weeks in first generation, 32.4 to 43.0 weeks in second, 38.5 to 52.7 weeks in third generation\n\n### Doses / concentrations\n\n### #1 - Doses / concentrations\n\nDose / conc.\n\n[Empty]\n\nRemarks\n\nDoses / Concentrations:\n0.1, 0.5, and 1.0% in feed\nBasis:\nnominal in diet\n\n### #2 - Doses / concentrations\n\nDose / conc.\n\n[Empty]\n\nRemarks\n\nDoses / Concentrations:\n143, 688, and 1345 mg/kg bw/day\nBasis:\nactual ingested\nmean calculated for whole dose groups, from food intake\n\nNo. of animals per sex per dose\n\n49, 45, and 55 mated females (doses 0.1%, 0.5%, and 1.0%, total in all generations), no data on males\n\nControl animals\n\n* yes, concurrent no treatment\n\nDetails on study design\n\n- Dose selection rationale: 2, 10, and 20 times the expected maximal human therapeutic dosage\n\n- Rationale for animal assignment (if not random): no data\n\n- Rationale for selecting satellite groups: mated and unmated groups, not further specified\n\n- Post-exposure recovery period in satellite groups: none\n\n- Section schedule rationale (if not random): animals maintained until spontaneous death\n\nStatistics\n\nNumber of mated females (over all generations)\n% of mated females having no litters, per dose (over all generations)\n% of litters not raised to weaning, per dose (over all generations)\nMean number of pups born per female, per dose (over all generations)\nMean number of pups weaned per female, per dose (over all generations)\n\nHigh dose level used\n\n[Empty]\n\nJustification for deviation from the high dose level\n\n[Not publishable]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\n### Effect levels\n\n### #1\n\nKey result\n\nDose descriptor\n\nNOAEC\n\nEffect level\n\n<\n1,000 \n\nmg/kg diet\n\nBased on\n\ntest mat.\n\nSex\n\nmale/female\n\nBasis for effect level\n\n* other:\n  Clearly reduced reproductive capacity at all dose levels: Half the females had no litter, only 26% of the pups born were raised to weaning age.\n\nRemarks on result\n\nnot determinable\n\nno NOAEC identified\n\n### Observed effects\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nClearly reduced reproductive capacity at all dose levels:\n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| Concentration in diet (%) | No. of mated females | % females w. no litters | % litters not raised to weaning | mean no. of pups born / female | mean no. of pups weaned / female |\n| 0.1 | 49 | 44.9 | 52.9 | 4.0 | 1.9 |\n| 0.5 | 45 | 55.6 | 79.3 | 3.9 | 0.8 |\n| 1.0 | 55 | 45.5 | 60.0 | 4.5 | 1.9 |\n\nMost of the litters not raised were cannibalized.\n\nOnly very occasional evidences of gross malformations were found in any dose.\n\nAfter the third generation, the study had to be terminated due to insufficient numbers of young.\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nThe study is considered to be relevant, but not reliable or suitable for risk assessment or classification and labeling purposes with regard to developmental or reproductive toxicology.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 8795,
          "status": "success"
        }
      },
      "S-01 | Summary": {
        "document_id": "IUC5-3f103670-6444-4ae4-8acb-71871753a766_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
        "markdown_content": "#### Toxicity to reproduction\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Empty]\n\nJustification\n\n[Empty]\n\nUse restricted to selected regulatory programmes\n\n[Empty]\n\n### Description of key information\n\nThe results of the literature search are inconclusive for the developmental toxicity potential of salicylamide.\n\nNo relevant information on fertility was identified in the literature search.\n\n### Key value for chemical safety assessment\n\nToxic effect type\n\n[Empty]\n\n### Effects on fertility\n\n### Effect on fertility: via oral route\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nStudy duration\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\n### Effect on fertility: via dermal route\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nStudy duration\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\n### Effect on fertility: via inhalation route\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nStudy duration\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\n### Effects on developmental toxicity\n\n### Effect on developmental toxicity: via oral route\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nStudy duration\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\n### Effect on developmental toxicity: via dermal route\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nStudy duration\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\n### Effect on developmental toxicity: via inhalation route\n\nLink to relevant study record(s)\n\n[Empty]\n\nEndpoint conclusion\n\nno information available\n\nDose descriptor\n\n[Empty]\n\nEffect level\n\n[Empty]\n\nStudy duration\n\n[Empty]\n\nExperimental exposure time per week\n\nhours/week\n\nSpecies\n\n[Empty]\n\n### Toxicity to reproduction: other studies\n\nLink to relevant study record(s)\n\n[Empty]\n\n### Mode of Action Analysis / Human Relevance Framework\n\n[Empty]\n\n### Justification for classification or non-classification\n\nThe publicly available studies are regarded as not adequate for use in classifcation and labelling.\n\n### Additional information\n\nOnly one reproductive toxicology study was identified in the literature (Wright 1967). Reproductive parameters are not measured in detail (44%-45% of all females across all dose groups and generations did not litter. However, no dose response and no further data given). The number of females to litter (%) and pups born that were raised to weaning age (%) were reduced in all treated groups with no dose response. However, the dams were dosed at maternally toxic doses and parental survival time was significantly reduced compared with controls for all dose groups. As was percentage of pups raised to weaning age. A NOAEL was not derived. This study is therefore not adequate for assessing reproductive toxicity of salicylamide.\n\nMany of the studies identified within the literature review start with the assumption that salicylamide is a teratogen, based on the results of early work conducted in hamster embryos in 1964. This study has many shortcomings and cannot be used for assessing the teratogenic potential of salicylamide. The subsequent studies also have substantial technical and scientific shortcomings (All achieved a Klimisch rating of 3), and the focus of most of the studies was investigating the effect of salicylamide on the incorporation of sulfate into foetal glycosaminoglycans. No study identified a NOAEL for developmental toxicity for salicylamide and none are regarded as adequate for use in risk assessment and classification and labelling.\n\n### Attached background material\n\nBack to top",
        "content_length": 4105,
        "status": "success"
      }
    },
    "7.9 Specific investigations": {
      "7.9.1 Neurotoxicity": {},
      "7.9.2 Immunotoxicity": {},
      "7.9.3 Endocrine disruption": {
        "7.9.3.1 Endocrine disrupter screening â in vitro": {},
        "7.9.3.2 Endocrine disrupter mammalian screening â in vivo (level 3)": {}
      },
      "7.9.4 Specific investigations: other studies": {},
      "7.9.5 Phototoxicity in vitro": {}
    },
    "7.10 Exposure related observations in humans": {
      "7.10.1 Health surveillance data": {},
      "7.10.2 Epidemiological data": {},
      "7.10.3 Direct observations: clinical cases, poisoning incidents and other": {
        "001 | Supporting | Experimental study": {
          "document_id": "IUC5-67305b4c-ad89-4329-965d-ed9416962e0c_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Direct observations: clinical cases, poisoning incidents and other\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\ndirect observations: clinical cases, poisoning incidents and other\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nsupporting study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nWell documented study, meets generally accepted scientific principles, acceptable for assessment.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [First-pass elimination of salicylamide in man following oral and rectal administration](608f0ee6-3986-3608-a867-3ae279a01adc_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\nStudy type\n\nstudy with volunteers\n\nEndpoint addressed\n\n* basic toxicokinetics\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nThe test item was applied to 6 human volunteers by oral or rectal administration. Blood samples were obtained in regular intervals to quantify free salicylamide in plasma. Urinary samples were also collected and checked for salicylamide and its conjugates (sulfate and glucuronide).\n\nGLP compliance\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](ddcbef69-fda3-3f17-9fd8-3dc15afb6567_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Method\n\nType of population\n\n* general\n\nSubjects\n\n- Number of subjects exposed: 6\n\n- Sex: male\n\n- Age: 23-26 years\n\n- Weight at study initiation: 65-85 kg\n\n- Fasting period before study: overnight\n\nEthical approval\n\nother:\nwritten infromed consent received\n\nRoute of exposure\n\n* oral\n* other:\n  rectal\n\nReason of exposure\n\nintentional\n\nExposure assessment\n\nestimated\n\nDetails on exposure\n\nSalicylamide (500 and 1500 mg/person) was administered orally and rectally in a cross-over design with at least one week between each administration.\n\nOrally, salicylamide was given as sodium salt aqueous solution. Salicylamide sodium salt was administered in 25 mL tap water immediately followed by 125 mL of tap water.\n\nRectally, 500 mg were given to three subjects as salicylamide sodium salt aqueous solution (5 mL, pH 10.5) and to three subjects as a suspension (5 mL, pH 7.0). In addition, 1500 mg were given as salicylamide sodium salt aqueous solution (10 mL, pH 10.5). Rectal application was performed after defecation using a syringe. Subjects remained seated for about 3 h after administration.\n\nExaminations\n\nBlood samples were collected at 5, 10, 15, 20, 30, 40, 60, 75, 90, 120, 150, and 180 min after administration. Urine samles were collected in regular intervals for 24 h.\n\nConcentrations of salicylamide in blood plasma and urine were measued using a GC with nitrogen selective detection. Sensitivity was 0.25 Âµg salicylamide/mL plasma and 5 Âµg salicylamide/mL urine.\n\nConjugates (sulfates, glucuronides) of salicylamide were detected after treatment of the samples according to the method described at de Boer et al., J Chromatogr. 1979, 162(3):457-60.\n\nMedical treatment\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nClinical signs\n\n[Empty]\n\nResults of examinations\n\nABSORPTION\n\nAfter oral administration of 500 mg salicylamide, very low plasma concentrations of unmodified salicylamide were measured. When 1500 mg were given orally, relatvely high concentrations of salicylamide in plasma were detected. The mean AUC values showed a 34.9-fold increase when comparing 500 to 1500 mg administration, indicating non-linearity of salicylamide pharmacokinetics. This could be due to saturation of metabolizing enzymes in liver or gut wall, below which practically no unchanged salicylamide is detected in plasma. This saturation seems to occur at doses of 1000 mg.\n\nFollowing rectal adminitration of 500 mg, almost no salicylamide could be determined in plasma. When salicylamide at 500 mg was given rectally as neutral suspension instead of basic aqueous solution, no measurable plasma levels could be detected. After rectal administration of 1500 mg of salicylamide, plasma concentrations were considerably lower compared to oral administration. The AUC after oral administration was more than 6 times higher compared to rectal administration, indicating the poor availability by the rectal route.\n\nData on absorption are summarized in table 1. Peak concentrations and times are given in table 4.\n\nDISTRIBUTION\n\nThe rapid elimination of salicylamide (1500 mg) from plasma after oral administration with a half-life of 31 min, respectively, compared to the relatively long excretion half life of salicylamide conjugates of 63 min in urine indicates that there is a certain distribution of salicylamide conjugates in the body.\n\nMETABOLISATION\n\nSulfates and glucuronides of salicylamide were detected in the samples.\n\nEXCRETION\n\nElimination of unchanged salicylamide from plasma was relatively fast with half-lives of 12 and 31 minutes after oral administration of 500 and 1500 mg salicylamide. After 24 h, 71.3 and 82.0 % of the orally administered doses of 500 and 1500 mg were excreted as conjugates.\n\nAfter rectal administration, the amount of salicylamide conjugates excreted in the urine was considerably lower compared to oral administration (45.6-47.6 and 75.6 % for 500 and 1500 mg salicylamide).\n\nExcretion half lives in the urine were significantly lower after oral administation (63 min) compared to rectal application (73 min).\n\nData on elimination are summarized in tables 2 and 3.\n\nEffectivity of medical treatment\n\n[Empty]\n\nOutcome of incidence\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\nTable 1: AUC values for salicylamide following oral and rectal administration.\n\n|  |  |  |  |  |\n| --- | --- | --- | --- | --- |\n| Subject No. | AUC oral [Âµg/min/mL] | | AUC rectal [Âµg/min/mL] | |\n| 500 mg | 1500 mg | 500 mg | 1500 mg |\n| 1 | 36 | 1225 | - (suspension) | 193 |\n| 2 | 73 | 767 | - (solution) | 56 |\n| 3 | 6 | 666 | - (suspension) | 62 |\n| 4 | 82 | 1197 | - (solution) | 182 |\n| 5 | 167 | 698 | 53 (solution) | 228 |\n| 6 | 93 | - | - (suspension) | - |\n| Mean | 76 | 911 |  | 144 |\n| SD | 55 | 277 |  | 80 |\n\nTable 2: Cumulative excretion of salicylamide conjugates (sulfates + glucuronides) as percentage of the administered dose\n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| Subject No. | AUC oral [Âµg/min/mL] | | AUC rectal [Âµg/min/mL] | | |\n| 500 mg | 1500 mg | 500 mg (sol.) | 500 mg (susp.) | 1500 mg |\n| 1 | 63.5 | 73.2 | - | 45.9 | 82.5 |\n| 2 | 76.5 | 79.8 | 47.6 | - | 74.6 |\n| 3 | 75.6 | 77.4 | - | 44.6 | 69.7 |\n| 4 | 64.7 | 95.5 | 46.3 | - | 71.4 |\n| 5 | 71.8 | 84.0 | 43.0 | - | 79.8 |\n| 6 | 75.8 | - | - | 52.4 | - |\n| Mean | 71.3 | 82.0 | 45.6 | 47.6 | 75.6 |\n| SD | 5.8 | 8.5 | 2.4 | 4.2 | 5.4 |\n\nTable 3: Elimination half-lives of salicylamide in plasma and salicylamide conjugates in urine after oral and rectal administration\n\n|  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- |\n| Subject | T1/2oral [min] | | T1/2rectal [min] | | T1/2urine [min] | |\n| 500 mg | 1500 mg | 500 mg | 1500 mg | 1500 mg oral | 1500 mg rectal |\n| 1 | 5 | 26 | - | 56 | 50 | 75 |\n| 2 | 12 | 30 | - | 38 | 70 | 75 |\n| 3 | 4 | 35 | - | 47 | 60 | 65 |\n| 4 | 25 | 30 | - | 25 | 80 | 90 |\n| 5 | 20 | 35 | 12 | 35 | 55 | 60 |\n| 6 | 5 | - | - | - | - | - |\n| Mean | 12 | 31 |  | 40 | 63 | 73 |\n| SD | 9 | 4 |  | 12 | 12 | 12 |\n\nTable 4: Peak plasma concentrations and peak times following oral and rectal administration of 1500 mg of salicylamide\n\n|  |  |  |  |  |\n| --- | --- | --- | --- | --- |\n| Subject No. | Cmax[Âµg/mL] | | tmax[min] | |\n| oral | rectal | oral | rectal |\n| 1 | 44.6 | 5.4 | 15 | 10 |\n| 2 | 32.0 | 3.0 | 10 | 5 |\n| 3 | 21.8 | 1.9 | 10 | 5 |\n| 4 | 33.0 | 10.1 | 15 | 5 |\n| 5 | 23.0 | 8.0 | 10 | 10 |\n| Mean | 30.9 | 5.7 | 12 | 7 |\n| SD | 9.2 | 3.4 | 2.7 | 2.7 |\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nAfter oral administration, salicylamide is absorbed very fast in the plasma with a mean peak time of 12Â±2.7 min. Peak concentration is then 30.9Â±9.2Âµg/mL (dose administered: 1500 mg). Elimination from plasma is also quite fast with half-lives of 12 and 31 min after administration of 500 and 1500 mg salicylamide, respectively. Excretion is performed mainly via urine after conjugation with sulfate or glucuronic acid. Urinary excretion half life is 63 min (dose: 1500 mg).\n\nExecutive summary\n\nThe test item salicylamide was applied to 6 human volunteers by oral or rectal administration at 500 or 1500 mg/person. Blood samples were obtained in regular intervals to quantify free salicylamide in plasma. Urinary samples were also collected and checked for salicylamide and its conjugates (sulfate and glucuronide).\n\nAfter oral administration, salicylamide is absorbed very fast in the plasma with a mean peak time of 12Â±2.7 min. Peak concentration is then 30.9Â±9.2 g/mL (dose administered: 1500 mg). Elimination from plasma is also quite fast with half-lives of 12 and 31 min after administration of 500 and 1500 mg salicylamide, respectively. Excretion is performed mainly via urine after conjugation with sulfate or glucuronic acid. Urinary excretion half life is 63 min (dose: 1500 mg).\n\nAfter rectal administration plasma concentration of free salicylamide and urinary concentration of conjugates are significantly lower compared to oral administration.\n\nBack to top",
          "content_length": 11117,
          "status": "success"
        },
        "002 | Key | Experimental study": {
          "document_id": "IUC5-0e34e628-33aa-40a2-995b-09248e9a7790_b47a4fdc-6682-44c3-848b-98f5bbb5333b",
          "markdown_content": "#### Direct observations: clinical cases, poisoning incidents and other\n\nJump to\n\nHide empty fields\n\n### Administrative data\n\nConfidentiality\n\n[Not publishable]\n\nJustification\n\n[Not publishable]\n\nUse restricted to selected regulatory programmes\n\n[Not publishable]\n\nEndpoint\n\ndirect observations: clinical cases, poisoning incidents and other\n\nType of information\n\nexperimental study\n\nAdequacy of study\n\nkey study\n\nRobust study summary\n\n[Not publishable]\n\nUsed for classification\n\n[Not publishable]\n\nUsed for SDS\n\n[Not publishable]\n\nStudy period: start date\n\n[Empty]\n\nEnd date\n\n[Empty]\n\nRemark\n\n[Empty]\n\nReliability\n\n2 (reliable with restrictions)\n\nRationale for reliability incl. deficiencies\n\nother:\nStudy published in a peer-reviewed journal, according to scientific standards, well-documented, but no individual data reported.\n\nData waiving\n\n[Empty]\n\nJustification for data waiving\n\n[Empty]\n\nJustification for type of information\n\n[Empty]\n\n### Attached justification\n\n### Cross-reference\n\n### #1 - Cross-reference\n\nReason / purpose for cross-reference\n\nreference to same study\n\nRelated information\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Data source\n\nReference\n\n* [Relationship of pKa and acute skin irrritation in humans](ceee54fc-ef3c-3192-9e7c-a6803c3dcfbd_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nData access\n\n[Not publishable]\n\nData protection claimed\n\n[Not publishable]\n\n### Materials and methods\n\nStudy type\n\nstudy with volunteers\n\nEndpoint addressed\n\n* skin irritation / corrosion\n\n### Test guideline\n\n### #1 - Test guideline\n\nQualifier\n\nno guideline followed\n\nGuideline\n\n[Empty]\n\nVersion / remarks\n\n[Empty]\n\nDeviations\n\n[Empty]\n\nPrinciples of method if other than guideline\n\nSkin irritation in human female volunteers was assessed before and after 1-day exposure to test substance-loaded hydrogel discs, and again 24 hours later, by assessment of erythema, edema, blood flow (by laser Doppler velocimetry), color, and primary irritation index.\n\nGLP compliance\n\nno\n\n### Test material\n\nTest material information\n\n[Test material information](164e9db7-ba3c-39cb-b2c3-e9b1256ddd3f_b47a4fdc-6682-44c3-848b-98f5bbb5333b)\n\nAdditional test material information\n\n[Empty]\n\nSpecific details on test material used for the study\n\n[Empty]\n\nSpecific details on test material used for the study (confidential)\n\n[Not publishable]\n\n### Method\n\nType of population\n\n* general\n\nSubjects\n\n- Number of subjects exposed: 16\n\n- Sex: female\n\n- Age: 35 - 45 years\n\n- Race: 10 hispanic (olive-complected skin), 5 white (type II skin), 1 white/Polynesian (slightly olive skin)\n\n- Demographic information: no data\n\n- Known diseases: none\n\n- Other: reasonably clear backs with no or few comedones, moles, and freckles\n\nEthical approval\n\nconfirmed, but no further information available\n\nsubjects consented to the study\n\nRoute of exposure\n\n* dermal\n\nReason of exposure\n\nintentional\n\nExposure assessment\n\nestimated\n\nDetails on exposure\n\nHydroxyethyl methacrylate (HEMA) hydrogel films were prepared by polymerization from HEMA, carefully extracted to remove free monomer, and cut into 1 cm2 discs, which were loaded with the test substance by soaking in a saturated solution in ethanol/water (7:3) and dried. Immediately before application, discs were soaked in a saturated aqueous solution of the test material, and applied to the scapular region of the test subjects. The loaded test discs were occluded with an ethylene vinyl acetate membrane and secured with tape.\n\nLoading of discs: determined by weight difference of the disc before and after loading, checked by extraction into a known volume of ethanol/water and analysis. Percent uptake per dry weight: 36.6 +- 5.9\n\nExaminations\n\n- Urine analysis: no\n\n- Haematology: no\n\n- Lung function parameters: no\n\n- Other: Skin erythema, edema (both graded by standard 0-4 visual scale, enhanced by scale 0.5 for borderline reaction), blood flow (by laser Doppler velocimetry), color, and primary irritation index, determined on treated skin area before exposure, after 1 day (at end of exposure) and after 2 days.\n\nMedical treatment\n\n[Empty]\n\n### Model and software\n\nModel name and version\n\n[Empty]\n\nSoftware name and version\n\n[Empty]\n\nRemarks\n\n[Not publishable]\n\n### Any other information on materials and methods incl. tables\n\n[Not publishable]\n\n### Results and discussion\n\nClinical signs\n\nNone\n\nResults of examinations\n\n- Erythema: statistically indistinguishable from control at 24 and 48 hours\n\n- Edema: statistically indistinguishable from control at 24 and 48 hours\n\n- Color: statistically indistinguishable from control at 24 and 48 hours\n\n- Laser Doppler velocity (LDV): statistically indistinguishable from control at 24 and 48 hours\n\n- Primary Irritation index (PII): statistically indistinguishable from control at 48 hours\n\nEffectivity of medical treatment\n\n[Empty]\n\nOutcome of incidence\n\n[Empty]\n\n### Additional information about applicability domain and reliability of (Q)SAR predictions\n\nFit with the applicability domain\n\n[Empty]\n\nJustification for the fit with the applicability domain\n\n[Empty]\n\nFit with the space defined by the training set of the model\n\n[Empty]\n\nMechanistic and metabolic considerations\n\n[Empty]\n\n### Similar substances with experimental data\n\nPerformance of the model for similar substances\n\n[Empty]\n\nConclusions on applicability domain and reliability\n\n[Empty]\n\nUncertainty\n\n[Empty]\n\n### Any other information on results incl. tables\n\n**Mean irritation scores:**\n\n|  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- |\n|  | Hours | Erythema | Edema | Color | LDV | PII |\n| Salicylamide | 24 | 0.05 Â± 0.15 | 0.03 Â± 0.12 | 5.3 Â± 2.2 | 44 Â± 15 |  |\n| Water control | 24 | 0.03 Â± 0.18 | 0.03 Â± 0.18 | 5.1 Â± 1.5 | 44 Â± 13 |  |\n| Salicylamide | 48 | 0.08 Â± 0.22 | 0.00 Â± 0.00 | 4.8 Â± 1.6 | 43 Â± 11 | 0.08 Â± 0.18 |\n| Water control | 48 | 0.06 Â± 0.21 | 0.00 Â± 0.00 | 4.7 Â± 1.4 | 42 Â± 12 | 0.08 Â± 0.24 |\n\n### Overall remarks, attachments\n\nOverall remarks\n\n[Not publishable]\n\n### Attachments\n\n### Applicant's summary and conclusion\n\nConclusions\n\nUnder the conditions of the study, human volunteers treated with salicylamide were not significantly different from a water control in any of the observed variables.\n\nExecutive summary\n\n[Empty]\n\nBack to top",
          "content_length": 6238,
          "status": "success"
        }
      },
      "7.10.4 Sensitisation data (humans)": {},
      "7.10.5 Exposure related observations in humans: other data": {}
    },
    "7.11 Toxic effects on livestock and pets": {},
    "7.12 Additional toxicological information": {}
  }
}